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Orthotopic liver transplantation (OLT) is the only curative therapy for end-stage liver diseases.  
To overcome organ shortage, organs from extended criteria donors, which would ordinarily be 
discarded, are used sometimes.  These organs provide additional grafts; however, they are more 
susceptible to ischemia-reperfusion (I/R) injury.  I/R injury, an unavoidable process during OLT, 
is a major cause of liver graft non-function and failure, requiring urgent re-transplantation, which 
further depletes the scare organ pool.  To date, no therapy is available to reduce or prevent I/R 
injury.   
Prostaglandins (PG) have well characterized vasodilatory and anti-platelet aggregatory 
actions.  Many PG analogues, including prostacyclin (PGI2), have been evaluated for their ability 
to reduce hepatic I/R injury after OLT.  Poor stability, intolerable side effects, and the inability to 
show a significant difference in primary endpoint have limited their clinical application so far.  
Treprostinil, a relatively new FDA-approved PGI2 analogue, has a higher stability, potency, and 
longer elimination half-life than other PGI2 analogues available.     
The objectives of this dissertation were to examine the efficacy of treprostinil in 
protecting the liver graft against I/R injury during OLT.  Proof of concept of treprostinil 
minimizing hepatic I/R injury was demonstrated in a rat OLT model.  Further analysis showed 
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that I/R injury significantly down-regulated CYP2E1, CYP2C11, and CYP3A mRNA, protein 
expression, and activity, as well as the expression of several hepatic transporters in liver graft 
post-OLT.  Treprostinil improved hepatic expression and activity of CYP450 enzymes and 
transporters.  In particular, Bsep mRNA expression was restored to normal and Mrp2 and P-gp 
protein expression were up-regulated.  In vitro studies confirmed that treprostinil does not inhibit 
or induce the metabolism of immunosuppressive medications.  These findings support co-
administration of treprostinil with cyclosporine A, tacrolimus, sirolimus, or mycophenolic acid to 
adult OLT patients without concern for any drug-drug interaction.  
 This is the first study to examine the efficacy of treprostinil for protection of liver grafts 
against I/R injury during OLT.  A clinical study has been initiated to examine the safety and 
efficacy of perioperative treprostinil administration to adult OLT patients.  Collectively, this 
work makes significant contributions to the field of liver transplantation and, potentially, solid 
organ transplantation. 
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1.0  INTRODUCTION  
   5 
The liver is the largest internal organ in the body and it plays a vital role in maintaining the 
body’s metabolic homeostasis.  More specifically, the liver serves a multitude of functions, with 
essential roles in biosynthesis, metabolism, secretion, detoxification, excretion, and bile 
formation as part of normal physiology.  The liver consists of parenchymal and nonparenchymal 
cells.  Parenchymal cells, i.e. hepatocytes, constitute approximately 80% of the total cell number, 
and the nonparenchymal cells of the sinusoid include the sinusoidal endothelial cells (SECs), the 
Kupffer cell, stellate cell, and the Pit cell [1].  These cells are arranged in a matrix that facilitates 
their cooperative interaction and are capable of synthesizing, extracting, metabolizing, and 
eliminating a variety of molecules. 
 The liver, a highly vascularized organ with a high blood flow, contains different 
vasculatures, including the portal vein, the hepatic artery, the liver sinusoid, and the hepatic vein.  
This liver cellular matrix is perfused by blood at low pressure through uniquely structured 
capillary-size blood vessels, called sinusoids, which are supplied by a unique source of blood, 
consisting of both arterial, coming from the common hepatic artery, and venous, coming from 
the portal vein inflow.  The portal vein flow has already circulated through the gut, pancreas, and 
spleen and is reduced in oxygen and pressure and is enriched in nutrients and toxins absorbed 
from the gut.  The portal vein constitutes 75 – 80% of the liver blood flow and the hepatic artery 
constitutes the remaining 20 – 25% [2].  Arterial blood is well oxygenated at an elevated 
pressure, relative to portal venous blood.  Venous and arterial blood mix together as they enter 
the sinusoids in the liver [2].  
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1.1 ORTHOTOPIC LIVER TRANSPLANTATION 
Since the first liver transplantation was carried out by Thomas E. Starzl in 1963, techniques in 
surgery, immunosuppression, and patient management have improved, making orthotopic liver 
transplantation (OLT) a routine procedure.  Currently, OLT is the only curative treatment 
available for patients with acute and chronic liver failure; however, donor shortage is a major 
factor limiting the number of organs available for transplantation.  In 2009, approximately 6,300 
liver transplantations were performed in the United States, while more than 17,000 patients were 
listed on the United Network for Organ Sharing waiting list [3].  The disparity between the 
number of organs available for liver transplantation and patients in need of livers as well as the 
number of patients who die while waiting for an available organ is shown in Figure 1.  
 
 
 
Figure 1: Number of patients on the waitlist for a liver transplantation in the USA (2000-2009) 
Number of patients waiting for an organ (top line, circles); number of liver transplantations (middle line, squares); 
number of patient deaths while on the donor waiting list (bottom line, triangles).  Reproduced from Organ 
Procurement and Transplantation Network (OPTN)/Scientific Registry of Transplant Recipients (SRTR) Annual 
Report Tables 1.3, 1.6, and 1.7.    
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The current shortage of cadaveric organ donors has forced the expansion of the donor 
pool and has led medical centers to accept marginal donors, i.e. extended criteria donors (ECD), 
including organs from older donors, non-heart beating donors, and grafts which have undergone 
prolonged cold storage in preservation solution [4].  Donor age greater than 70 years old has 
been associated with lower patient and graft survival [5] and an increased likelihood of steatosis 
[6].  Non-heart beating donors are confounded by prolonged warm ischemia before cold 
preservation, which is associated with a high risk of primary graft non-function [7].  The 
duration of cold ischemic storage has been associated with an increase in preservation damage 
resulting in sinusoidal endothelial cell damage and hypercoaguability, leading to a longer post-
operative course and decreased graft survival [8]. 
 In summary, while ECD organs provide the much needed additional grafts, they are also 
more susceptible to I/R injury, resulting in an increase in delayed or primary graft non-function, 
leading to prolonged hospitalization and, consequently, hepatic dysfunction and/or allograft 
failure [4, 9].  Thus, amelioration of I/R injury will improve the short- and long-term transplant 
outcomes; however, no treatment is currently available to prevent or minimize I/R injury. 
1.1.1 Primary non-function 
In liver transplantation, I/R injury is the main cause of both initial poor function and primary 
non-function of the allograft [4].  The incidence of primary non-function (PNF) of the 
transplanted liver, often as a result of I/R injury, is approximately 2 – 23% of OLT [8, 10].  
There is no simple and clear definition of primary non-function (PNF) and it varies from center 
to center.  Characteristic manifestations of PNF include failure of the newly implanted graft to 
make bile, very high and rapidly rising levels of serum aminotransferases, severe coagulopathy 
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which can progress to hypoglycemia, hepatic encephalopathy, and acute renal failure within the 
first 48 hours post-transplantation [11-13].  The causes of PNF can be broadly classified into four 
categories: donor-related factors (discussed above); procurement-related factors, i.e. I/R injury; 
host-related factors, i.e. hyperacute rejection, intercurrent diseases; and technical surgical factors, 
i.e. vascular occlusion or blood loss [14].  Primary non-function of the allograft leads to 
significant morbidity, necessitating re-transplantation [15], thereby further depleting the already 
limited donor organ pool.  Any therapy to reduce the incidence of I/R injury would greatly 
increase the number of available organs for transplantation as well as the clinical outcomes in 
transplant patients.  
1.2 ISCHEMIA AND REPERFUSION INJURY 
Ischemia is defined as a state of no blood flow.  Consequently, an interruption of blood supply 
prevents the delivery of oxygen and nutrients to the ischemic tissue.  When the cause of ischemia 
is relieved, and molecular oxygen is reinstituted through the circulation, the reperfusion rescues 
the ischemic tissue but also enhances the injury caused during the ischemic period by oxidative 
stress and inflammatory-mediated reactions [16-18].  The pathophysiology of liver I/R injury 
includes direct cellular damage as a result of the ischemic insult as well as delayed graft 
dysfunction following reperfusion.   
Clinically, hepatic I/R injury can occur in a setting of elective liver surgery, trauma, 
shock, and liver transplantation.  The surgical procedure of liver transplantation inherently 
involves cold preservation (ischemia) and warm reperfusion of the transplanted graft, resulting in 
varying degrees of hepatic injury.  Ischemia and reperfusion (I/R) injury, an unavoidable process 
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in liver transplantation, is a major cause of both initial poor function and primary allograft non-
function, leading to organ dysfunction and early graft failure, carrying a high mortality rate of if 
patients are not re-transplanted immediately . 
  During liver transplantation, to a greater or lesser extent, the surgical procedure exposes 
a liver graft to three different types of ischemia: 1) in-situ warm ischemia, which occurs before 
organ procurement; 2) ex-situ cold ischemia, during graft preservation; and 3) in-situ rewarming 
ischemia, during engraftment [8]. Warm (37 oC) and cold (4 oC) ischemia share some common 
pathways of injury, yet there are important differences between the two and they each possess 
distinct processes and mechanisms of injury, which ultimately result in end-organ failure [19].  
One of the biggest distinctions between the two types of ischemia are the targets of injury; 
hepatocytes are the primary targets of warm ischemia [20, 21], whereas sinusoidal endothelial 
cells [22-24] are predominantly injured during cold ischemia, and are primarily involved in the 
disruption of the microcirculation.  Warm ischemia typically occurs as a result of hepatic trauma, 
including hypovolemic shock, hepatic resection, or inflow occlusion during liver surgery, or 
when the flow of blood has been temporarily stopped, yet the organ remains in the body.  
Alternatively, cold ischemia occurs exclusively during graft preservation when the liver graft is 
stored in cold preservation solution before transplantation.    
At the time of organ harvest, the donor liver is perfused with and stored in University of 
Wisconsin (UW) preservation solution, where it remains ischemic until it is transplanted into the 
recipient.  During cold ischemia, the organ is transiently cooled and deprived of oxygen, which 
initiates a cascade of cellular injuries.  Subsequent injury occurs upon engraftment when the 
graft is subjected to warm reperfusion with normothermic blood, resulting in varying degrees of 
hepatic injury and graft dysfunction, or in worst cases, allograft non-function [25].  The actual 
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injury to the liver graft following ischemia is mainly detected post-reperfusion, once the oxygen 
supply, blood elements, and nutrients are restored and able to interact with hepatocytes and other 
cells present in the liver, leading to liver injury and impaired hepatic function [26, 27].  
Ironically, while the reestablishment of blood flow to the liver represents a vital requirement for 
the recovery of cellular and organ function, reperfusion enhances ischemia-induced tissue and 
cellular damage further, potentially causing significant damage to the cellular architecture and 
function of the liver.  Essentially, I/R injury begins as a disturbance in microcirculatory flow and 
is manifested by platelet, red blood cell, and polymorphonuclear (PMN) adhesion to endothelial 
cells causing sinusoidal congestion, followed by oxidative stress and pro-inflammatory response 
[18, 28, 29].  
The liver is a highly aerobic, oxygen-dependent organ and I/R injury can affect all 
oxygen-dependent liver cells that require an uninterrupted blood supply.  One of the first 
consequences of ischemia is tissue anoxia, which causes a drop in the cellular energy metabolism 
and enzyme function, resulting in adenosine triphosphate (ATP) depletion.  Subsequent failure of 
the ATP-dependent plasma membrane pump (Na+/K+ ATPase) causes the inability to pump 
sodium out, intracellular sodium accumulation, and cellular edema [18, 30, 31].  Failure of the 
membrane ion pump also disrupts cellular homeostasis and causes an efflux of potassium, which 
activates voltage-dependent Ca2+ channels and leads to an influx of Ca2+, thereby further 
disrupting cellular processes and functions [32].  Aerobic cells require mitochondrial oxidative 
phosphorylation for their energy supply and, as such, all aerobically metabolizing tissues and 
cells are potential targets of I/R injury. 
Reactive oxygen species (ROS) and pro-inflammatory cytokines also play an important 
role in liver injury.  A critical result of ischemia is activation of the Kupffer cells, also known as 
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the liver resident macrophages, which are one of the main sources of vascular reactive oxygen 
formation by xanthine oxidase during the initial reperfusion phase [33, 34], and significantly 
contribute to liver dysfunction and cell injury during reperfusion.  In addition, Kupffer cells have 
the capacity to release a wide range of cytokines that critically determine the subsequent 
reactions of other immune cells and hepatocytes, as well as the degree of organ damage [35].  In 
the early stages of reperfusion, increased superoxide and other ROS derived from the activation 
of various sources play a crucial role in tissue damage.  The accumulation of hypoxanthine 
during ischemia allows for a burst of superoxide and hydrogen peroxide production yielding 
hydroxyl radical when oxygen is reintroduced into the blood vessel, during reperfusion and 
causing impaired cellular functions [36].  The energy state at the time of reperfusion is an 
important indicator of cell and graft recovery. 
Initially, all of these processes are reversible so that upon reintroduction of oxygen, cells 
can recover; however, if anoxia is prolonged further, irreversible cellular damage will occur.  
Secondary results of the energy and oxygen disturbance during the ischemic phase are reflected 
by the destruction of cellular and subcellular structures, increased membrane permeability during 
the reperfusion phase, which ultimately culminate in tissue structural alterations and lead to 
cellular dysfunction [29].  
In summary, ischemic injury is a complex, multi-factorial pathophysiological process, in 
which cells undergo a series of metabolic, structural and functional damage.  The process of I/R 
injury to the liver combines interrelated factors that produce a cascade of events, which can 
ultimately lead to graft failure.  The extent of injury to the liver graft following reperfusion 
varies tremendously and largely depends on the duration of cold ischemia, and strongly predicts 
both the short- and long-term clinical outcome. [37].  Numerous efforts have been focused on 
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identifying an agent that is capable of interfering with and or reducing as many of these 
processes as possible with the goal of preventing I/R injury during OLT.  Before discussing 
therapeutic approaches to prevent I/R injury, the importance of liver microcirculation and the 
involvement of platelets and cytokines in the development of I/R injury will be discussed in this 
chapter.  
1.2.1 Liver microcirculation  
Hepatic microcirculation is extremely important to maintain the physiology and function of the 
whole organism.  Specifically, it supplies the liver tissue with oxygen and nutrients, serves as a 
gate for leukocyte entrance in hepatic inflammation, and is responsible for the clearance of 
toxins and foreign bodies from the bloodstream [38].  Hepatic circulation comprises a unique 
system of capillaries called sinusoids, which are lined by fenestrated endothelium with high 
permeability that allows maximum contact between hepatocytes and blood [39].   
The liver sinusoid is a specific capillary network system where a variety of metabolic 
substances are exchanged between hepatic blood flow and hepatic parenchymal cells [40].  
Within the sinusoid, the SEC accounts for approximately 70% of the cell population [17, 40].  
Liver sinusoidal endothelial cells line the inner surface of the sinusoid to form a vital and 
dynamic structure that is essential for vascular homeostasis. The unique morphology of the liver 
SECs permits interactions between lymphocytes and hepatocytes [38].  The sinusoidal cells 
lining the endothelium are responsive to a wide variety of substances and, by contracting or 
swelling, they can selectively regulate the patency of the sinusoidal lumen, thereby altering the 
rate and distribution of blood flow [39].  
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The morphology of SECs is characterized by sieve-like plate structure clustering of the 
open fenestrae in their cytoplasm and no basement membrane along the space of Disse, shown in 
Figure 2.  The SEC porosity and lack of an organized basement membrane are important for 
oxygen diffusion to hepatocytes.  The fenestrae are dynamic structures that contract and dilate in 
response to alterations in sinusoidal blood flow and perfusion pressure, and act as a selective 
sieving carrier to control the extensive exchange of material between the blood and the liver 
cells, which contribute to the homeostatic control of the hepatic microcirculation [38].   
 
 
 
Figure 2: Lumen of rat hepatic sinusoid with the endothelial cell coating by SEM 
SEC, sinusoidal endothelial cell; fenestrations (white, arrows). Original magnification x10,000. 
 
The vascular endothelium-leukocyte interaction represents a central role in the pathogenesis of 
I/R-induced microvascular injury.  Liver SECs are particularly vulnerable to cold ischemic injury 
[41] and during I/R injury, endothelial cells become activated to express an array of surface 
adhesion molecules, which primes the endothelium for further PMN interactions.  This 
interaction is mediated by the expression of endothelial cell adhesion molecules, e.g. intracellular 
adhesion molecules (ICAM) and vascular adhesion molecules (VCAM), on the surfaces of both 
SEC 
1 um 
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vascular endothelial cells and leukocytes which subsequently produce several cell-damaging 
factors, to further promote hepatic injury [42].  The combination of Kupffer cell activation and 
SEC swelling with an increase in vasoconstrictors, e.g. endothelin and thromboxane (TxA2), and 
a decrease in vasodilators, e.g. prostacyclin, leads to sinusoidal narrowing.  Upon reperfusion 
there is increase in neutrophil and platelet adhesion and aggregation in the sinusoids.  The end 
result is a significant reduction of microcirculatory blood flow [31].  A deteriorated hepatic 
microcirculation and subsequent neutrophil emigration and increased vascular permeability are 
responsible in part for tissue injury [43].   
Ischemic injury to the endothelium disrupts the delicate homeostasis in the 
microcirculation and promotes the attraction, activation, adhesion, and migration of 
polymorphonuclear neutrophils, causing local tissue destruction by release of proteases and 
oxygen free radicals.  Eventually, damage to liver SECs leads to the loss of microvascular 
integrity and decreased blood flow.  Increasing blood flow to the liver during reperfusion is 
essential for a good post-operative prognosis [17, 44].  
1.2.2 Platelets 
Platelets are well known for their important role in homeostasis in which the formation of a 
platelet aggregate is the first measure to seal a damaged blood vessel.  Platelets are involved in 
multiple pathological processes, including inflammatory states and regeneration [45].  Platelets 
respond to both local and systemic inflammatory responses and are recruited to the liver where 
they adhere to activated sinusoidal endothelial cells in a liver exposed to cold or warm I/R injury 
[46-48].  Platelets are also attracted to the liver in response to inflammatory stimuli where they 
can translocate to enter the Space of Disse and attach to hepatocytes [45].  The mechanism by 
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which platelets induce organ damage is presumably by inducing apoptosis in SECs, a process 
which is facilitated by the presence of leukocytes and Kupffer cells [47, 49].  In addition, the 
extent of platelet adhesion to the liver endothelium has been shown to correlate with organ 
function in human liver transplantation recipients [50].  Therefore, inhibition of platelet 
aggregation is an important step in reducing hepatic I/R injury. 
1.2.3 Cytokines 
During hepatic I/R injury, which is characterized by an acute inflammatory response, several 
substances, including pro-inflammatory cytokines, are locally released to promote 
vasoconstriction, platelet aggregation, and leukocyte adherence.  Pro-inflammatory cytokines are 
produced at the site of injury and are responsible for initiating and maintaining the inflammatory 
response, resulting in further organ injury [51].  The initial phase of I/R injury involves the 
release of ROS and the inflammatory cascade mediated by a variety of pro-inflammatory 
cytokines, including Tumor Necrosis Factor-α (TNF-α), Interleukin (IL)-1β, IL-6 by Kupffer 
cells [52].  In particular, TNF-α, IL-1β and -6, are known to mediate acute phase changes in 
hepatic protein synthesis at the transcriptional level, which contribute to disturbances in normal 
liver circulation [51, 53].  TNF-α is among the earliest cytokines activated [54] and is a central 
propagating factor [55].  TNF-α works primarily by stimulating many transcription factors, 
including nuclear factor-kappaB (NF-κB), which control and induce the gene expression of 
secondary inflammatory mediators, including IL-1, IL-6, chemokines, and vascular cell adhesion 
molecules [42].  TNF-α and IL-1β are also potent inducers of IL-6, which work together to up-
regulate the expression of adhesion molecules, giving rise to increased leukocyte-sinusoidal 
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endothelial cell interactions, resulting in further tissue injury [56].  IL-6 is an important mediator 
of the hepatic acute-phase response during injury.  Not only does IL-6 induce neutrophil 
activation, but it may also delay the phagocytic disposal of dysfunctional neutrophils, thereby 
prolonging the injurious effects of these cells [57].  Pro-inflammatory mediators work together 
with the expression of adhesion molecules, i.e. ICAM-1, VCAM-1, and P- and E-selectins, to 
further promote liver graft infiltration of neutrophils and further contribute to the progression of 
hepatic injury[42].  
In summary, the primary targets of cold I/R injury are the liver SECs [58].  Damage to 
SECs leads to loss of microvascular integrity and decreased blood flow, while promoting the 
attraction, activation, adhesion, and migration of neutrophils to the endothelium. Platelet 
aggregation, local tissue destruction, up-regulation of inflammatory cytokines, and structural 
alterations in tissue leads to hepatocellular dysfunction [9, 29].  Each one of these factors 
represent a pharmacological target to reduce or prevent hepatic I/R injury.   
1.3 EFFECTS OF INFLAMMATION ON DRUG DISPOSITION 
Inflammation and pro-inflammatory cytokines are known to markedly impair hepatic 
detoxification pathways by suppressing the expression of several hepatic transporters and 
metabolic enzymes, thereby, altering drug disposition.  Considering that the liver is the most 
important site of drug metabolism and clearance, inflammation-mediated changes in the 
activities or expression of drug metabolizing enzymes or hepatic transporters can have major 
implications when the capacity of the liver, such as the case during liver transplantation, to 
handle drugs is severely compromised, leading to altered hepatic clearance of drugs [59].   
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1.3.1 Drug Metabolism Pathways 
The liver is the major organ responsible for the metabolism and clearance of endogenous and 
exogenous compounds in humans, and it expresses numerous drug-metabolizing enzymes, while 
some metabolism also occurs in the gut, lung, kidney, and brain.   
The concentration of a drug in the blood (or plasma) is determined by the process of 
absorption, distribution, metabolism, and excretion.  Metabolism can be broadly classified as 
either phase I (functionalization) or phase II (conjugation) reactions.  Often, but not always, 
these two processes occur sequentially.  Phase I reactions introduce a functional group or 
uncover a chemically reactive group on the parent compound, and the products may either be 
pharmacologically active or inactive and usually represent substrates for Phase II enzymes, 
which act to increase the polarity of a compound, through the process of conjugation, yielding a 
metabolite known as a “conjugate”, that is more readily excreted.  The process of converting a 
drug to a metabolite is often referred to as biotransformation and the four main categories of 
biotransformation include: oxidation, reduction, hydrolysis, and conjugation.  The first three 
comprise Phase I, while the fourth comprises Phase II reactions.     
1.3.1.1 Phase I Metabolism  
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing proteins having an 
iron protoporphyrin IX as the prosthetic group.  Their name comes from the spectral absorbance 
peak of their carbon-monoxide-bound species which was determined to be at 450 nm [60].   
Phase I metabolism is dominated by the microsomal mixed-function oxidase (MMFO) 
system which is involved in the metabolism of endogenous compounds (steroid hormones and 
fatty acids) as well as the biotransformation of xenobiotics.  The CYP450-catalysed mixed-
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function oxidation reaction is the most commonly studied drug metabolism reaction [61] and is 
carried out by incorporating one atom of molecular oxygen into the substrate while reducing the 
other atom of oxygen to water, with the corresponding enzymes being categorized as mono-
oxygenases.  Components of the system include cytochrome P450 (CYP450) and NADPH-
CYP450 reductase, where CYP450 are the substrate- and oxygen-binding site of the enzyme 
system and the reductase serves as an electron carrier, transferring electrons from NADPH to the 
CYP450 complex [62].  As a result, xenobiotics can undergo hydroxylations, epoxidations, N-, 
S-, or O-dealkylations, deaminations, or N- or S-oxidations, and oxidative dehalogenations, 
sulphoxide formation, dehydrogenations, and deaminiation of mono-and diamines [63].   
CYP450 isoforms are found in almost all living organisms and are widely distributed, but 
the largest concentration of CYP450s is located in the liver, predominantly in the membrane of 
the endoplasmic reticulum (ER).  Analysis of the human genome has identified 57 human 
CYP450 enzymes involved in the metabolism of xenobiotics [64], which are comprised of four 
major families: CYP1, CYP2, CYP3, and CYP4 of which CYP3A4 is the most abundant and 
constitutes approximately 30% of the hepatic CYPs in human liver [65].  In rat, the CYP1, 
CYP2, and CYP3 families are largely involved in biotransformation of xenobiotics.  Several 
CYP enzymes have orthologous forms in humans and rodents, although there are some 
differences in the expression and catalytic activities between human and rat CYP orthologs [66].  
In rat liver, the mRNA of several members of the CYP3A subfamily, including CYP3A1/23, 
CYP3A2, CYP3A9, and CYP3A18 have been detected [67].  CYP2C11 and CYP2C12 are major 
and constitutlively expressed CYP450 gene products in male and female rat liver, respectively 
[68, 69].  In rat liver, CYP2E1 demonstrates approximately 80% amino acid homology with the 
human form of CYP2E1 [70].  
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1.3.1.2 Phase II Metabolism  
Phase II conjugation leads to the formation of a covalent linkage between a functional group on 
the parent compound (or on a Phase I metabolite) with endogenously derived glucuronic acid, 
sulphate, glutathione, amino acids or acetate to produce a highly polar and water-soluble 
conjugate to that is more readily excreted in the urine or bile.  The uridine diphosphate 
glucuronyltransferases (UGT) superfamily represents an important family of proteins that 
catalyze the transfer of glucuronic acid from UDP-glucuronic acid (UDPGA) to the substrate 
molecule, to enhance water solubility and excretion. The UGTs have been classified into two 
subfamilies, namely UGT1A and 2B, and are located in the ER, which has physiological effects 
in neutralization of reactive intermediates formed by the CYP450 enzyme system.  Major Phase 
II reactions include glucuronidation, sulphation, acetlyation, and conjugation with glutathione or 
amino acids.  The net effect is usually considered to be inactivation or detoxification.   
1.3.2 Drug Transport System 
The liver plays an important role in the enterohepatic circulation of bile acids, as well as the 
detoxification of endogenous and exogenous compounds through biotransformation and biliary 
excretion of these compounds.  Hepatic drug elimination is a highly coordinated event, as drug 
disposition depends not only on the metabolism of a compound but also on the active uptake and 
efflux by specific transport proteins.  Drug transporters are a class of membrane-bound proteins 
involved in the transport of numerous endogenous compounds as well as xenobiotics and their 
metabolites.  Hepatic drug transporters serve a multitude of functions and play a critical role in 
the liver mediating drug uptake into hepatocytes and the translocation of compounds, such as 
bile acids, electrolytes, and xenobiotics, across biological membranes and elimination into bile.  
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Several lipophillic compounds move from the plasma into hepatic cytosol by simple or 
facilitated diffusion; however, numerous transport proteins are available on the sinusoidal 
(basolateral) membrane of the hepatocyte to mediate uptake of amphipathic and polar organic 
compounds.  In addition, hepatic efflux transport proteins located on the apical (canalicular) side 
of the hepatocyte play an important role in the excretion of drugs and metabolites from the 
hepatic cytosol into the bile [71, 72].  Due to their wide tissue distribution and high level of 
expression in the liver, intestine, kidney, placenta, and blood-brain barrier, drug transporters of 
several gene families serve a major role in defining the disposition of many xenobiotics and 
impact the elimination of drugs by mediating the cellular uptake and export of compounds into 
and out of cells responsible for the degradation of compounds, and are categorized as uptake and 
efflux transporters, discussed below.  
1.3.2.1 Uptake Transporters 
A major function of the liver is the uptake of a large number of endogenous organic anionic 
compounds and xenobiotics from the circulation.  Hepatic uptake of xenobiotics, waste products, 
and conjugated bile acid from the sinusoidal (basolateral) plasma membrane of the hepatocyte 
occurs by members of the superfamily of solute carriers (SLC), including the sodium-dependent 
taurocholate co-transporting polypeptide (NTCP, SLC10A) [73], the sodium-independent 
transport proteins including the organic anion transporter polypeptides (OATP, SLCO21A), and 
the organic cation transporter (OCT, SLC22A) families [74].  The substrate specificity for these 
transporters is broad and there is strong overlap between various members of the transporter 
families.  The varied affinities of these transporters for different compounds in portal blood 
provide specific and redundant means for extracting bile salts and other compounds from the 
blood and excreting them from the hepatocytes [75].    
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1.3.2.2 Efflux Transporters  
The bile canalicular membrane of the mammalian hepatocyte contains several primary active 
transporters which couple ATP hydrolysis to facilitate the transport of specific substrates into 
bile canaliculus [76, 77].  The largest family of hepatic drug transporters are comprised of the 
ATP-binding cassette “ABC” transporters [78], and are involved in the cellular efflux of 
xenobiotics and endogenous compounds from the hepatic cytosol into the bile.  
The formation of bile serves two vital functions: 1) it is a major route for the elimination 
of drugs, toxins and waste products, and 2) it ensures the secretion of bile salts, which are crucial 
for lipid emulsification and subsequent lipid absorption in the intestine.  Members of the ABC 
family of transporters include the multi-drug resistance protein (MDR1/P-glycoprotein, P-gp), 
multi-drug resistance associated protein (MRP) members 1-6.  MRP2, encoded by the ABCC2 
gene, is one of the most studied family members as it is involved in the biliary transport of 
glutathione and its conjugates.  An important endogenous substrate for MRP2 is conjugated 
(glucuronidated) bilirubin.  The hepatic canalicular membrane contains P-glycoprotein (P-gp), 
encoded for by the ABCB1 gene, responsible for cellular efflux of numerous clinically relevant 
therapeutic agents.  P-gp is expressed at the apical epithelium of the liver, intestine, kidney and 
blood-brain barrier [79]. The human genome contains a single MDR1 (P-gp), whereas two 
orthologs of human MDR1 exist in rodents, denoted as mdr1a/b (Abcb1a/b).  Other MDR gene 
family members include the liver canalicular bile salt export pump, BSEP/Bsep (or sister of P-
gp, spgp) and the hepatic phospholipid transporter MDR3 (mdr2 in rodents).  BSEP/Bsep pumps 
bile salts out of the hepatocyte, across the canalicular membrane and into bile and is the major 
transporter responsible for hepatic bile acid excretion and generation of bile flow.  The location 
of the aforementioned transporters is illustrated in Figure 3. 
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The activity and expression of drug transporters can be regulated by various factors 
including environmental, genetic, oxidative stress and inflammation.  The following section will 
provide an overview of the effect of inflammation on drug disposition.   
 
 
 
Figure 3: Hepatic drug transporters in human and rodent 
Modified from Faber et. al [80] 
1.3.3 Effect of Pro-inflammatory Cytokines on Drug Metabolism and Drug Transport 
During the host response to inflammation, inflammatory mediators, including pro-inflammatory 
cytokines, have been associated with altered content, expression, and activity of CYP450 
enzymes and drug transporters, consequently leading to alterations in the absorption, distribution, 
metabolism, and elimination of several drugs [81-85].  Usually, most CYP450s and drug 
transporters are down-regulated although a few may be refractory or actually up-regulated.  The 
losses in drug metabolism and transport are channeled predominantly through the production of 
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cytokines that ultimately modify the expression and function of specific transcription factors, e.g. 
Nuclear Factor-Kappa B (NF-κB).   
Acute inflammation of the liver typically begins with activation of the Kupffer cells, 
which initiates intracellular signaling cascades and culminates in cell activation.  Cytokines and 
other pro-inflammatory mediators, e.g. ROS, are released and adhesion molecules for leukocytes 
are expressed on the plasma membrane of non-parenchymal cells.  In particular, TNF-α is 
released from KCs early and plays a major role in precipitating downstream events.  
Hepatobiliary transporters are important determinants of drug clearance; they regulate the 
access of drugs to the drug-metabolizing enzymes as well as control drug concentrations in the 
hepatocytes, and are essential for normal bile formation and efficient drug metabolism. 
Alterations in the functionality, protein, and mRNA expression of transporters occur to varying 
degrees by drugs, metabolites, oxidative stress, and cytokines.  During the early post-transplant 
period, these effects can significantly alter drug disposition in this patient population, which has 
major implications when the capacity of the liver, and other organs, to handle drugs is severely 
compromised [81, 86-89].   
In addition, CYP450 activity represents an important marker of liver function in graft 
post-transplantation and decreased levels can influence the clinical response and, in worse cases, 
precipitate hepatic dysfunction or lead to graft non-function and or failure.  Several studies have 
indicated that drug metabolizing abilities post-transplantation are a reliable indicator of liver 
function in vivo [90-93].  In most cases, the decreased CYP activity is accompanied or preceded 
by decreases in hepatic levels of the corresponding P450 mRNAs and proteins (Morgan, 1997).  
Hepatic I/R injury has been shown to lead to damaged hepatocytes and bile duct cells, 
resulting in altered biliary secretion of endogenous compounds and altered pharmacokinetics of 
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drugs in the recipients.  Previous observations in liver transplant patients of a high RIA to HPLC 
ratio for cyclosporine A (RIA measuring parent and metabolite, while HPLC measuring the 
parent drug), indicated that formation of the metabolites was not altered but that biliary transport 
of the formed metabolites was, in grafts which exhibited early poor function post-OLT [94].  It 
was later shown that cyclosporine A is a P-gp substrate [95].  Similarly, ceftriaxone, a third 
generation cephalosporin, is excreted (approximately 40%) into the bile by the MRP2 protein 
and a lower clearance of this drug has been reported following OLT, suggesting hepatic 
dysfunction at the transporter level [96].   
Hepatic I/R injury is frequently associated with cholestasis, where the bile flow is greatly 
diminished and bile constituents begin to accumulate in hepatocytes, which causes an increase in 
oxidative stress and inflammation, and subsequently leads to hepatotoxicity.  Experimental 
studies have shown impaired hepatobiliary transport systems and the development of cholestasis 
as a result of down-regulation of canalicular transporters [97]. The result of reduced drug 
clearance, which accompanies inflammation and reduced blood flow, could be toxic or produce 
sub-therapeutic plasma drug concentrations.  Therefore, an agent that is capable of suppressing 
the pro-inflammatory cascade following reperfusion, while improving hepatic metabolism and 
transport capacity, would significantly improve the liver graft function and improve patient 
outcomes post-OLT. 
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1.4 PHARMACOLOGICAL APPROACHES TO PREVENT LIVER I/R INJURY 
Due to the many pathways and factors involved in the development and progression of I/R 
injury, many pharmacological approaches have been explored as therapies to minimize I/R-
induced hepatic injury, including anti-inflammatory, antioxidant, and vasodilatory therapy.  
Activation of Kupffer cells releases a variety of potentially harmful mediators, including 
TNF-α and ROS.  Eliminating Kupffer cells with gadolinium chloride has been shown to 
improve SEC structure and reduce hepatic I/R injury [98].  The role of TNF-α in initiating 
hepatic I/R injury has also been well documented [55, 99, 100].  Approaches to block TNF-α 
signaling pathway upon reperfusion include TNF-α antibodies, pretreatment with pentoxifylline, 
a methylxanthine derivative, which prevents TNF-α synthesis and release in KCs [100], or the 
use of TNF-receptor 1 knockout mice [55, 99, 101]. 
Antioxidant therapy, e.g. Vitamin E, also known by its chemical name α-tocopherol, is an 
important antioxidant which works as a radical scavenger to inhibit ROS generation.  A 
randomized clinical trial in 47 patients undergoing partial liver resection demonstrated that pre-
operative administration of Vitamin E to the recipient reduced liver enzymes (ALT and AST) 
and decreased intensive care unit stays [102].  Treatment with a multivitamin containing two 
antioxidants- α-tocopherol and ascorbate, in patients undergoing major liver surgery failed to 
show a significant difference in lactate levels, which correlated with ischemic times post-
operatively [103].  Allopurinol has also been tested for its inhibition of xanthine oxidase 
pathway, though no significant improvement in patient outcome was achieved [104].  
Agonists of endothelin (ET)-1 have been shown to cause contraction of isolated stellate 
cells in culture and to narrow the lumens of sinusoids in isolated perfused livers and well as 
intact cells [39], thereby, making ET-receptor antagonists targets for attenuation of 
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microcirculation disturbances [105].  To promote vasodilation, nitric oxide [106], carbon 
monoxide [107], and the prostaglandin (PG) class of drugs, including PGI2 [17] have been tested.  
The focus of this dissertation is the use of treprostinil, a PGI2 analogue, for protection of liver 
grafts against I/R injury in orthotopic liver transplantation.  
A summary of the mechanisms involved in hepatic I/R injury and some of the therapeutic 
strategies are illustrated below, in Figure 4.  
 
 
 
Figure 4: Targets of hepatic I/R injury 
Ca2+: calcium; ET: endothelin; HC: hepatocytes; KC: Kupffer cell; PAF: platelet activating factor; Plts: platelets; 
PMNs: polymorphonuclear leukocytes; ROS: reactive oxygen species; SEC: sinusoidal endothelial cell; IL: 
interleukin; modified from Montalvo-Jave et al. [16].  
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1.5 PROSTAGLANDINS IN VASCULAR HOMEOSTASIS  
Prostaglandins (PG) are a family of biologically active polyunsaturated fatty acids derived from 
arachidonic acid that possess a critical responsibility in maintaining vascular homeostasis of 
microcirculation.  The first step in PG synthesis is the liberation of arachidonic acid from 
membrane-bound lipids via the enzymatic actions of Phospholipase A2 and subsequent 
enzymatic metabolism through the action of cyclooxygenase, shown in Figure 5.  Prostaglandins 
contain a cyclopentane ring with two side chains, α and ω, and based on the ring modifications, 
they are classified into types A to I (PGA-PGI), then further classified by the number of double 
bonds (1, 2, or 3) in their side chains [108].  The enzyme responsible for PGI2 synthesis is 
prostacyclin synthase which is localized to the endoplasmic reticulum in endothelial cells and to 
the nuclear and plasma membranes in smooth muscle cells [109, 110].   
Classically, PGI2 mediates its biological effects through binding to cell surface 
prostacyclin receptors (IP), which couple via the stimulatory G protein, leading to activation of 
adenylyl cyclase and an increase in intracellular cyclic adenosine monophosphate (cAMP) 
signaling, which acts as a second messenger to inhibit platelet aggregation, cell proliferation and 
inflammatory mediator release [109, 111, 112].  The IP receptor is located on a variety of cells, 
including platelets, vascular smooth muscle, and endothelial cells, where PGI2 acts locally [113].  
The increase in cAMP leads to activation of protein kinase A and the subsequent 
phosphorylation of specific target proteins in platelets, resulting in anti-platelet activity as well as 
relaxation of vascular smooth muscle [108].  At the endothelial level, prostacyclin exerts anti-
inflammatory and anti-platelet activity and promotes an antithrombotic surface, which is required 
for proper function and maintenance of vascular integrity [114].   
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Prostacyclin is a potent endogenous inhibitor of platelet aggregation, which is reported to 
be 30-40 times more potent than PGE1 [115] and is involved in the complex interactions between 
vessel wall, blood and platelet function.  These actions provide protection against excessive 
vasoconstriction, platelet deposition, and cellular proliferation in the vessel wall [116].  
Interestingly, prostacyclin is extremely unstable and its activity disappears within 15 seconds of 
boiling or within 10 minutes at 22 oC at neutral pH, and in blood at 37 oC it has a half-life of 2-3 
minutes [117, 118].  Alkaline pH increases the stability of PGI2 so that at pH 10.5 (25 oC) it has a 
half-life of 100 hours, whereas at 4 oC, the half-life is reduced to 14.5 minutes [119].  Several 
analogues with improved stability have been developed, and are described in Section 1.5.1.  
 
 
 
Figure 5: Biosynthetic pathway of prostaglandins 
PG: Prostaglandin; TxA2: thromboxane. Modified from Narumiya et al. [108] 
   29 
1.5.1 Prostacyclin Analogues  
Several prostacyclin analogues have received FDA approval for their use in treatment of 
pulmonary arterial hypertension (PAH).  PAH is a rare disease characterized by a progressive 
elevation of pulmonary vascular resistance and pulmonary artery pressure, which often leads to 
right ventricular failure, ultimately resulting in death [120].  While the principle pharmacological 
effects of all prostanoids are similar due to their actions on the IP receptor, there are notable 
differences in the pharmacokinetics and metabolism, with a wide range in half-lives.  Also, the 
modes of application of PGI2 analogues vary from continuous intravenous infusion of 
epoprostenol to inhaled application of iloprost, to oral administration of beraprost, and 
subcutaneous infusion of treprostinil.  In addition, the doses vary, ranging from pg/kg/min to 
ng/kg/min.  As such, there is no set dose and each analogue is titrated to response. 
1.5.1.1 Epoprostenol  
Prostacyclin has been stabilized as a pharmaceutical preparation (epoprostenol) by freeze-drying 
and reconstitution in an alkaline glycine buffer [121].  Intravenous (IV) epoprostenol (Flolan®, 
GlaxoSmithKline, Durham, NC) is approved by the US Food and Drug Administration (FDA) 
for the treatment of PAH associated with the scleroderma spectrum of disease, and the structure 
is shown in Figure 6A [122].  
At neutral blood pH, epoprostenol is rapidly and spontaneously hydrolyzed to 6-keto-
PGF1α [119] and enzymatically metabolized to 6, 15-diketo-13, 14-dihydro-PGF1α [122].  
Neither metabolite has the same degree of biological activity as the parent compound.  Although 
this agent is an effective therapy for PAH, the administration of epoprostenol is complex.  
Epoprostenol requires daily reconstitution under sterile conditions and ice packs to be changed 
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every 12 hours unless the cassette is changed every 8 hr making it a cumbersome and 
inconvenient treatment option in this patient population.  Adverse effects include headaches, jaw 
pain, nausea, diarrhea, hypotension, and leg pain [123].  Long-term epoprostenol infusion is 
associated with problems due to its short half-life (2-3 minutes), which requires continuous IV 
infusion through a permanent catheter into a large central vein with an ambulatory infusion pump 
with all the associated risks which range from local infections, thromboembolic events, or life-
threatening sepsis [116].  Abrupt discontinuation of the infusion, i.e. catheter displacement or 
pump malfunction, can lead to episodes of worsening PAH and hemodynamic decompensation.  
Any interruptions in administration, could be life-threatening, in addition to its significant 
systemic side effects [113].  Due to these limitations, additional PGI2 analogues have been 
developed.  
1.5.1.2 Iloprost  
Iloprost (Ventavis®, Actelion Pharmaceuticals, San Francisco, CA) is an inhaled synthetic 
prostacyclin analogue, that produces potent pulmonary vasodilation and inhibits platelet 
aggregation [124].  In the U.S., iloprost has been approved by the FDA for oral inhalation using 
the I-neb® AAD® (Adaptive Aerosol Delivery) System or Prodose® AAD® Systems and the 
chemical structure is shown in Figure 6B.  In Europe, iloprost has been approved for use with 
two compressed air nebulizers with AAD® Systems (Halolite and Prodose) as well as with two 
ultrasonic nebulizers Ventaneb® and I-Neb®.  The half-life of iloprost is approximately 20-30 
minutes and the bioavailability after inhalation has not been determined [124].  Administration of 
this analogue is not ideal; patients are required to inhale 6-12 doses per day, which still may not 
be sufficient to cover a 24 hr cycle [123].  Adverse effects include flushing, headache, and 
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cough.  The long-term efficacy of iloprost is still under investigation and need to be addressed by 
large clinical trials.  
1.5.1.3 Beraprost  
Beraprost is a synthetic prostacyclin analogue that has been developed as an orally active agent.  
Beraprost acts by binding to prostacyclin membrane receptors to inhibit the release of 
intracellular calcium, which causes relaxation of the smooth muscle cells and vasodilation [125].  
The half-life is between 30 – 45 minutes [126] and the chemical structure is shown in Figure 6C.  
Adverse effects include jaw pain, headache, flushing, diarrhea, and palpitations.  A randomized, 
placebo-controlled trial was performed in the US and while the drug showed some benefit after 3 
and 6 months of treatment, no benefit was seen at 9 or 12 months [125].  Based on these data, 
beraprost has not been approved in the US.   
1.5.1.4 Treprostinil  
Treprostinil is a chemically stable PGI2 analogue, shown in Figure 6D.  In 2002, the US FDA 
approved treprostinil (Remodulin®, United Therapeutics, Durham, NC) for treatment of PAH.  
Treprostinil has an elimination half-life of 3-4 hours and it is rapidly and completely absorbed 
after subcutaneous (SC) administration with an absolute bioavailability of 100% and steady-state 
plasma concentrations are reached after approximately 10 hours [113].  Treprostinil is stable in 
sterile water or 0.9% sodium chloride at room temperature, which allows for IV or SC infusion 
without the need for ice packs.  Also, its solubility at physiologic pH enables SC delivery, 
thereby avoiding the potential complications of the epoprostenol IV delivery system.  
For patients with PAH, treprostinil provides an alternative to previous PGI2 analogues 
and has favorable pharmacokinetic and stability characteristics.  The longer stability in the 
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delivery system (up to 48 hours at room temperature) and a longer half-life increases the 
feasibility of rescue upon unintended interruptions or pump malfunctions, as well as the ease of 
dosage preparation. Treprostinil has many advantages over other PGI2 analogues, including a 3-
fold longer half-life and 6-fold increase in cAMP response than other PGI2 analogues [127], 
which make treprostinil an attractive candidate for protection of the liver graft against I/R injury 
during OLT. 
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Figure 6: Chemical structures of prostacyclin analogues 
A) Epoprostenol, B) Iloprost, C) Beraprost, and D) Treprostinil. Modified from Olschewski et al. [128] 
 
During liver transplantation, improving microcirculation through the liver graft during 
reperfusion and inhibiting platelet aggregation and pro-inflammatory cytokines are essential for a 
good post-operative prognosis [129, 130].  PGI2 is mainly synthesized in endothelial cells and 
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regulates various physiological processes occurring at the interface between the blood and 
endothelium [13], which may serve to protect the liver graft against I/R injury during OLT by 
maintaining hepatic blood flow, counteracting the activity of vasoconstrictors and platelet 
aggregation as well as the release of pro-inflammatory cytokines.  Despite extensive research, 
previous PG analogues tested for protection of liver grafts against I/R injury in OLT have been 
limited due to intolerable doses or failure to meet primary endpoints and, to date, have not 
successfully made their way into the clinic.  Treprostinil has the potential to restore therapeutic 
levels of PGI2 in liver SECs, thereby maintain vascular homeostasis, improve hepatic blood flow 
through the sinusoids, reduce platelet aggregation and inflammatory cytokines, and, ultimately, 
serve as a therapeutic option to protect liver grafts against I/R injury during orthotopic liver 
transplantation.   
1.6 CLINICAL EXPERIENCE WITH PROSTACYCLIN ANALOGUES IN LIVER 
TRANSPLANTATION  
Numerous strategies have been investigated as options to improve the ischemic tolerance of the 
liver and to minimize I/R injury in patients undergoing OLT, and the prostaglandin class of drugs 
is one such strategy [131-134].  Animal and human studies have shown a decrease in the ratio of 
PGI2 and TXA2 in I/R injury [135, 136] suggesting a potential therapeutic benefit of this class of 
drugs.  Analogues of PGE1 and PGI2 have been examined for their ability to protect the liver 
from I/R-induced injury due to their role in maintaining hepatic blood flow via dilation of the 
arterial and vascular bed, by inhibiting platelet aggregation [137], cell adhesion molecules, 
neutrophil activation, the generation of reactive oxygen species, leukocyte activation, migration, 
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and adherence, and inhibit the production and expression of pro-inflammatory cytokines [13, 
17].  Considering the many factors involved in I/R injury and the role of PGs in maintaining 
vascular and cellular homeostasis, as well as the primary target of I/R injury being the liver SECs 
[138, 139], PGI2 has a particular relevance in the setting of hepatic I/R injury associated with 
OLT.   
Since the late 1980s, PG analogues, i.e. PGE1 and PGI2, have been tested for their ability 
to reduce I/R-induced liver injury in several animal models [131-133, 137, 140] and in clinical 
liver transplantation [10, 141-149].  A summary of clinical trials investigating the use of PG 
analogues to reduce I/R injury in OLT is provided in Table 1.  Early studies using intravenous 
PGE1 were promising in minimizing primary liver graft non-function; however the clinical 
application of PGE1 and PGI2 has been limited by their inherent instability and very short half-
life, thus requiring intolerable doses in addition to not showing a significant difference in patient 
outcomes compared to placebo or historical control. In order to successfully treat an OLT patient 
with PGI2, it is crucial to understand the shortcomings of previous trials and identify an agent 
capable of overcoming previous limitations.  
Grieg et al. studied 16 patients with PNF.  Six patients were listed for re-transplantation 
and ten patients were started on an infusion of PGE1 within 4-34 hours post-transplantation and 
continued for 4-7 days [10].  The untreated group had a 33% survival rate whereas the PGE1 
treated group had a 90% survival rate.  Secondary findings of a significant decrease in peak 
serum aminotransferases and normalization of clotting factors were also reported.  The authors 
concluded that PGE1 reduced hepatocellular necrosis and improved liver function but 
recommended larger placebo controlled studies to confirm these findings.   
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 In 1992 -1993, UPMC reported inferior results in liver recipients with positive cytotoxic 
crossmatch that occurs in about 20% of liver transplant cases, i.e., the presence in the recipient of 
preexisting antidonor cytotoxic antibodies [150].  Combined treatment with intravenous PGE1 
and high doses of prednisone reduced the number of adverse outcomes [149].  A large number of 
patients who were crossmatch-negative also were treated in this study, and PGE1 treatment 
conferred important benefits in these recipients and it also significantly improved kidney 
function in liver recipients [147].  This finding was later confirmed in an extensive study in 
which patients treated with steroids and PGE1 had only a single case of primary liver graft non-
function (1 in 174 cases) compared to an incidence of 5.9% in historical controls who were 
treated with steroids only, though some patients did not tolerate PGE1 [148].  That same year, in 
1995, Henley et al. reported results from a double-blind, randomized placebo-controlled, single 
center trial of continuous infusion of PGE1 started during the anhepatic phase in 172 patients 
undergoing orthotopic liver transplantation. Although the trial failed to show an effect of 
treatment on patient and graft survival, the study’s primary endpoint, the study did show 
significantly shorter post-transplant ICU and hospitalization stays, reduced needs for renal 
support, and less need for surgical intervention other than re-transplantation in the active 
treatment group [141].    
Results from a subsequent randomized, double-blinded, multicenter trial of PGE1 infusion 
immediately following restoration of portal and arterial flow [142] were similar to those reported 
by Henley [141] and Takaya [147-149], although this study failed to demonstrate a difference 
between the two groups in the primary endpoint- reduction of PNF, peak serum aminotransferase 
and alkaline phosphatase levels were lower, and bile volumes were higher in the PGE1 group.  
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Also, infusion of PGE1 ameliorated post-transplant renal dysfunction, and a reduction in ICU 
days (PGE1: 4.0 ± 3.6 vs. placebo: 10.5 ± 17.1, P<0.01).  
One small placebo controlled study in patients evaluated the effect of a seven day 
infusion of PGI2 [144] immediately following reperfusion on hepatic dysfunction by measuring 
hepatic-splanchnic oxygenation and serum aminotransferase.  One year survival was 100% in 
placebo- and PGI2-treated groups; AST levels were lower in the PGI2 group, compared to 
placebo.  The study also demonstrated an improved hepatic-splanchnic oxygenation assessed by 
hepatic venous oxygen saturation (SvhO2) levels at 24 and 48 hours post-OLT, suggesting that 
treatment with PGI2 improves early microvascular blood flow by augmenting hepatic-splanchnic 
oxygenation.  
The previous studies have focused on treating the transplant recipient post-reperfusion of 
the liver graft.  Knowing that reperfusion exacerbates cold ischemic injury, PGI2 treatment 
commenced prior to reperfusion in the recipient may provide the most beneficial therapy for 
improving graft function.  A randomized trial treated the donor during liver retrieval of 106 
patients undergoing OLT with a 500 µg bolus of epoprostenol (PGI2) or no drug as control 
immediately before cold perfusion [143].  Significant reduction of peak levels of transaminases 
in the PGI2 group was observed, although neither group experienced PNF, and no differences 
between number of hospitalization days in the PGI2 and control group were noted.   
In summary, the prostaglandin-class of drugs, including prostacyclin and its analogues, 
could represent an important advancement toward the goal of reducing transplant related 
morbidity, mortality and associated costs by providing these benefits. Additionally, the reduction 
in serum creatinine and reduced need for post operative dialysis observed in some studies has 
implications in protecting the kidneys from the nephrotoxic affects of the immunosuppressant 
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agents, especially during the early post-operative period.  Routine use of PGE1 and PGI2, 
however, has been limited by its instability, short half life, and failure to show primary endpoint.  
Hepatic I/R injury remains a significant limitation in clinical liver transplantation and the need 
for therapy to reduce I/R injury is imminent, however, no therapy is currently available.  Due to 
its pharmacological properties, treprostinil has the potential to ameliorate I/R injury in human 
liver transplantation.  
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Table 1: Summary of previous clinical studies using PGI2 analogues to prevent I/R injury in OLT 
Author  Year PG analogue RTC Infusion 
timing 
Subjects 
PG/control 
Safety Outcomes 
    Pre Post    
Greig [10] 1989 Alprostadil 
(PGE1) 
No  X 10/6 Not reported Graft and patient 
survival:  80 and 
90% in PGE1 vs. 17 
and 33% in 
placebo, 
respectively. 
Takaya 
[149] 
1992 Alprostadil  Yes   X 14 Not reported  Superior renal 
function; graft 
protection with 
PGE1 
Takaya 
[147] 
1993 PGE1 Yes X X 41 Not reported  Improved renal 
function with PGE1 
Takaya 
[148] 
1995 Alprostadil No X X 174/304 1 death, 1 PNF, 1 
hepatic artery 
thrombosis, 1 
excessive bleed 
intra-op in PGE1 
PNF: 1.1 vs. 5.9% 
in PGE1 vs. 
historical control, 
respectively.  
Henley 
[141] 
1995 Alprostadil Yes X  78/82 2 patients 
withdrawn by 
attending without 
meeting PNF 
criteria 
Reduced ICU and 
hospital stay, renal 
support; Improved 
graft and patient 
survival; renal 
function with PGE1 
Klein 
[142] 
1996 Alprostadil Yes   X 58/60 10 patients 
discontinued (7 
placebo, 3 PGE1); 
death, liver 
failure, other 
Lower incidence of 
renal dysfunction 
and shorter ICU 
days with PGE1. 
Neumann 
[145] 
1999 Epoprostenol 
(PGI2) 
Yes   X 15/15 1 excluded  for 
bleeding, not 
related to PGI2 
infusion 
Improved ΔSO21; 
Initial poor 
function in 2 
control, 0 PGI2; 1 
PGI2 re-transplant 
Klein 
[143] 
1999 Epoprostenol  Yes X   53/53 Hypotension 
requiring 
catecholamine 
(30 PGI2, 26 
control) 
Donor with PGI2; 
Significant ALT 
and AST 
reductions (peak 
and AUC) 
RTC: Randomized controlled Trial; Infusion time in relation to transplantation; 1ΔSO2: a measure of hepatic-
splachnic oxygenation 
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1.7 HYPOTHESIS AND STUDY AIMS 
The process of I/R injury to the liver graft during OLT combines interrelated factors that produce 
a cascade of events, which can ultimately lead to hepatic graft failure.  Due to the multiple 
factors that contribute to hepatic I/R injury, conventional approaches that target one of these 
factors have not succeeded in solving this problem.  Considering the many factors involved in 
I/R injury, including increasing blood flow to the liver and inhibition of platelet aggregation and 
pro-inflammatory cytokines, and the role of PGI2 in maintaining cellular homeostasis, an agent, 
such as treprostinil, capable of combating the multiple factors involved in the development of I/R 
injury would have a particular relevance in the setting of I/R injury in OLT.  Such an agent 
would be a tremendous advancement to the field of liver transplantation and, perhaps, in solid 
organ transplantation. 
The ultimate goal for the use of treprostinil in liver transplantation is to protect the liver 
grafts against I/R-associated hepatic injury in adult patients undergoing OLT, and to increase the 
number of suitable grafts available for transplantation and patients who successfully recover 
from OLT.   The first step to fulfill this goal is to examine the hypothesis that treprostinil, based 
on the pharmacological properties, will protect the liver graft against I/R injury during rat OLT.  
This hypothesis is based on the ability of treprostinil, a prostacyclin analogue, to inhibit pro-
inflammatory cytokine expression, increase blood flow to the liver, and preserve homeostasis in 
the liver graft during transplantation, primarily by preserving liver SEC structure during cold 
storage and post-OLT.  We further hypothesized that I/R injury, as an inflammatory response, 
following OLT would significantly down-regulate the expression and activity of CYP450 drug 
metabolizing enzymes and drug transporters and that treprostinil would improve the metabolic 
and functional capacity of the liver graft post-transplantation.  
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To examine these hypotheses, it was first necessary to determine whether or not 
treprostinil was able to protect the liver graft against I/R injury in a rat OLT model, and this is 
discussed in Chapter 2.  The effects of I/R injury and treprostinil on 1) CYP450-mediated 
metabolism and 2) mRNA and protein expression of hepatic drug transporters in liver graft tissue 
post-OLT, has been examined in Chapter 3 and Chapter 4,  respectively.  In vitro studies to 
determine whether or not treprostinil could be safely co-administered without concern for a drug-
drug interaction studies between treprostinil and cyclosporine A, tacrolimus, sirolimus, and 
mycophenolic acid has been carried out in Chapter 5.  The conclusions and future research 
recommendations are discussed in Chapter 6.  Lastly, a Phase I/II clinical study in adult OLT 
patients has been initiated to examine the preliminary safety, efficacy, and pharmacokinetics of a 
two-day peri-operative course of treprostinil in adult patients undergoing OLT, and the protocol 
is presented in Appendix A.   
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2.0  TREPROSTINIL AMELIORATES ISCHEMIA-REPERFUSION INJURY IN RAT 
ORTHOTOPIC LIVER TRANSPLANTATION* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*N. Ghonem, J. Yoshida, D.B. Stolz, A. Humar, T.E. Starzl, N. Murase, and R. Venkataramanan. 
Treprostinil, a Prostacyclin Analogue, Ameliorates Ischemia-Reperfusion Injury in Rat 
Orthotopic Liver Transplantation. Submitted to American Journal of Transplantation, October 
2010. 
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2.1 INTRODUCTION 
Liver transplantation is the only therapy available for end-stage liver diseases; however, donor 
shortage is a major factor limiting the number of organs available for liver transplantation.  The 
current shortage of deceased donors has forced the expansion of the donor pool and has led 
centers to accept ECDs, i.e. older, non-heart beating, high steatosis, and those with prolonged 
ischemia.  These organs provide the much-needed additional grafts; however, they are more 
susceptible to I/R injury, which is an unavoidable process during liver transplantation and is a 
major cause of initial liver graft dysfunction [9, 29]. The need for therapy to reduce I/R injury in 
liver transplantation is imminent, unfortunately no treatment is available.  
Since the late 1980s, PG analogues, i.e. PGE1 and PGI2, have been explored as a potential 
therapy to reduce I/R injury in several animal models [131-133, 137, 140] and in clinical liver 
transplantation [10, 141-149], primarily due to their vasodilatory and platelet anti-aggregatory 
effects.  Some studies have shown PG therapy to be useful for prevention of liver injury 
following transplantation; however the clinical utility of PGE1 and PGI2 is limited due to their 
inherent instability, intolerable side effects, a very short half-life, and the inability to show a 
significant difference in primary endpoint.  Treprostinil sodium, a relatively new PGI2 analogue, 
is FDA-approved (Remodulin®) for the treatment of pulmonary arterial hypertension.  
Advantages of treprostinil include a longer elimination half-life and increased potency (three- 
and six-fold, respectively) as well as its stability at room temperature and neutral pH [127]. 
These advantages enable lower doses and correspondingly lower side effects, to achieve 
therapeutic efficacy.  Treprostinil has the potential to minimize I/R-associated hepatic injury in 
liver transplantation due to its cytoprotective effects, including its ability to preserve cellular 
homeostasis and microcirculation within the vasculature.  Use of an agent, such as treprostinil, in 
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the clinic may ultimately increase the number of suitable grafts available for transplantation, and 
improve overall patient outcome.  To the best of our knowledge, no PGI2 analogue has ever been 
tested for its ability to prevent I/R injury in a rat OLT model.  Therefore, the objective of this 
study was to examine the efficacy of treprostinil in protection of the liver grafts against I/R 
injury during rat OLT.  
2.2 MATERIALS AND METHODS 
2.2.1 Animals  
All procedures were performed according to the guidelines of the National Research Council’s 
Guide for the Humane Care and Use of Laboratory Animals and approved by the Institutional 
Animal Care and Use Committee at the University of Pittsburgh.  Male Lewis rats weighing   
200 - 300 g (Harlan Sprague Dawley, Inc, Indianapolis, IN) were maintained in a laminar-flow, 
specific-pathogen–free atmosphere at the University of Pittsburgh with a standard diet and water 
supplied ad libitum.  
2.2.2 Orthotopic Liver Transplantation Model 
The basic techniques of liver harvesting and OLT without hepatic arterial reconstruction were 
performed as previously described [151]. Briefly, rats were anesthetized with isoflurane 
inhalation and a midline incision in the abdominal cavity was made and the liver graft was 
excised and immediately flushed with cold UW solution, stored in UW solution at 4 oC for 18 
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hours, and orthotopically transplanted into recipients.  All surgeries were performed by the same 
surgeon.   
2.2.3 Treprostinil Administration 
Treprostinil (1 mg/ml) and placebo (sodium chloride, metacresol, sodium citrate, water for 
injection) were provided by United Therapeutics, Inc. (Durham, NC).  Treprostinil (100 
ng/kg/min) or placebo was administered to donor and recipient animals subcutaneously via an 
Alzet osmotic pump (Durect Corp., Cupertino, CA).  The surgeon was blinded to treatment. 
2.2.4 Experimental Design  
Donor animals received treprostinil or placebo 24 hours before hepatectomy and the 
corresponding recipient animal received the same treatment.  Recipients were sacrificed at 1, 3, 
6, 24, and 48 hours post-transplantation to examine the early events after I/R injury.  In 
additional sets of experiments, a group of recipients were treated with treprostinil or placebo 
(same dose) for 24 hours before surgery and until the time of sacrifice.  Only liver enzymes 
levels were measured in this additional group.   
2.2.5 Post-operative Care 
Recipients were kept under a heating lamp for approximately 2 hours and were given regular 
food and water ad libitum. The general condition of the rats was checked three times daily.  
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2.2.6 Liver Enzymes Levels 
Blood was collected at 6, 24, and 48 hours post-transplantation.  Serum alanine aminotransferase 
(ALT) and aspartate aminotransferase (AST) levels were measured by standard enzymatic 
methods in the clinical laboratory at UPMC. 
2.2.7 Histopathology 
Liver graft tissues were fixed in 10% buffered formalin, embedded in paraffin, cut into 6 um 
sections, and stained with hematoxylin and eosin (H&E). The percentage of necrotic area was 
estimated by the morphometric analysis of five randomly selected low-power fields (40x) per 
H&E section.  Neutrophils were stained with naphthol AS-D chloroacetate esterase-staining kit 
(Sigma Diagnostics, St. Louis, MO). Positively stained cells were counted in five high-power 
fields (200x) per section. 
2.2.8 RNA Extraction and Real Time RT-PCR Analysis 
Total RNA was extracted from liver tissue (50 – 100 mg) using TRIzol reagent (Invitrogen, 
Carlsbad, CA) according to manufacturer’s instructions.  RNA concentration was determined by 
UV absorbance at 260/280 nm (μQuant Microplate 25 Spectrophotometer) and RNA integrity 
was checked by 0.5% agarose gel electrophoresis stained with ethidium bromide.  Two 
micrograms of total RNA from each sample was used to generate first-strand cDNA by use of 
the First Strand cDNA synthesis kit (Promega, Madison, WI).  A reaction mixture containing 
200 U monkey myeloblastosis virus reverse transcription reaction (MMLV, Promega, Madison, 
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WI)-Reverse transcriptase, 1 mM dNTPs and 25 U RNasein (Promega) was added to the 
previous mixture and incubated at 37 °C for 60 minutes.  DNase-I treated total RNA from each 
sample was mixed with 0.5 µg of Random Hexamers (Promega) heated to 70 °C for 5 minutes 
then cooled to 4 °C.  Hepatic mRNA levels were measured by SYBR® Green PCR Master mix 
using primers purchased from Super Array Biosciences (Frederick, MD), listed in Table 2.  
Samples were analyzed in triplicate and relative gene expression was measured using the 
comparative CT method, using GAPDH as internal control.   
 
Table 2: Real-Time PCR assay IDs for genes detected by SYBR® green gene expression assays 
Gene Symbol Gene Name RefSeq Accession # 
TNF-α Tumor Necrosis Factor (TNF superfamily, member 2) NM_000594.2 
IL-1β Interleukin 1, beta NM_000576.2 
IL-6 Interleukin 6 NM_000600.3 
IL-10 Interleukin 10 NM_000572.2 
IFN-γ Interferon, gamma NM_000619.2 
Serpine1  Serpin peptidase inhibitor, clade E, member 1 NM_012620 
Pecam1 Platelet endothelial cell adhesion molecule 1 NM_031591 
ICAM-1 Intracellular cell adhesion molecule 1 NM_012967 
VCAM-1 Vascular cell adhesion molecule 1 NM_012889 
VEGF-α Vascular endothelial growth factor A NM_031836 
P-Selectin P-Selectin NM_013114 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase NM_017008.3 
   47 
2.2.9 Electron Microscopy 
Scanning electron microscopy (SEM) and transmission electron microscopy (TEM) analysis 
were performed on 2.5% gluteraldehyde in PBS perfusion-fixed liver, as previously described 
[152].  After labeling, tissue was dehydrated through graded-ethanol (30-100%), critical point 
dried (Emscope, CPD 750, Ashford, Kent, UK), and overcoated with carbon (108Carbon/A 
Coater, Watford, UK).  Tissues were visualized on a JEM-6335F SEM and a JEM 1210 TEM 
(JEOL, Peabody, MA).    
2.2.10 Hepatic Tissue Blood Flow  
A Laser-Doppler flow meter probe (ALF21N; Advance, Tokyo, Japan) was placed on the surface 
of the medial, left, and right hepatic lobe to measure hepatic-tissue blood flow in liver graft 
before and after transplantation. Measurements were repeated five times and recorded by the 
surgeon without knowledge of the treatment groups.   
2.2.11 Protein Estimation 
The protein concentration was determined according to the procedure of Bradford [153], using 
bovine serum albumin (BSA) as a standard.  The concentration was calculated based on the 
standard curve of known bovine serum albumin (BSA) concentration (0.025 – 0.4 mg/ml).  
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2.2.12 Hepatic Levels of Cyclic AMP  
Cyclic adenosine monophosphate (cAMP) levels were measured using an enzyme-linked 
immunosorbent assay (ELISA; R & D Systems, Frederick, MD) according to the manufacturer’s 
instructions.  Liver tissue was homogenized and assayed in triplicate. The optical density was 
calculated against a standard curve to determine the concentration of cAMP.   
2.2.13 Hepatic Levels of Adenine Nucleotides  
Liver samples were immediately frozen in liquid nitrogen and stored at –80 oC until the 
extraction procedure.  The frozen tissue was weighed (approximately 0.1 gm) and homogenized 
with a Polytron homogenizer (Brinkmann Inc., Westbury, NY) in 1.0 mL of ice-cold 6 % 
perchloric acid containing 0.77 mM ethylenediaminetetraacetic acid (EDTA).  The homogenate 
was centrifuged for 10 minutes at (4 oC) 10,000g (Beckham J25.15 Rotor) and the pH of 
supernatant was adjusted to 5-7 with 69% K2CO3 solution.  Following centrifugation (15 
minutes at 10,000g, 4 oC), the concentration of adenosine triphosphate (ATP), adenosine 
diphosphate (ADP), and adenosine monophosphate (AMP), hypoxanthine, xanthine, inosine, and 
adenosine were measured by high performance liquid chromatography (HPLC) with a Waters 
HPLC 2695 Alliance, Photodiode Array Detector, monitored at 254 nm (Waters, Inc., Milford, 
MA).  Reverse-phase column (E. Merk, Darmstadt, Germany; LiChrospher® 100 RP-18 (5 um), 
4 x 250 mm) was used with a precolumn (Waters; RCSS Guard-PAK) at 27oC.  The mobile 
phase consisted of A, 0.15 M ammonium dihydrogen phosphate buffer, pH 5-7 and B, 
acetonitrile and methanol (50:50) containing 1% triethanolamine.  The concentration  of ATP, 
ADP, and AMP, hypoxanthine, xanthine, inosine, and adenosine were calculated from a standard 
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curve constructed at the same time by means of standard powder (>99% pure) of ATP, ADP, and 
AMP, hypoxanthine, xanthine, inosine, and adenosine dissolved in the appropriate solution for 
each experiment.  Total adenine nucleotides (TAN) = ATP + ADP + AMP.   
2.2.14 Treprostinil Plasma Concentration 
The plasma concentration of treprostinil was measured by an ultra performance liquid 
chromatographic system equipped with a triple quadrupole tandem mass spectrometer (AB/MDS 
Sciex API-5000) detector operated in negative TurboIonSpray® mode.  Treprostinil-d4 was used 
as the internal standard.  Separation of treprostinil from extracted matrix materials was 
performed using a Waters BEH C18 (2.1 x 100 mm, 1.7 μm) column (Waters, Milford, MA) 
operated at 65 °C. The gradient mobile phase system consisted of (A) 0.1% formic acid in water 
and (B) 0.1% formic acid in acetonitrile at a flow rate of 0.775 mL/min.  The C.V. was less than 
2 % for this assay.  
2.2.15 Statistical Analysis 
Data are represented as the mean ± standard error of mean (SEM).  Comparisons between the 
groups were performed using Student’s t test or one-way ANOVA with Tukey’s post-hoc test 
using Prism software version 4.0 (GraphPad, San Diego, CA).  Significance was defined as P-
value < 0.05.  
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2.3 RESULTS 
2.3.1 Clinical Course and Assessment of Tolerability 
Following vascular anastomoses, there was no excessive bleeding in the treprostinil-treated 
group, relative to placebo.  Bile formation was immediate upon reperfusion of the liver graft in 
the treprostinil-treated group.  Treprostinil-treated animals functioned normally and appeared to 
recover sooner after surgery than the placebo-treated animals, which appeared weaker 
throughout the post-OLT period.  No difference in body weight was noted between the two 
treatment groups. 
2.3.2 Hepatic I/R Injury  
In the placebo-treated group, serum ALT and AST levels reached a peak of 2810 ± 202 and 4445 
± 951 IU/L, respectively, at 24 hours post-transplantation (Figure 7A and 7B).  Donor plus 
recipient treatment with treprostinil significantly reduced serum ALT and AST levels to 807 ± 
140 and 1231 ± 112 IU/L, respectively.  In the recipient only placebo-treated group, serum ALT 
and AST levels reached a peak of 2519 ± 239 and 5822 ± 222 IU/L, respectively at 24 hours 
post-reperfusion.  Liver injury was also reduced in the recipient only treprostinil-treatment 
group, albeit to a lesser extent then donor plus recipient treatment, reaching values of 1367 ± 306 
and 1469 ± 296 IU/L, respectively, shown in Figure 8A and 8B. 
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Figure 7: Hepatic injury in donor + recipient groups 
Serum ALT (A) and AST (B) levels at 6, 24, and 48 hrs post-reperfusion. *P < 0.05, **P < 0.01, ***P < 0.001 vs. 
placebo (n=3-4/group).   
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Figure 8:  Hepatic injury in recipient only groups 
Serum (A) ALT and (B) AST levels at 6, 24, and 48 hrs after reperfusion. *P < 0.05, ***P < 0.001 vs. placebo (n=3-
4/group).  
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B 
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At 48 hours post-transplantation, the necrotic area in the treprostinil-treated group (0.8 ± 0.03%) 
was significantly reduced, compared to placebo (41.7 ± 10.0%), shown in Figure 9.  Placebo-
treated grafts showed massive necrosis and severe congestion (Figure 10A), which was 
attenuated by treprostinil administration, shown in Figure 10B.  These results indicate that 
treprostinil-treated rats experienced a relatively low degree of hepatic injury, compared to 
placebo-treated rats.  
 
 
Figure 9: Percentage of necrotic area in liver grafts 
Comparison of necrotic area (%) in placebo- and treprostinil-treated animals at 48 hours post-transplantation. 
*P<0.05 vs. placebo (n=3-5/group).  
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Figure 10:  Representative histopathological images of liver grafts 
Necrotic area (arrows) in (A) placebo- and (B) treprostinil-treated animals at 48 hours post-reperfusion. H&E-
stained, original x40.  
 
2.3.3 Neutrophil Accumulation in Hepatic Tissue 
Neutrophil extravasation and accumulation contribute to the progression of I/R injury in liver 
[154].  The number of infiltrating neutrophils into the hepatic sinusoids rapidly increased in the 
liver grafts of placebo-treated animals, shown in Figure 11. In contrast, treprostinil 
administration reduced the number of neutrophils at 1, 3, and 48 hours after reperfusion, 
compared to placebo.  At 48 hours post-transplantation, neutrophils homogenously infiltrated the 
hepatic sinusoids in placebo-treated animals (Figure 12A), whereas treatment with treprostinil 
significantly reduced neutrophil infiltration, shown in Figure 12B.  
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Figure 11: Neutrophils in liver graft 
Comparison of neutrophil infiltration in placebo- and treprostinil-treated group at 1, 3, and 48 hrs post-reperfusion.  
Values are expressed as the number of cells per field of 1 mm2. *P < 0.05 vs. placebo (n=3-4/group). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: Neutrophil infiltration 
Neutrophil infiltration (arrows) in (A) placebo- and (B) treprostinil-treated animals; original x200. 
  
B 
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2.3.4 Cytokine Response 
The mRNA levels of pro-inflammatory cytokines peaked at one hour post-transplantation.  
Specifically, the mRNA expression of TNF-α, and IFN- γ were significantly increased in placebo 
group, which were suppressed by treprostinil administration (Figures 13A and 13B, 
respectively). Tissue mRNA levels of IL-6 (Figure 13C) were lower also in the treprostinil-
treated group vs. placebo.  The increase in IL-1β mRNA expression in placebo- and treprostinil-
treated group was minimal (Figure 13D).  This effect may be attributed to the circulation half-life 
of IL-1 of approximately 6 minutes [54], making its detection less likely than other cytokines.  
IL-10 has been shown to exert anti-inflammatory effects by inhibiting the activity of IkB kinase 
complex to prevent NF-kB translocation [155].  Treprostinil increased IL-10 mRNA levels, 
compared to placebo (Figure 13E).  Together, a reduction of pro-inflammatory cytokines and an 
increase in IL-10 expression is likely to have significantly contributed to the protective effect of 
treprostinil.  
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Figure 13: Peak mRNA expression of cytokines 
(A) TNF-α, (B) IFN-γ, C) IL-1β, and D) IL-6 in liver graft at 1 hr; (E) IL-10 in liver graft at 3 hrs post-OLT.  *P < 
0.05, **P < 0.01 vs. placebo (n = 3).  
 
Adhesion molecules and selectins promote leukocyte adhesion and migration, and thrombosis, 
which contribute to the progression of hepatic I/R injury [156].  To determine if treprostinil 
reduced cellular infiltration via blockade of these molecules, the mRNA expression of Serpine1, 
Pecam, ICAM-1, VCAM-1, P-selectin, and VEGF-α were examined at 1 and 3 hr post-OLT, 
shown in Figures 14A-F.  No remarkable differences in serpine1, PECAM, VCAM-1, VEGF-α, 
or P-Selectin expression between the treprostinil and placebo-treated group were observed, 
C D 
E 
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which indicate that treprostinil protected the liver graft against I/R injury independent of these 
pathways.  Notable findings in the treprostinil-treated group are reduced ICAM-1 mRNA levels 
at 3 hr post-OLT compared to placebo-treated group, with no significant difference between 
normal liver, shown in Figure 14C.  ICAM-1 is known to play an important role in the adhesion 
and infiltration of leukocytes in the vascular lining and parenchyma [157].  The results suggest 
that reduced ICAM-1 levels in the treprostinil-treated group participated in the reduction of 
hepatic injury in liver grafts.  
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Figure 14: Hepatic mRNA expression of adhesion molecules 
A) Serpine1, B) Pecam, C) ICAM-1, D) VCAM-1, E) VEGF, and F) P-selectin in liver graft at 1 and 3 hr post-OLT. 
#P < 0.05, †P < 0.01 vs. normal liver (n = 3). 
2.3.5 Liver Sinusoidal Endothelial Cells  
Having previously shown that the 18-hour cold ischemic storage induces significant SEC 
damage with many retracted cells [41], we conducted SEM analysis to investigate SEC ultra 
structural changes during the restorative period after OLT.  Figure 15A shows normal liver with 
intact SECs and typical fenestrations (arrows).  In contrast, at 1 hour post-reperfusion, placebo-
treated grafts showed a significant retraction of SECs (Figure 15B).  Furthermore, at 3-6 hours 
post-OLT, large areas of destroyed structural SEC lining with platelet infiltration within the 
sinusoidal surface was visible.  Stolz et al. [41] have shown that SECs recover from I/R-induced 
SEC denudation in approximately 24 -48 hours post-reperfusion.  Interestingly, as early as 1-3 
hours post-reperfusion, treprostinil-treated group showed preserved SECs (Figure 15C).  More 
impressive is that by 6 hours post-reperfusion, the treprostinil-treated group had detectable 
segments of intact liver SECs with show typical fenestration, similar to that of control.   
F E 
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Figure 15: Rat liver SEC analysis by SEM 
(A) Normal liver showing typical fenestration (arrows), (B) placebo- and (C) treprostinil-treated animals at 1, 3, and 
6 hours post-OLT. Data are representative of 3 separate animals. SEC, sinusoidal endothelial cell; P, platelet 
aggregation. 
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Additional morphological and intracellular detail was acquired using TEM analysis of liver graft 
early post-transplantation.  Normal liver with typical fenestration and close association with 
hepatocyte microvilli and space of Disse, shown in Figure 16A.  In placebo-treated animals, at 1 
hour post-reperfusion (Figure 16B), the sinusoidal surface of the placebo group was completely 
devoid of SECs, the space of Disse was greatly reduced, while macrophages and red blood cells 
infiltrated the sinusoidal space.  At 3-6 hours post-reperfusion, the placebo group developed 
sinusoidal congestion, endothelial cell detachment, increased platelet deposition, and hepatocytes 
showed vacuolization. Alternatively, treprostinil administration significantly alleviated these 
structural abnormalities.  Figure 16C shows that as early as 1 hour post-transplantation, liver 
graft from the treprostinil-treated group had preserved SEC fenestration and sinusoidal 
congestion was minimized.  Further, at 3 hours post-OLT, the restored proximity of SECs to 
hepatocyte microvilli and the space of Disse were visible, and a lack of platelet aggregation was 
noted.  By 6 hours post-reperfusion, the structure of SECs resembled that of a normal liver 
sinusoid.  These findings indicate that treprostinil preserved liver graft SEC structure and 
inhibited platelet, red blood cell, and macrophage infiltration into the sinusoid, thereby avoided 
hindrance of blood flow through the liver microvasculature in the early post-OLT period.  These 
findings indicate that treatment with treprostinil restored SEC structure similar to that of a 
normal rat as early as 6 hours post-OLT.    
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Figure 16: Rat Liver SEC analysis by TEM 
(A) normal, (B) placebo- and (C) treprostinil-treated liver grafts at 1, 3, and 6 hours post-OLT.  Data are 
representative of 3 separate animals. SEC, sinusoidal endothelial cell; M, macrophage; P, platelet aggregation; R,  
red blood cells.   
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2.3.6 Hepatic Tissue Blood Flow  
Hepatic tissue blood flow decreased to 56% of the pre-OLT levels and further decreased to 51% 
of the pre-ischemic levels at 3 hours post-reperfusion, in the placebo-treated group, shown in 
Figure 17.  Administration of treprostinil significantly increased pre-OLT hepatic tissue blood 
flow in donor graft to 150% of control.  At time zero, immediately post-reperfusion, hepatic 
tissue blood flow only dropped to ~80% of control in treprostinil-treated grafts.  Continuous 
treatment with treprostinil maintained approximately 70% of control blood flow at 3 hours post-
transplantation.  These results suggest that treprostinil preserved microcirculation through an 
increase in liver graft blood flow post-reperfusion.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17: Hepatic tissue blood flow in placebo- and treprostinil-treated animals 
Blood flow measured by Laser Dopper Flow-Meter immediately before donor graft harvest (Pre-OLT), immediately 
after reperfusion (time zero), and at 3 hours post-transplantation.  Results are expressed as a percentage of the pre-
OLT level in control group.  *P < 0.05, ***P < 0.001 vs. placebo (n = 3-6). 
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2.3.7 Tissue Concentration of Cyclic Adenosine Monophosphate 
To confirm that treprostinil acts as an agonist at cell surface prostanoid receptors (IP), cAMP 
levels were measured in hepatic tissue (Figure 18).  There was no difference in cAMP levels in 
the placebo-treated group compared to normal liver at all time points measured.  Alternatively, in 
the treprostinil-treated group, cAMP levels significantly increased to 353.2 ± 9.7 and 363.1 ± 
23.9 pmol/gm at 1 and 3 hours post-OLT, respectively, compared to normal (178.4 ± 36.7 
pmol/gm).  By 48 hours post-transplantation, the amount of cAMP increased to 438.2 ± 11.8 
pmol/gm in the treprostinil-treated group, compared to 166.4 ± 66.7 pmol/gm in the placebo-
treated group.  These results confirmed that treprostinil is a potent stimulator of the IP receptor.   
 
 
 
 
 
 
 
 
 
 
Figure 18: Hepatic tissue levels of cAMP 
Measured by ELISA. *P < 0.05 vs. placebo; #P < 0.05, †P < 0.01 vs. normal liver (n = 3-6). 
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2.3.8 Tissue Concentration of Adenosine Nucleotides 
The concentration of ATP soon after the onset of reperfusion of ischemic liver has been reported 
to be a good predictor of hepatic function [158].  Therefore, we examined whether an 
improvement of hepatic function after reperfusion by treprostinil was a result of a preserved 
energy metabolism.  Figures 19A-D shows the changes in hepatic tissue levels of adenine 
nucleotides after reperfusion.  The normal value of ATP in hepatic tissue was 6.8 ± 0.3 nmol/mg, 
and is shown in Figure 19A.  In the placebo-treated group, the post-ischemic tissue content of 
ATP was significantly reduced early post-OLT, an effect which lasted at all time points 
thereafter, until sacrifice at 48 hr post-OLT.  Cold storage caused an 80% reduction in ATP at 1 
hour post-reperfusion and levels only recovered to 30% (2.1 ± 0.3 nmol/mg) of normal, which 
resulted in a less than 50% recovery of total adenine nucleotides (10.7 ± 2.3 nmol/mg) at 48 
hours post-transplantation, compared to normal (22.5 ± 1.5 nmol/mg), shown in Figure 19D.  
While the re-synthesis of ATP remained suppressed in the placebo group, ATP levels 
significantly increased in the treprostinil-treated group, reaching nearly 80% (5.4 ± 1.6 nmol/mg) 
of normal by 48 hours post-reperfusion.  Furthermore, at 1 hour post-reperfusion, total adenine 
nucleotide levels in the treprostinil-treated group had fully recovered to 100% of normal values 
(26.5 ± 6.2 vs. 22.5 ± 1.5 nmol/mg, respectively).  These results suggest that treprostinil restored 
energy metabolism in the liver graft early post-OLT.   
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Figure 19: Hepatic tissue levels of adenine nucleotides 
(A) ATP, (B) ADP, (C) AMP, and (D) TAN at 1, 3, and 48 hrs post-OLT. *P < 0.05 vs. placebo; #P < 0.05, †P < 
0.01 vs. normal liver, (n = 3). TAN, total adenine nucleotide 
 
 
Accumulation of hypoxanthine is converted to xanthine by xanthine oxidase, which is 
accompanied by free radical production and capable of cell injury [159].  The increase in hepatic 
tissue levels of hypoxanthine (Figure 20A) and corresponding rise in xanthine (Figure 20B) in 
both the placebo- and treprostinil-treated groups suggested that treprostinil protected hepatic 
grafts from I/R injury independent of the xanthine oxidase pathway.  Alternatively, the preserved 
A B 
C D 
   67 
hepatic tissue levels of adenosine (Figure 20C) and increased levels of inosine (Figure 20D) in 
the treprostinil-treated groups is likely to have contributed to the resynthesis of ATP, which is 
dependent on available total adenine nucleotides as salvageable precursors for AMP synthesis 
after cold storage [32].  
 
  
 
 
Figure 20: Hepatic tissue levels of purines 
(A) hypoxanthine, (B) xanthine, (C) inosine, and (D) adenosine in liver grafts at 1, 3, and 48 hrs post-OLT. #P < 
0.05, †P < 0.01 vs. normal liver (n=3) 
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2.3.9 Treprostinil Plasma Concentration 
Based on therapeutic responses of treprostinil and corresponding plasma concentrations, a 
plasma concentration between 5-10 ng/ml was targeted for this study (Figure 21).  To achieve 
this concentration, the dose of treprostinil (100 ng/kg/min) was selected, which is within the 
range of tolerated doses in previous animal studies (Personal communication - Mike Wade, PhD, 
United Therapeutics, Inc.).  To reach steady-state plasma concentration at the time of 
hepatectomy and transplantation, it was necessary to begin treprostinil administration 
approximately 18 hrs prior to surgery.  Plasma concentrations in the placebo-treated group and 
normal rat plasma were below the limit of quantification (< 0.025 ng/mL).    
 
 
 
Figure 21: Treprostinil plasma concentration 
Plasma samples from treprostinil-treated animals at 1, 3, and 48 hours post-OLT (n = 3). 
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2.4 DISCUSSION 
Previous clinical studies using intravenous PGE1 were promising in minimizing ischemic injury, 
but the sample size was too small [10].  In the early 1990s, Takaya and colleagues [147, 149] 
demonstrated that PGE1 protected the liver graft from antibody-mediated rejection in crossmatch 
positive recipients comparable to negative cross matches and it also significantly improved 
kidney function in liver recipients.  Later, in 1995, Henley et al. [141] initiated PGE1 treatment 
during the anhepatic phase in patients undergoing OLT, but there was no significant effect on the 
primary end-points of patient or graft survival. However, the study showed significantly shorter 
intensive care unit stays and hospitalizations post-transplantation, reduced needs for renal 
support and less need for surgical intervention other than re-transplantation in the treatment 
group.  The same year, Takaya et al. [148] reported successful treatment of adult liver recipients 
for PNF with postoperative PGE1 therapy. Despite improved 1-year graft survival and a lower 
incidence of PNF in the PGE1 group vs. historical control, some patients did not tolerate PGE1.  
Subsequently, Neumann et al. [144] showed that epoprostenol (PGI2) improved early 
microvascular blood flow and that it could be safely administered to adult patients post-
operatively; however the primary endpoint of this study was not met.   
Prostaglandins (PGE1 and PGI2) play a critical role in maintaining vascular homeostasis 
of microcirculation, which contributes to its wide range of protective effects against I/R-induced 
liver injury [2, 17, 138].  Stable PGI2 analogues have been shown to produce vasodilation of 
pulmonary and systemic arterial vascular beds and inhibition of platelet aggregation [127].  In 
addition, PGI2 analogues have been reported to maintain blood flow, inhibit local vascular 
thrombosis, and decrease leukocyte activation by inhibiting TNF-α production and other pro-
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inflammatory cytokines, neutrophil activation and adhesion to the vascular endothelium, and 
counteract the activity of vasoconstrictors and platelet aggregation [17, 139].   
In this study we evaluated the effect of treprostinil, a commercially available PGI2 
analogue, for protection of liver grafts against I/R injury during OLT.  Advantages of treprostinil 
over other PGE1 and PGI2 analogues include its increased stability, as well as longer elimination 
half-life, and increased potency (three- and six-fold, respectively) [127].  The current study 
provided evidence for the multiple factors involved in I/R injury and for the protective effect of 
treprostinil, which included morphological evidence of a preserved SEC structure, preserved 
energy stores, in addition to the class-wide effects of PGs.  Treprostinil has the potential to 
minimize I/R injury during clinical OLT, and ultimately increase the number of suitable grafts 
available for transplantation and improve overall patient outcomes.  
To a greater or lesser extent, the surgical procedure of human liver transplantation 
exposes the liver graft to three different types of ischemia, warm ischemia- before organ 
procurement; cold ischemia- during graft preservation; and rewarming ischemia- during graft 
implantation [8].  Most experimental models in the rodent employ a technique of clamping the 
hepatic artery and or the portal vein to induce hepatic I/R injury.  While this procedure occludes 
hepatic blood flow and induces ischemic damage to the liver, it does not reflect the ischemic 
injury which occurs during graft preservation, when liver grafts are stored in cold UW 
preservation solution, before implantation into the recipient, i.e. in clinical OLT.  The primary 
targets of cold I/R injury are the liver SECs, whereas hepatocytes are the main targets in warm 
ischemia [58].  Damage to SECs leads to loss of microvascular integrity, decreased blood flow, 
and an accumulation of neutrophils in the liver allograft.  Further platelet aggregation, local 
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tissue destruction, up-regulation of inflammatory cytokines, and structural alterations in tissue 
leads to hepatocellular dysfunction [9, 29].  Several mechanisms of ischemic injury share a 
common pathway, however, there are important differences between the warm and cold ischemia 
model, most notably being the targets of cellular injury, which require the OLT model to fully 
characterize I/R injury during clinical OLT.  
SECs have a crucial role in the overall homeostasis with the microvasculature, 
accounting for approximately 70% of the cell population within the liver sinusoid [40] and 
destruction of these cells during I/R injury significantly augments liver graft injury post-
transplantation [29].  Ischemic injury to the endothelium disrupts the delicate homeostasis in the 
microcirculation [29], leading to prominent intra-sinusoidal coagulation, which promotes 
neutrophil activation and adhesion, platelet aggregation, resulting in a reduced hepatic blood 
flow and impeding hepatic microcirculation. Treprostinil-treated animals exhibited an almost 
completely preserved SEC lining, complete with fenestration resembling that of normal, as early 
as six hours post-reperfusion, indicating the effects of treprostinil on leukocyte adherence is part 
of its favorable interactions between leukocytes and endothelial cells.  A result of this interaction 
is the prevention of damage to SECs, which includes attenuation of swelling of sinusoidal lining 
cells and hepatocytes to avoid hindrance of blood flow through the liver microvasculature during 
reperfusion. Improved preservation of the endothelial cell lining, along with a reduced release of 
pro-inflammatory cytokines, will avoid accumulation and activation of granulocytes, thereby 
limiting local concentration of deleterious cytotoxic oxygen free radicals.  Increasing blood flow 
to the liver during reperfusion and inhibition of platelet aggregation and pro-inflammatory 
cytokines are essential for a good post-operative prognosis, and treprostinil appears to have 
accomplished these goals.   
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The initial ischemic injury is a result of tissue deprivation of oxygen, which disturbs the 
intracellular energy metabolism and enzyme function, resulting in a depletion of adenine 
nucleotides leading to cellular edema [160].  Secondary results of the oxygen disturbance and 
progressive degradation of energy metabolism are reflected by the destruction of tissue and 
cellular structures [29].  Cyclic AMP, an important intracellular second messenger in many cell 
types, is reported to produce an efflux of ischemia-induced accumulated intracellular calcium, 
which prevents ATP depletion, stabilizes the hepatocellular membrane, and preserves 
intracellular adenine nucleotides [161].  The reduction of intracellular calcium results in 
vasodilation [161].  Addition of the membrane permeable cAMP analogue, dibutyryl-cAMP, to 
preservation solution resulted in significantly enhanced metabolic activity and secretion function 
demonstrated by cumulative bile production of reperfused liver following 24 hr cold graft 
storage [162].  Traditionally, PGI2 and its analogues exert their biological effects by binding to 
cell surface IP receptors, which couple via the stimulatory G protein to stimulate adenylyl 
cyclase and activate intracellular cAMP [111] to act as a second messenger of PGI2 on vascular 
smooth muscle, platelets, endothelial cells, and neutrophils [161].  The concentration of cAMP 
depends on the balance between its synthesis and degradation in the cytoplasm; this molecule is 
formed by ATP in the reaction catalyzed by adenylyl cyclase, and catabolized by cyclic 
nucleotide phosphodiesterase [163].  Thus, homeostasis within the vasculature is achieved by 
maintaining the PGI2/TxA2 balance, where each substance has opposing effects on cAMP [109], 
thereby regulating various physiological processes occurring at the interface between the blood 
and endothelium.   
Loss of SEC viability, as determined morphologically, was completed after 24 hours or 
longer of ischemic storage [164].  While cold storage times for human transplantation varies 
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widely, animal studies focus on storage times of up 18 hrs, with some extended to 24 hrs or 
more.  We employed a rat model with 18 hr of cold ischemic storage to induce significant 
hepatic injury.  Considering the many factors involved in I/R injury and the role of PGI2 in 
maintaining cellular homeostasis, treprostinil has a particular relevance in the setting of I/R 
injury in OLT. Treprostinil therapy could be administered to patients undergoing OLT as a 
clinical strategy against hepatic I/R injury because of its simple method of application prior to, 
during the surgery, and the early post-transplant period.  After demonstrating efficacy in the 
current treatment model (donor plus recipient), additional animals were included to examine the 
efficacy of treprostinil in a treatment model (recipient only) which more closely resembles that 
of the clinical situation.  Results from the recipient only treatment group showed significantly 
reduced hepatocellular injury, supporting the clinical utility of this agent.  Recently, Sakai et al. 
demonstrated that treprostinil could be safely administered at doses >100 ng/kg/min to adult 
patients with pulmonary arterial hypertension, who were not therapeutically controlled by other 
PGI2 analogues.  This conversion enabled two of the patients to successfully undergo OLT [165].  
No hemodynamic issues were observed during surgery, indicating safety of treprostinil 
administration during OLT.  
In conclusion, the process of I/R injury to the liver during OLT combines interrelated 
factors that produce a cascade of events, which can ultimately lead to hepatic graft failure. I/R 
injury remains a significant limitation in clinical liver transplantation.  The significance of this 
study is in demonstrating that treprostinil is an effective approach to ameliorate hepatic I/R 
injury associated with rat OLT.  In addition, the results of this study strongly support clinical 
investigation of treprostinil as a potential therapy for the protection of liver grafts against I/R 
injury during OLT.  This finding is an important advancement to the field of liver transplantation 
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and, potentially, to the field of solid organ transplantation.  Amelioration of hepatic graft injury 
with treprostinil may improve both short- and long-term transplant outcomes.  
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3.0  EFFECT OF ISCHEMIA-REPERFUSION INJURY ON DRUG METABOLISM 
DURING RAT ORTHOTOPIC LIVER TRANSPLANTATION* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*N. Ghonem, J. Yoshida, N. Murase, S.C. Strom, and R. Venkataramanan.  Ischemia-reperfusion 
decreases CYP450 Metabolism during Rat Orthotopic Liver Transplantation.  Submitted to Drug 
Metabolism and Disposition, January 2011. 
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3.1 INTRODUCTION 
Ischemia-reperfusion injury, an inflammatory disease-state manifested during OLT, significantly 
contributes to the impaired function of the transplanted liver graft.  Inflammatory mediators, 
including pro-inflammatory cytokines, have been shown to reduce the metabolism of drugs 
primarily by the down-regulation of cytochrome P450 (CYP450) enzymes expression and or 
activity [85].  An alteration in drug metabolism as a result of inflammation or infection has major 
implications when the capacity of the liver, such as the case during liver transplantation, and 
other organs to handle drugs is severely compromised.  Decreased catalytic activities of hepatic 
CYP450 enzymes can cause dose-dependent drug toxicity associated with impaired in vivo drug 
clearance [85, 166, 167].  The resulting outcomes of reduced drug clearance, which accompanies 
inflammation and states of reduced blood flow, could be toxic or sub-therapeutic plasma drug 
concentrations [168].   
The CYP450 enzyme system reflects the liver’s ability to metabolize drugs [169] and 
several studies have indicated that CYP activity is an important indicator of liver graft function 
post-transplantation [90-93].  Experimental animal studies have shown that live bacterial, viral, 
and parasitic infections are each capable of down-regulating the activities and or expression of 
CYP450 enzymes in the liver during inflammation [85, 166, 170].  Several models of 
inflammation, i.e. partial hepatectomy or LPS-stimulation, have also been used to examine the 
effect of inflammation on different subsets of hepatic P450s in vivo [85, 171].  Limited data exist 
on the direct effect(s) of hepatic I/R injury on CYP450 expression and activity in an OLT model, 
following graft storage in cold UW solution.  Therefore, to more closely examine the hepatic 
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injury which occurs during clinical liver transplantation, we performed this study to examine the 
effect of I/R injury on the CYP450 mRNA and protein expression and activity on the major rat 
hepatic CYP450 enzymes and the impact of treatment with treprostinil to prevent I/R injury in a 
rat OLT model.  
3.2 MATERIALS AND METHODS 
3.2.1 Chemicals 
Chlorzoxazone (CZN), 6-hydroxychlorzoxazone (6-OH CZN), nicotinamide adenine 
dinucleotide phosphate-oxidase (NADPH), and testosterone (TST) were purchased from Sigma 
(St. Louis, MO).  2α-, 6β-, and 16α-hydroxytestosterone (2α-, 6β-, and 16α-OH TST, 
respectively) were purchased from Steraloids (Newport, RI).  Midazolam (MDZ) and 1-
hydroxymidazolam (1-OH MDZ) were purchased from Toronto Research Chemistry (Ontario, 
CA).  Methanol and water [high-performance liquid chromatography (HPLC) grade] were 
purchased from Thermo Fisher Scientific (Waltham, MA).  All other chemicals used were of 
HPLC grade or the highest purity available.  
3.2.2 Animals 
All procedures were performed according to the guidelines of the National Research Council’s 
Guide for the Humane Care and Use of Laboratory Animals and approved by the Institutional 
Animal Care and Use Committee at the University of Pittsburgh.  Male Lewis rats weighing 200 
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- 300 g (Harlan Sprague Dawley, Inc, Indianapolis, IN) were maintained in a laminar-flow, 
specific-pathogen–free atmosphere at the University of Pittsburgh with a standard diet and water 
supplied ad libitum.  
3.2.3 Orthotopic Liver Transplantation 
The basic techniques of liver harvesting and OLT without hepatic arterial reconstruction were 
performed as previously described [151]. Briefly, rats were anesthetized with isoflurane 
inhalation and a midline incision was made in the abdominal cavity and the donor liver was 
excised and immediately flushed with cold UW solution, stored in UW solution at 4 oC for 18 
hours, and orthotopically transplanted into recipients.  All surgeries were performed by the same 
surgeon.   
3.2.4 Treprostinil Administration 
Treprostinil (1 mg/ml) and placebo (sodium chloride, metacresol, sodium citrate, water for 
injection) were provided by United Therapeutics, Inc. (Durham, NC).  Treprostinil (100 
ng/kg/min) or placebo was administered to donor and recipient animals subcutaneously via an 
Alzet osmotic pump (Durect Corp., Cupertino, CA).  The surgeon was blinded to treatment. 
3.2.5 Experimental Design  
Donor animals received placebo or treprostinil (100 ng/kg/min) for 24 hours before hepatectomy 
and corresponding recipient animals received placebo or treprostinil for 24 hours before 
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transplantation and until the time of sacrifice, to ensure steady-state concentrations.  Recipients 
were sacrificed at 1, 3, 6, and 48 hours post-transplantation.  
3.2.6 RNA Extraction and Real Time RT-PCR Analysis 
Total RNA was extracted from liver tissue (50 – 100 mg) using TRIzol reagent (Invitrogen, 
Carlsbad, CA) according to manufacturer’s instructions.  RNA concentration was determined by 
UV absorbance at 260/280 nm (μQuant Microplate 25 Spectrophotometer) and RNA integrity 
was checked by 0.5% agarose gel electrophoresis stained with ethidium bromide.  Two 
micrograms of total RNA from each sample was used to generate first-strand cDNA by use of 
the First Strand cDNA synthesis kit (Promega, Madison, WI).  A reaction mixture containing 
200 U monkey myeloblastosis virus reverse transcription reaction (MMLV, Promega, Madison, 
WI)-Reverse transcriptase, 1 mM dNTPs and 25 U RNasein (Promega) was added to the 
previous mixture and incubated at 37 °C for 60 minutes.  DNase-I treated total RNA from each 
sample was mixed with 0.5 µg of Random Hexamers (Promega) heated to 70 °C for 5 minutes 
then cooled to 4 °C.  Hepatic mRNA levels were measured with the TaqMan® system using 
primers purchased from Applied Biosystems, listed in Table 3.  Samples were analyzed in 
triplicate and relative gene expression was measured using the comparative CT method, with 
GAPDH as internal control.   
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Table 3: Real-Time PCR assay IDs for genes detected by TaqMan® gene expression assays 
Gene  Symbol                                        Gene Name RefSeq Accession # 
CYP3A1/3A23 Cytochrome P450, family 3, subfamily a, polypeptide 1/23 NM_013105.2 
CYP3A2 cytochrome P450, family 3, subfamily a, polypeptide 2 NM_153312.2 
CYP3A18 cytochrome P450, family 3, subfamily a, polypeptide 18 NM_145782.1 
CYP2E1 cytochrome P450, family 2, subfamily e, polypeptide 1 NM_031543.1 
CYP2C7 cytochrome P450, family 2, subfamily c, polypeptide 7 NM_017158.1 
CYP2C11 cytochrome P450, family 2, subfamily c, polypeptide 11 NM_019184.2 
CYP2D3 cytochrome P450, family 2, subfamily d, polypeptide 3 NM_173093.1 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase NM_017008.3 
3.2.7 Preparation of Liver Microsomes 
Snap-frozen slices of liver were used to prepare microsomes by a standard differential 
centrifugation procedure with minor modifications [172].  Briefly, liver pieces were 
homogenized with 3 volumes of a homogenization buffer (50 mM Tris-HCl buffer, 1.0% KCl, 
and 1 mM EDTA, pH 7.4) using an electrical homogenizer (Polytron, Brinkmann Instruments, 
Westbury, NY). The crude homogenate was centrifuged (Optima XL-100K ultracentrifuge, 
Beckman Instruments, Palo Alto, CA) at 10,000g for 20 minutes (4 °C). The supernatant was 
further centrifuged at 105,000g for 65 min at 4 °C. The microsomes were reconstituted using a 
manual glass homogenizer (Wheaton, Millville, NJ) with 50 mM Tris-HCl buffer (pH 7.4) 
containing 20% glycerol.  Aliquots were immediately stored at -80 °C until used. The protein 
content of microsomes was determined by the Bradford method [153] using BSA as standard.  
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3.2.8 Western Blot Analysis of Microsomal P450 Protein Expression 
Protein levels of CYP2E1, 2C11, and 3A2 in rat liver microsomes were measured by western 
blot analysis.  Microsomal protein (25 ug) was separated by SDS-polyacrylamide gel 
electrophoresis (10% NuPAGE, Invitrogen, Carlsbad, CA).  The proteins were transferred to a 
PVDF membrane, briefly incubated in Ponceau S (Sigma-Aldrich) to ensure equal protein load 
on membrane and complete transfer, then blocked overnight with TBST containing 5% Non Fat 
Dry Milk (Bio-Rad).  After washing in TBST, membranes were probed with polyclonal rabbit 
anti-rat CYP2E1, CYPC11, or CYP3A2 antibodies (1:10,000; 1:4,000, and 1:5000, respectively; 
Abcam, Cambridge, MA).   Next, the membranes were washed and probed with a secondary 
monoclonal goat anti-rabbit IgG antibody coupled to horseradish peroxidase (1:20,000; Abcam).  
Immunodetection was performed using an ECL detection kit (Thermo Scientific, Rockford, IL).  
The density of the protein bands were quantified using ImageJ software 1.40 (National Institutes 
of Health, Bethesda, MD).  Values were normalized to GAPDH (1:30,000; Abcam).   
3.2.9 Microsomal Incubations 
Conditions for each substrate were optimized by varying the time of incubation, the protein 
concentration, and substrate concentration such that each reaction took place in the linear 
working range.  The incubation included microsomes, MgCl2 (10 mM), and phosphate buffer 
(0.1 mM), pH=7.4.  The samples were pre-incubated in a shaking water bath for 5 min at 37 °C 
before addition of NADPH (1 mM) to initiate the reaction. All reactions were terminated upon 
addition of ice-cold methanol.  Following termination, samples were centrifuged at 3,000 rpm for 
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10 minutes at 4 oC and samples were analyzed immediately.  Normal liver represent samples 
from healthy rats not subjected to OLT.   
3.2.10 Chlorzoxazone Assay  
The formation of 6-OH CZN from CZN was used to measure CYP2E1 activity.  Microsomal 
incubations contained 0.75 mg/ml microsomal protein and 200 uM of CZN.  Samples were 
incubated for 30 minutes at 37 oC in a shaking water bath.  The concentration of 6-OH CZN was 
measured using an Alliance HPLC system (Waters 2695, Milford, MA) with a Photodiode Array 
detector (Waters 2998) set at 297 nm.  The mobile phase consisted of acetonitrile: 0.25% acetate 
(18:82) pH 3.8 at a flow rate of 1.2 ml/min and 6-OH CZN was separated using a Symmetry® 
C18 (4.6 x 250 mm, 5 um) column (Waters).   The formation rate was calculated from a standard 
curve of known concentration of 6-OH CZN (0.15 – 10 ug/ml).  The C.V. was less than 10% for 
this assay. 
3.2.11 Testosterone Assay  
The main male-specific isoform of cytochrome P-450 is 2C11 which gives a high yield of 
oxidized testosterone in positions 2α- and 16α- [173, 174]. Therefore, the formation of 2α- and 
16α-OH TST from TST was used to measure CYP2C11 activity and the formation of 6β-OH 
TST was used to measure CYP3A activity.  Microsomal incubations consisted of 0.5 mg/ml 
microsomal protein and 150 uM TST, final volume 0.25 mL.  Samples were incubated for 20 
minutes at 37 oC in a shaking water bath.  The concentrations of 2α-, 6β-, and 16α-OH TST were 
measured by HPLC-UV.  Compounds were separated using a LiChrospher® 100 C18 (4.6 x 250 
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mm, 5 µm) column (Merck, Gibbstown, NJ).  The mobile phase consisted of 60% methanol in 
water.  The HPLC system consisted of an autosampler (Waters 717, Milford, MA) and solvent 
delivery system (Waters 501) attached to a UV detector (Waters 486), set at 242 nm. The 2α-, 
6β-, and 16α-hydroxylation activities of TST were calculated from a standard curve of known 
concentration (0.2 -10 ug/ml). The C.V. was less than 10% for this assay.    
3.2.12 Midazolam Assay  
Midazolam is predominantly metabolized to 1-OH MDZ by CYP3A1 and CYP3A2 in rats and 
thus it can be used as a biomarker of CYP3A activity in vivo [174].  Microsomal incubations 
contained 0.375 mg/ml microsomal protein and 0.3 uM of MDZ. The samples were incubated for 
20 minutes in a shaking water bath at 37 oC. The mobile phase consisted of (A) 2 mM 
ammonium acetate with 0.1 % formic acid in 5% methanol and (B) 100% methanol at a flow rate 
of 0.3 ml/min.  MDZ and 1-OH MDZ were separated using a Symmetry® C18 (2.1 x 50 mm, 3.5 
um) column (Waters) with a Symmetry® (2.1 x 10 mm, 3.5 um) guard column (Waters). The 
Alliance HPLC (Waters 2695, Milford, MA) was attached to a Quatromicro™ mass 
spectrometer (Waters), operated in positive electrospray ionization.  The selected reaction 
monitoring transitions of m/z 326.05 → 291.05 (collision energy 28 eV, cone voltage 55) for 
MDZ; m/z 341.87 → 323.97 (collision energy 20 eV, cone voltage 37) for 1 -OH MDZ; m/z 
331.09 → 295.97 (collision energy 28 eV, cone voltage 55) for deuterated midazolam were 
monitored. Parameters were optimized to obtain the highest [M+H] ion abundance and were as 
follows: source temperature, 100 °C; capillary voltage, 0.8 kV; desolvation temperature, 500 °C; 
cone gas flow, 50 L/hr; desolvation gas flow, 50 L/hr.  Analytical data were analyzed using 
Masslynx software version 4.1 (Waters).  The formation rate of 1-OH MDZ was calculated by 
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use of a standard curve of known concentration of 1-OH MDZ (1.25 – 25 ng/ml).   The C.V. was 
less than 5% for this assay. 
3.2.13 Statistical Analysis 
Data are represented as the mean ± SEM. One-way ANOVA was performed to determine the 
difference between groups, followed by Bonferroni post-hoc analyses, using Prism software v4.0 
(GraphPad, San Diego, CA).  Differences were considered significant at a P-value < 0.05.  
3.3 RESULTS 
3.3.1 Hepatic I/R Injury 
In Chapter 2, we demonstrated that treprostinil significantly reduced serum ALT and AST levels 
compared to the placebo-treated groups (Figures 7 and 8).  Corresponding areas under the curve 
(AUC) from 0 to 48 hours post-reperfusion of serum ALT and AST were calculated by non-
compartmental analysis using WinNonlin® software (Pharsight, Mountain View, CA).  In both 
the donor + recipient (D+R) and recipient only (R) treatment groups, administration of 
treprostinil resulted in significantly lower AUC values, compared to the placebo-treated group, 
listed in Table 4 and 5, respectively.  The results indicate that treprostinil-treated rats 
experienced significantly less hepatic injury than placebo-treated rats in both treatment groups.  
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Table 4: AUC0 -48 hrs post-reperfusion serum ALT and AST in donor + recipient treatment group 
D+R, donor + recipient treatment;*P < 0.05, ***P < 0.001 vs. placebo (n=3-4). 
 
 
 
 
 
 
 
Table 5: AUC0 -48 hrs post-reperfusion serum ALT and AST in recipient only treatment group  
R, recipient only treatment; **P < 0.01, ***P < 0.001 vs. placebo (n=3-4). 
 
3.3.2 CYP450 mRNA Expression  
The effect of I/R injury on the mRNA expression of CYP enzymes in hepatic tissue at 6 and 48 
hours post-OLT was examined by real time RT-PCR.  At 6 hr post-OLT, differences between the 
placebo- and treprostinil-treated groups were observed and data are shown in Figure 22.  In the 
placebo-treated group, hepatic mRNA expression of CYP2E1 was reduced to 18% of normal.  In 
contrast, treprostinil improved mRNA expression by two-fold, to 38% of normal.  CYP2C11 was 
reduced to 20% of normal compared to 40% in treprostinil-treated group.  CYP3A2 expression 
was reduced to 15% of normal, and treprostinil improved it to 27% of normal.  In addition, 
Group (Treatment) AUC0-48 hr post-OLT (IU*hr/L) 
 ALT AST 
Placebo (D+R) 106,650 ± 7,888 188,470 ± 40,540 
Treprostinil (D+R) 32,650 ± 2,479*** 52,246 ± 5,380* 
Group (Treatment) AUC0-48 hr post-OLT (IU*hr/L) 
 ALT AST 
Placebo (R) 102,165 ± 2,811 197,281 ± 13,710 
Treprostinil  (R) 51,339 ± 10,366** 63,779 ± 2,325*** 
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mRNA expression of CYP3A1/23, 3A18, and 2C7 were also reduced in the placebo group to 37, 
27, and 26%, respectively.  Treprostinil administration improved the mRNA expression of these 
CYP enzymes to 81, 45, and 42%, respectively.  No difference in CYP2D3 mRNA expression 
was observed; levels were reduced to 62% in both the placebo- and treprostinil-treated groups. 
 
 
Figure 22: Hepatic mRNA expression of CYP450 enzymes at 6 hours post-OLT 
*P < 0.05, **P < 0.01, *** P <0.001 vs. normal liver (n=3). 
 
 
The mRNA expression of CYP450 enzymes at 48 hours post-OLT is shown in Figure 23.  The 
suppression of hepatic mRNA expression of CYP2E1 in the placebo-treated group slightly 
improved to 29% of normal, whereas the levels in the treprostinil-treated group further improved 
to 49% of normal.  Interestingly, the mRNA expression CYP2C11 in both the placebo-treated 
group and treprostinil-treated group remained at approximately 30% of normal.  No change in 
CYP3A2 mRNA expression was observed and levels remained at 15 and 22% of normal in 
placebo and treprostinil-treated animals, respectively.  Alternatively, the hepatic mRNA 
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expression of CYP3A1/23 continued to decline to 18% of normal in the placebo-treated group 
while expression was almost doubled in the treprostinil-treated group to 30% of normal.   
 
Figure 23: Hepatic mRNA expression of CYP450 enzymes at 48 hours post-OLT 
*P < 0.05, **P < 0.01, *** P <0.001 vs. normal liver (n=3). 
 
3.3.3 CYP450 Protein Expression  
The effect of I/R injury on the protein expression of CYP2E1, CYP2C11, and CYP3A2 in liver 
graft at 48 hr post-OLT was examined using western blot analysis.  The protein levels of all three 
CYP450 enzymes were significantly decreased in the placebo-treated group, compared to normal 
liver.  Shown in Figure 24, the protein expression of CYP2E1 was reduced to 63% of normal in 
placebo and treprostinil restored expression to 96% of normal.  The protein expression of 
CYP2C11 was significantly reduced to 58% of normal levels, and treprostinil significantly 
improved expression to 67% of normal (Figure 25).  In this model system, CYP3A2 was the 
enzyme most significantly down-regulated by I/R injury, with protein levels reduced to 27% of 
normal in the placebo group, shown in Figure 26.  Treprostinil significantly improved CYP3A2 
protein expression by more than two-fold of placebo, to 62% of normal.  The results indicate that 
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the impact of I/R injury on CYP450 protein expression persisted at least up to 48 hr post-OLT 
and treatment with treprostinil attenuated this injury and significantly improved the protein 
expression of CYP2E1, 2C11, and CYP3A2 in liver graft following OLT.   
 
 
 
Figure 24: Hepatic microsomal CYP2E1 protein 
A) Western blot analysis of normal (lanes 1-2), treprostinil-treated (3-5), and placebo-treated (6-8) animals at 48 hr 
post-OLT. (B) Data are expressed as a percentage of normal liver, normalized to GAPDH expression; *P < 0.05 vs. 
normal liver; #P < 0.05 vs. placebo.  
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Figure 25: Hepatic microsomal CYP2C11 protein 
(A) Western blot analysis of normal (lanes 1-2), treprostinil-treated (3-5), and placebo-treated (6-8) animals at 48 hr 
post-OLT. (B) Data are expressed as a percentage of normal liver, normalized to GAPDH expression; ***P < 0.001 
vs. NL; †P < 0.01 vs. placebo. 
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Figure 26: Hepatic microsomal CYP3A2 protein 
(A) Western blot analysis of normal (lanes 1-2), treprostinil-treated (3-5), and placebo-treated (6-8) animals at 48 hr 
post-OLT. (B) Data are expressed as a percentage of normal liver, normalized to GAPDH expression; ***P < 0.001 
vs. normal liver; ‡P < 0.001 vs. placebo.  
 
3.3.4 CYP450 Enzyme Activity in Liver Graft Post-OLT  
The impact of I/R injury on the drug metabolizing activity of CYP2E1, CYP2C11, and CYP3A 
was examined at 1, 3, and 48 hr post-OLT in rat liver microsomes.  The enzymatic activity of 
CYP2E1 was determined using chlorzoxazone as a substrate.  The formation rate of 6-
hydroxychlorzoxazone in normal rat liver was 0.59 ± 0.01 umol/min/mg, shown in Figure 27.  In 
the placebo group, no significant changes in CYP2E1 activity occurred early post-OLT, but at 48 
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hours post-transplantation, CYP2E1 activity in the placebo group was reduced to 35% (0.21 ± 
0.05 umol/min/mg) of normal.  In contrast, treprostinil significantly improved CYP2E1 activity 
at all time points, and at 48 hr post-OLT, CYP2E1 activity was increased by more than two-fold 
that of placebo, to 73% of normal (0.43 ± 0. 11 umol/min/mg). 
 
 
Figure 27: Hepatic CYP2E1 activity 
Formation rate of 6-OH CZN in rat liver microsomes from normal, placebo-treated, and treprostinil-treated group at 
1, 3, and 48 hr post-OLT; *P < 0.05, **P < 0.01 vs. normal liver; #P <0.05 vs. placebo. 
 
 
The major component of microsomal CYPs in male rat liver is CYP2C11 [175].  The enzymatic 
activity of CYP2C11 was determined using two substrates: 2α- and 16α-hydroxytestosterone, for 
which the formation rates in normal liver were 100.4 ± 15.9 and 190.7 ± 31.9 nmol/min/mg 
(Figure 28A and 28B), respectively.  While no significant changes were observed at 1 and 3 hr 
post-OLT, the hydroxylation of testosterone markedly decreased in the placebo group to 16% 
(16.2 ± 7.1 nmol/min/mg) and 25% (47.9 ± 14.6 nmol/min/mg) of normal, respectively, at 48 hr 
post-OLT.  In contrast, treprostinil improved CYP2C11 activity to 56% and 40% of normal (55.8 
± 14.4 and 75.4 ± 28.3 nmol/min/mg, respectively) at 48 hr post-OLT.    
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Figure 28: Hepatic CYP2C11 activity 
Formation rate of (A) 2α-hydroxytestosterone and (B) 16α-hydroxytestosterone in rat liver microsomes from 
normal, placebo-treated, and treprostinil-treated group at 1, 3, and 48 hr post-OLT; *P < 0.05 vs. normal liver. 
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The activity of CYP3A was determined using two substrates, 6β-OH TST and 1-OH MDZ, 
shown in Figures 29A and 29B.  The normal formation rate of 6β-OH TST was 94.5 ± 18.4 
nmol/min/mg, shown in Figure 29A.  Initially, at 1 and 3 hour post-OLT, the formation rate of 
6β-OH TST in both the placebo (202 ± 32.3 and 181.3 ± 48.0 nmol/min/mg, respectively) and 
the treprostinil-treated group (179 ± 15.7 and 195.7 ± 25.7 nmol/min/mg, respectively) slightly 
increased, which could be attributed to substrate specificity.  By 48 hr post-OLT, the activity in 
the placebo group significantly declined to 30% of normal (28.7 ± 7.7 nmol/min/mg).  
Alternatively, the treprostinil-treated group experienced less injury than the placebo group and 
preserved activity to 64% of normal (60.2 ± 12.6 pmol/min/mg).   
The normal formation rate of 1-OH MDZ was 5.5 ± 0.2 pmol/min/mg (Figure 29B).  At 1 
and 3 hours post-OLT, the formation rate of 1-OH MDZ in the placebo group decreased to 49% 
and 62% of normal (2.67 ± 0.17 pmol/min/mg and 3.4 ± 0.29 pmol/min/mg, respectively).  
Similar results were observed in the treprostinil-treated group; at 1 hr post-OLT, the formation 
rate of 1-OH MDZ had decreased to 49% with a slight improvement to 69% of normal at 3 hr 
post-OLT (2.7 ± 0.2 and 3.8 ± 0.3 pmol/min/mg, respectively).  At 48 hr post-OLT, however, the 
formation rate of 1-OH MDZ in the placebo group further decreased to 18% of normal (1.0 ± 0.4 
nmol/min/mg), whereas the activity in the treprostinil-treated group was maintained at 54% of 
normal (3.0  ± 0.5 nmol/min/mg).  The data indicate that I/R injury significantly reduced 
CYP450 activity and that treprostinil significantly improved CYP450 activity in the liver graft 
post-OLT.  
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Figure 29: Hepatic CYP3A2 activity 
Formation rates of (A) 6β-hydroxytestosterone and (B) 1-hydroxymidazolam  in rat liver microsomes of normal, 
placebo-treated, and treprostinil-treated group at 1, 3, and 48 hr post-OLT; *P < 0.05, **P < 0.01, *** P < 0.001 vs. 
normal liver; †P < 0.05 vs. placebo. 
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3.4 DISCUSSION 
During the host response to inflammation, inflammatory mediators, including release of pro-
inflammatory cytokines, have been associated with altered content, expression, and activity of 
CYP450 enzymes, consequently leading to alterations in the metabolism and elimination of 
certain drugs [85].  Several studies have demonstrated that the catalytic activities of many 
hepatic CYP450 enzymes in experimental models of liver inflammation or infection and in man 
are down-regulated, which can cause dose-dependent drug toxicity associated with impaired in 
vivo drug clearance [166, 167].  In most cases, the decreased activity is accompanied or preceded 
by decreased hepatic levels of the corresponding CYP450 mRNA and protein expression [85].  
The losses in drug metabolism are predominantly mediated through the production of pro-
inflammatory cytokines, which ultimately modify the expression and function of specific 
transcription factors.  There is evidence for both transcriptional and post-transcriptional down-
regulation of CYP450 mRNA by inflammatory stimuli [176]. Other proposed mechanisms that 
apply to specific P450s involve post-translational steps including enzyme modification and 
increased degradation [170].  
Administration of LPS is a classic model of bacterial sepsis, perhaps the best 
characterized model to investigate CYP450 down-regulation by inflammation, although different 
concentrations of LPS and cytokines administered in vivo or in vitro can have enzyme-selective 
effects on CYP450 expression [85, 177].  In addition, different models of inflammation or 
infection can result in different rates of drug clearance and or reduced microsomal metabolism of 
drugs [178].  The down-regulation of CYP2C11 following treatment with bacterial LPS, 
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turpentine, or by other inflammatory responses has been shown to primarily occur via decreased 
mRNA expression, which is followed by a similar decrease in its protein levels [85, 179, 180].  
Additional studies have shown that the CYP2C11 promoter contains a binding site for NF-kB, 
and that mutation of the promoter to inhibit NF-kB binding also prevented suppression of 
CYP2C11 transcription by either Il-1 or LPS [175].  Alternatively, CYP2E1 has been shown to 
be most affected by inflammation at the protein level [181, 182], through post-translational 
mechanisms, i.e. protein stabilization, to prevent degradation [70, 183-185]. 
Central to the mechanism of I/R-associated liver injury is the activation of the pro-
inflammatory cascade resulting in formation of pro-inflammatory cytokines.   Serum and hepatic 
mRNA levels of TNF-α, IL-6, and ICAM-1 were significantly up-regulated early post-OLT 
following 18 hr cold liver graft storage [107, 186].   Prostacyclin analogues have been shown to 
inhibit leukocyte activation by inhibiting TNF-α production, neutrophil activation and adhesion 
to endothelial cells [44, 139].  In Chapter 2, we demonstrated that treprostinil reduced 
significantly elevated hepatic tissue mRNA levels of TNF-α, IFN-γ, IL-6, and ICAM-1 early 
post-OLT, as well as increased hepatic blood flow before and immediately post-OLT.  In 
addition, treprostinil has been shown to inhibit the mRNA expression of multiple cytokines 
including IL-6, TNF-α and IL-1β by blocking the translocation of NF-kB in vitro [187].   
In a model of cold graft storage followed by reperfusion using a recirculating method, 
Izuishi et al. [169] examined the effects of prolonged cold graft storage on CYP content, protein 
and activity.  Significant changes were only observed after 48 hours of cold storage, which does 
not translate to the clinical setting.  Alternatively, in a rat model of partial (70%) ischemia, 1 
hour of warm ischemia followed by 3 hours reperfusion resulted in no significant changes in 
CYP2E1 or CYP2C11 protein, whereas CYP2E1, CYP2C11, and CYP3A2 activity decreased by 
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17, 34, and 30% [188-190].  Thirdly, in a porcine model of warm ischemia, after 6 hours of 
partial hepatic occlusion, the activities of CYP2C, CYP2E1, and CYP3A were decreased to 62, 
62, and 31%, respectively; however, CYP3A4 protein expression remained unchanged [191].  It 
is difficult to translate the results from a model of warm I/R injury or a liver graft reperfused ex 
vivo to the clinical setting, as it involves cold ischemia and warm reperfusion, thereby invoking 
different cellular injuries and, consequently, different patterns in host response.  While there are 
a plethora of studies demonstrating the effects of inflammation and infection on CYP enzyme 
regulation, there is a paucity of data that directly examine the effect(s) of I/R injury during OLT, 
which more accurately represents hepatic CYP450 regulation during clinical liver 
transplantation.  Therefore, to more accurately characterize the direct effects of I/R injury during 
OLT on hepatic CYP450 expression and activity, the current study was performed.  We 
hypothesized that I/R injury, an inflammatory disease-state manifested during OLT, would 
significantly impair CYP mRNA, protein, and activity in the liver graft, and that treprostinil 
would improve the expression and activity of CYP450 isoforms post-transplantation by 
inhibiting the inflammatory response and improving hepatic tissue blood flow. 
The finding that CYP2E1 protein expression was reduced to 62% of normal at 48 hr post-
OLT in the placebo group, and that treprostinil administration preserved CYP2E1 protein 
expression to 96% of normal (Figure 25), supports the hypothesis that CYP2E1 protein is 
stabilized, and suggests that treprostinil might interact with different sites on the CYP2E1 protein 
to stabilize or prevent degradation. Treprostinil improved the protein expression and activity of 
all CYP450 enzymes examined. The patterns of mRNA and protein expression and 
corresponding CYP450 activity support the idea that different inflammatory mediators regulate 
P450 expression at different levels and are enzyme-specific.  The discrepancy between our 
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results and those discussed above are most likely due to the difference in I/R models and the 
CYP450 substrates selected. Inhibition of pro-inflammatory cytokines is most likely one of the 
major mechanisms responsible for improved hepatic CYP450 expression and activity in the 
treprostinil group.  Furthermore, activity of CYP450 enzymes are an important indicator of liver 
graft function in vivo [90-93].  Decreased levels can influence the clinical response and, in worse 
cases, precipitate hepatic dysfunction or lead to graft failure.  The results presented herein 
indicate a discrpenacy between protein expression and CYP450 activity, which could possibly be 
the result of an accumulation of non-functional protein.  
The need to ameliorate I/R injury in liver transplantation is imminent; however, no 
treatment is currently available.  An agent that is capable of suppressing the inflammatory 
response as well as improving hepatic blood flow would greatly improve hepatic function in 
clinical liver transplantation.  Treprostinil has the potential to serve as a therapeutic option to 
protect the liver graft against I/R injury in OLT and to greatly improve CYP450 function post-
OLT.   
In conclusion, the results from the current study demonstrated that the activity of the 
major rat CYP450 enzymes were significantly reduced, secondary to reduced CYP450 protein 
and mRNA expression in rat liver graft post-reperfusion. Treprostinil administration significantly 
reduced hepatic I/R injury and improved the CYP450 expression and function in rat liver graft 
tissue post-OLT.    
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4.0  EFFECT OF ISCHEMIA-REPERFUSION INJURY ON HEPATIC DRUG 
TRANSPORTERS DURING RAT ORTHOTOPIC LIVER TRANSPLANTATION* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*N. Ghonem, J. Yoshida, N. Murase, S.C. Strom, and R. Venkataramanan.  Changes in the 
Expression of Hepatic Drug Transporters during Rat Orthotopic Liver Transplantation.  
Submitted to Journal of Pharmacology and Experimental Therapeutics, January 2011. 
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4.1 INTRODUCTION  
The liver plays an important role in the detoxification of endogenous and exogenous compounds 
through biotransformation as well as enterohepatic circulation of bile acids and biliary excretion 
of these compounds.  Numerous endogenous compounds and xenobiotics are transported across 
membranes during the process of absorption, distribution, and clearance by transporters that are 
expressed in various organs.    
Hepatic transporters contribute to the translocation of substances across biological 
membranes and play a critical role in the body’s defense mechanism by aiding in the disposition 
and elimination of a variety of physiological substrates, metabolic products, and xenobiotics, to 
prevent the accumulation of potentially harmful compounds.  Hepatic transporters also play a 
significant role in the overall pharmacokinetics of various drugs. Alterations in the expression of 
hepatic drug transporters as a result of inflammation or infection have been reported [81-84, 
192].  In rodents, treatment with endotoxin, or its LPS component released from gram negative 
bacteria, can translocate across the intestinal mucosa into the circulation and has been shown to 
result in a pronounced alteration in the expression of hepatic transporters at the basolateral and 
canalicular membrane, including Ntcp (Slc10a1), Oatp (Slc1a1 and Slc1a2), and Oct (Slc22a1), 
as well as the ABC transporters Mdr1a/P-glycoprotein (Abcb1a), Bsep (Abcb11), and Mrp2 
(Abcb2) [86, 193], which correlated to elevated levels of inflammatory cytokines, including 
TNF-α, IL-1β, -6, and IFN-γ [194].   
Pro-inflammatory cytokines, e.g. TNF-α, IL-1β, and ICAM, are increased in the context 
of I/R injury associated with rat OLT [107, 186].  Limited data are available on the effect(s) of 
I/R injury on the expression of hepatic transporters in a relevant animal OLT model.  To better 
understand and characterize the effects of I/R injury on hepatic drug transport proteins during 
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liver transplantation, it is important to have a model that simulates the clinical conditions, 
including cold ischemic injury followed by warm reperfusion injury.  The purpose of this study 
was to examine the effects of I/R injury and evaluate the protective effect of treprostinil on the 
hepatic expression of uptake and efflux drug transporters in a clinically relevant rat OLT model.  
4.2 MATERIALS AND METHODS 
4.2.1 Animals 
All procedures were performed according to the guidelines of the National Research Council’s 
Guide for the Humane Care and Use of Laboratory Animals and approved by the Institutional 
Animal Care and Use Committee at the University of Pittsburgh.  Male Lewis rats weighing   
200 - 300 g (Harlan Sprague Dawley, Inc, Indianapolis, IN) were maintained in a laminar-flow, 
specific-pathogen–free atmosphere at the University of Pittsburgh with a standard diet and water 
supplied ad libitum.  
4.2.2 Orthotopic Liver Transplantation 
The basic techniques of liver harvesting and OLT without hepatic arterial reconstruction were 
performed as previously described [151]. Briefly, rats were anesthetized with isoflurane 
inhalation and a midline incision was made in the abdominal cavity and the donor liver was 
excised and immediately flushed with cold UW solution, stored in UW solution at 4 oC for 18 
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hours, and orthotopically transplanted into recipients.  All surgeries were performed by the same 
surgeon.   
4.2.3 Treprostinil Administration 
Treprostinil (1 mg/ml) and placebo (sodium chloride, metacresol, sodium citrate, water for 
injection) were provided by United Therapeutics, Inc. (Durham, NC).  Treprostinil (100 
ng/kg/min) or placebo was administered to donor and recipient animals subcutaneously via an 
Alzet osmotic pump (Durect Corp., Cupertino, CA).  The surgeon was blinded to treatment. 
4.2.4 Experimental Design 
Donor animals received placebo or treprostinil (100 ng/kg/min) for 24 hours before hepatectomy 
and corresponding recipient animals received placebo or treprostinil for 24 hours before 
transplantation and until the time of sacrifice, to ensure steady-state concentrations.    Recipients 
were sacrificed at 1, 3, 6, and 48 hours post-transplantation.  
4.2.5 RNA Extraction and Real Time RT-PCR Analysis 
Total RNA was extracted from liver tissue (50 – 100 mg) using TRIzol reagent (Invitrogen, 
Carlsbad, CA) according to manufacturer’s instructions.  RNA concentration was determined by 
UV absorbance at 260/280 nm (μQuant Microplate 25 Spectrophotometer) and RNA integrity 
was checked by 0.5% agarose gel electrophoresis stained with ethidium bromide.  Two 
micrograms of total RNA from each sample was used to generate first-strand cDNA by use of 
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the First Strand cDNA synthesis kit (Promega, Madison, WI).  A reaction mixture containing 
200 U monkey myeloblastosis virus reverse transcription reaction (MMLV, Promega, Madison, 
WI)-Reverse transcriptase, 1 mM dNTPs and 25 U RNasein (Promega) was added to the 
previous mixture and incubated at 37 °C for 60 minutes.  DNase-I treated total RNA from each 
sample was mixed with 0.5 µg of Random Hexamers (Promega) heated to 70 °C for 5 minutes 
then cooled to 4 °C.  Real-time RT-PCR was performed with the SYBR®  Green system using 
primers purchased from Super Array Biosciences (Frederick, MD), listed in Table 6. Samples 
were analyzed in triplicate and relative gene expression was measured using the comparative CT 
method, with GAPDH as internal control.   
 
Table 6: Real-time PCR assay IDs for genes detected by SYBR® gene expression assays 
Gene Symbol Gene Name RefSeq 
Accession# 
Slc10a1 Solute carrier family 10 (sodium/bile acid cotransporter family),  
member 1 
NM_017047.1 
Slco1a1 Solute carrier organic anion transporter family, member 1a1 NM_017111.1 
Slco1a4 Solute carrier organic anion transporter family, member 1a4 NM_131906.1 
Slc22a1 Solute carrier family 22 (organic cation transporter), member 1 NM_012697.1 
Abcb1  ATP-binding cassette, sub-family B (Mdr), member 1 NM_133401.1 
Abcb4 ATP-binding cassette, sub-family B (Mdr), member 2 NM_012690.1 
Abcc2 ATP-binding cassette, sub-family C (Mrp), member 2 NM_012833.1 
Abcc3 ATP-binding cassette, sub-family C (Mrp), member 3 NM_080581.1 
Abcb11 ATP-binding cassette, sub-family B (Mdr), member 11 NM_031760.1 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase NM_017008.3 
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4.2.6 Liver Membrane Isolation 
Snap-frozen slices of liver were used to isolate total liver membranes by a standard differential 
centrifugation procedure with minor modifications [172].  Briefly, liver pieces were 
homogenized with 3 volumes of a homogenization buffer (50 mM Tris-HCl buffer, 1.0% KCl, 
and 1 mM EDTA, pH 7.4) using an electrical homogenizer (Polytron, Brinkmann Instruments, 
Westbury, NY). The crude homogenate was centrifuged (Optima XL-100K ultracentrifuge, 
Beckman Instruments, Palo Alto, CA) at 10,000g for 20 minutes at 4 °C. The supernatant was 
further centrifuged at 105,000g for 65 min at 4 °C. Membrane pellets were resuspended using a 
manual glass homogenizer (Wheaton, Millville, NJ) with 50 mM Tris-HCl buffer (pH 7.4) 
containing 20% glycerol.  Aliquots were immediately stored at -80 °C until used. The protein 
content of microsomes was determined by the Bradford method [153] using BSA as standard.    
4.2.7  Western Blot Analysis   
Protein levels of Mrp2 and P-gp in rat liver membranes were measured by western 
immunoblotting. Liver protein (25 ug) was separated by SDS-polyacrylamide gel electrophoresis 
(10% NuPAGE, Invitrogen, Carlsbad, CA).  The proteins were transferred to a PVDF membrane, 
briefly incubated in Ponceau S (Sigma-Aldrich) to ensure equal protein load on membrane and 
complete transfer, then blocked for 1-2 hours in TBST containing 5% Non Fat Dry Milk (Bio-
Rad).  After appropriate washings, membranes were probed overnight with monoclonal mouse 
anti-rat C-219 (P-gp) and M2 III-6 (Mrp2) antibodies (1:400; Abcam, Cambridge, MA).  Next, 
the membranes were washed and probed with a secondary monoclonal rabbit anti-mouse IgG 
antibody coupled to horseradish peroxidase (1:20,000; Abcam).  Immunodetection was 
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performed using an ECL detection kit (Thermo Scientific, Rockford, IL).  The density of the 
protein bands were quantified using ImageJ software 1.40 (National Institutes of Health, 
Bethesda, MD).  Values were normalized to GAPDH (1:30,000; Abcam) and results are 
expressed as percentage of normal liver.  
4.2.8 Serum Bilirubin 
Blood was collected at 1, 3, 6, 24, and 48 hrs post-OLT and serum bilirubin levels were 
measured by standard enzymatic methods in the clinical laboratory at UPMC (Pittsburgh, PA). 
4.2.9 Statistical Analysis 
Data are presented as the mean ± SEM. Comparisons between the groups were performed by 
one-way ANOVA with Tukey post-hoc test using GraphPad Prism software Version 4.0 (San 
Diego, CA).  Differences were considered significant at a P-value < 0.05.  
4.3 RESULTS 
4.3.1 Hepatic Drug Transporter mRNA Expression  
The effect of I/R injury on the mRNA expression of hepatic drug transporters in rat liver graft 
tissue was studied at 1, 3, 6, and 48 hrs post-OLT.  The mRNA levels of Oatp1a1, Oatp1a4, 
Ntcp, and Oct1 were significantly decreased post-OLT, shown in Figures 30A-D, respectively.  
Specifically, at 48 hr post-OLT, the mRNA levels in the placebo-treated group had decreased to 
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57 ± 14.3%, 8.2 ± 1.2%, 43.1 ± 1.5%, and 35.9 ± 5.0% of normal (Figure 30A-D), respectively.  
While no improvement in Oatp1a1 mRNA expression group was observed (50.3 ± 5.2% of 
normal), treprostinil improved mRNA expression of Oatp1a4, Ntcp, and Oct1 to 24.1 ± 1.6%, 
56.9 ± 6.9%, and 42.1 ± 5.1% of normal, respectively.   
 
   
 
   
Figure 30: Hepatic mRNA expression of hepatic uptake transporters 
(A) Oatp1a1/Slc1a1, (B) Oatp1a/Slc1a4, (C) Ntcp/Slc10a1, and (D) Oct1/Slc22a1 in liver graft tissue at 1, 3, 6, and 
48 hr post-OLT. *P < 0.05, **P < 0.01, and ***P < 0.001 vs. normal (n=3). 
 
 
A B 
C D 
A 
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The mRNA levels of hepatic efflux transporters were also down-regulated in liver grafts post-
OLT.  At 6 hr post-OLT, the mRNA expression of P-gp (Mdr1a) was significantly reduced to 14 
± 5.2% of normal, whereas treprostinil significantly up-regulated P-gp expression to 144 ± 
40.1% of normal at 3 hr post-OLT and improved expression to almost three-fold that of placebo 
(40 ± 14.3%) at 6 hrs post-OLT, shown in Figure 31A.  At 48 hrs post-OLT, no improvement in 
the placebo group was observed (16 ± 7% of normal), whereas treprostinil improved levels to 
approximately two-fold of placebo (30 ± 7.3%).  At 6 hr post-OLT, Mdr2 (Abcb4) and Mrp2 
(Abcc2) levels declined to 31 ± 6.4% and 10 ± 3.1% of normal, respectively, in the placebo-
treated group.  In contrast, treprostinil improved Mdr2 and Mrp2 to 50 ± 7.6% and 20 ± 5.5% of 
normal (Figure 31B and 31C), respectively.  Mrp3 (Abcc3) expression gradually increased in the 
placebo-treated group to a peak of 77 ± 8.5% of normal at 48 hr post-OLT, where treprostinil 
restored Mrp3 expression to normal by 6 hr post-OLT (Figure 31D).  In the placebo-treated 
group, Bsep (Abcb11) levels reached a low of 27 ± 15.2% of normal at 48 hr post-OLT.  
Treprostinil preserved Bsep mRNA expression similar to normal throughout the post-operative 
study period, shown in Figure 31E.  The results indicate that hepatic drug transporters are 
significantly altered post-OLT and suggest that treprostinil may be involved in transcriptional 
regulation or stabilization of some of these transporter proteins.      
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Figure 31: Hepatic mRNA expression of efflux transporters 
(A) P-gp/Mdr1a, (B) Mdr2/Abcb4, (C) Mrp2/Abcc2, (D) Mrp3/AbcC3, and (E) Bsep/AbcC11 at 1, 3, 6, and 48 hr 
post-OLT.  Results are expressed as a percentage of NL, *P < 0.05, **P < 0.01, ***P < 0.001 vs. normal; #P < 0.05 
vs. placebo (n=3).  
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4.3.2 Mrp2 and P-gp Protein Expression in Liver Graft Post-OLT   
To determine whether the changes in mRNA also occurred at the protein level, hepatic 
microsomal expression of Mrp2 and P-gp protein at 48 hr post-OLT were studied since this time 
point demonstrated the most significant changes in mRNA expression in the liver grafts of 
placebo- and treprostinil-treated animals.  In the placebo-treated group, the expression of Mrp2 
and P-gp were 144.1 ± 13.3% and 124.5 ± 3.7% of normal, respectively, shown in Figure 32 and 
33.   Interestingly, in contrast to mRNA down-regulation, in the treprostinil-treated group, Mrp2 
and P-gp protein was up-regulated to 179 ± 7.6% and 159 ± 5.4% of normal, respectively.  Also, 
the appearance of Mrp2 protein bands as doublets (190 and 200 kDa) was observed.  The results 
indicate a discrepancy exists between Mrp2 and P-gp mRNA and protein levels in liver graft as a 
result of I/R injury post-OLT. 
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Figure 32: Hepatic microsomal Mrp2 protein expression 
(A) Western blot analysis of normal (lanes 1-2), treprostinil-treated (3-5), and placebo-treated (6-8) animals at 48 hr 
post-OLT. (B) Data are expressed as a percentage of normal liver, normalized to GAPDH expression; *P < 0.05 vs. 
normal. 
1      2         3       4       5        6       7       8 
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A 
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Figure 33: Hepatic microsomal P-gp protein expression 
(A) Western blot analysis of normal (lanes 1-2), treprostinil-treated (3-5), and placebo-treated (6-8) animals at 48 hr 
post-OLT. (B) Data are expressed as a percentage of normal liver, normalized to GAPDH expression; *P < 0.05, 
***P < 0.001 vs. normal; †P < 0.01 vs. placebo.  
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4.3.3 Serum Bilirubin 
Bilirubin is rapidly and selectively taken up into the liver [195, 196], biotransformed upon 
conjugation and secreted into bile across the canalicular membrane of hepatocytes by Mrp2 [197, 
198].  Serving as a marker of hepatic function, serum bilirubin concentrations were measured at 
1, 3, 6, 24, and 48 hrs post-reperfusion in placebo- and treprostinil-treated groups.  Normal rats 
not subjected to OLT served as a baseline value of 0.17 ± 0.06 mg/dl, shown in Figure 34.  In the 
placebo, total serum bilirubin peaked at 3-hr post-OLT (0.38 ± 0.11 mg/dl) and gradually 
returned to baseline by 24 hrs post-OLT.  Alternatively, treprostinil-treated animals had a lower 
peak at 1 hr post-OLT (0.30 ± 0.10 mg/dl) and returned to baseline by 3 hr post-OLT.  These 
results indicate that treprostinil maintained biliary excretion of bilirubin early post-OLT, which 
suggests that treprostinil preserved the hepatobiliary transport processes early post-OLT.  
 
 
Figure 34: Serum bilirubin in placebo- and treprostinil-treated group, compared to normal liver (n=3). 
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4.4 DISCUSSION 
During liver transplantation, I/R injury often leads to damaged hepatocytes and bile duct cells, 
resulting in altered biliary secretion of endogenous compounds and altered pharmacokinetics of 
drugs in the recipients as a consequence of down-regulated hepatic drug transport expression.  
While the role of hepatic transporters continues to evolve, evidence of their role in drug 
disposition after liver transplantation was observed several years ago.  Initial observations of a 
high RIA to HPLC ratio for cyclosporine A (RIA measuring parent and metabolite, while HPLC 
measuring the parent drug), indicated that formation of the metabolites was not altered but that 
biliary transport of the formed metabolites was, in grafts which exhibited early poor function 
post-OLT [94].  It was later shown that cyclosporine A is a P-gp substrate [95].  Similarly, 
ceftriaxone, a third generation antibiotic, is excreted (approximately 40%) into the bile by the 
MRP2 protein and a lower clearance of this drug has been reported following OLT, suggesting 
hepatic dysfunction at the transporter level [96].  Thirdly, the plasma chlorzoxazone metabolic 
ratio (metabolite/parent) in liver transplant recipients was significantly elevated post-
transplantation compared to healthy controls [199].  At the time, the results were attributed to an 
increase in CYP2E1 activity via the induction response by cytokines; however, the multiple 
mechanisms involved in drug disposition including transport proteins are now recognized.  
Several of the immunosuppressive medications that transplant patients take to prevent rejection 
are substrates for various hepatic transport proteins and consequently alterations in protein 
expression could further complicate transplantation outcomes.   
The hepatic excretion of a large variety of endogenous and exogenous compounds from 
hepatocytes into bile is an ATP-dependent process, which is performed primarily by members of 
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the ATP-binding cassette (ABC) protein superfamily, including the Mdr and Mrp subfamilies 
[72].  In Chapter 2, we demonstrated that hepatic tissue levels of ATP were significantly reduced 
in liver grafts post-reperfusion and that administration of treprostinil restored ATP levels in liver 
grafts soon after reperfusion and lasted throughout the post-operative period studied.  Extending 
this finding, we hypothesized that liver graft activity of hepatic uptake and efflux drug 
transporters would be down-regulated after OLT, secondary to reduced tissue ATP.  Given that 
pro-inflammatory cytokine expression is increased after OLT, we hypothesized that expression 
of hepatic transporters would be decreased post-OLT.  Since treprostinil increased hepatic 
concentration of ATP and decreased the mRNA expression of pro-inflammatory cytokines, we 
expected treprostinil to minimize the loss of expression and activity of these hepatic transporters.  
Mrp2 is a 190 kDa glycoprotein located in the canalicular membrane of the hepatocytes 
and several lines of evidence have shown that Mrp2 protein is under post-transcriptional 
regulation, in addition to classical translational regulation [200].  Regulation of Mrp2/MRP2 
function occurs by at least three distinct levels, including endocytic retrieval from the canalicular 
membrane of the hepatocyte, transcriptional, and translational regulation [201].  Glycosylation is 
critical for normal health and development, as it is an important step for proper protein folding, 
stabilization, localization, and function of newly synthesized proteins and it is also a common 
post-translational modification of membrane proteins [202].  Some glycoproteins require 
glycosylation for their trafficking from the ER to the apical membrane of the hepatocyte.  In 
particular, Bsep is reported to require at least two of its four N-linked glycans for proper protein 
stability, intracellular trafficking and functional activity [203].   
P-gp (Mdr1a/b), a 170 kDa glycoprotein, is present at low levels along the canalicular 
membrane in normal rodent liver [72, 204].  While over-expression of P-gp has been shown to 
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confer resistance against a broad variety of natural product drugs [205], up-regulation of these 
proteins during oxidative stress has also been shown to serve as a protective mechanism to 
preserve hepatic efflux as a mechanism to reduce hepatic accumulation of bile salts and down-
stream consequences [192].  The expression of transport proteins is highly variable and subject 
to complex transcriptional regulation, predominately regulated by nuclear hormone receptors.  
Nuclear receptor regulation of hepatic transporter expression by Farnesoid X receptor and 
Pregnane X receptor have been shown to be involved in the regulation of bile acid levels and 
Bsep expression [206].  This particular area of research requires further investigation.   
Following tissue injury, e.g. LPS, the acute phase reaction lasts approximately 24 hrs 
[207] so it was not unusual that Mrp2 and P-gp protein expression in the placebo-treated group 
had returned to normal by 48 hr post-OLT (Figure 32 and 33, respectively).  Interestingly, Mrp2 
and P-gp protein expression in the treprostinil-treated groups rebounded at 48 hr post-OLT. 
Further, immunodetection of a second Mrp2 band at 200 kDa in the treprostinil-treated group is 
indicative of post-translational modification by protein glycosylation, which is consistent with 
previous findings [207, 208].  The discrepancy between mRNA and protein expression of Mrp2 
suggests that treprostinil mediates post-transcriptional and translational regulation of certain 
transporters.  Similar discrepancies between the mRNA and protein expression of Mrp2 [209, 
210] and BSEP [207] have been described, which supports the theory that different ABC 
transporters are mediated by post-transcriptional and translational regulation in vitro and in vivo 
as well as in different species.  
The C219 antibody recognizes an epitope on all classes of P-gp, including Mdr1, Mdr2, 
and Bsep [211].  The up-regulation of P-gp protein expression in the treprostinil-treated group 
may be a cumulative effect of significantly increased P-gp and Mdr2 and preserved Bsep mRNA 
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expression (Figures 31A, 31B, and 31E, respectively). Administration of dibutyryl cAMP has 
been shown to stimulate bile flow [212] and influence sorting of Mrp2 to the apical membrane 
[213].  In Chapter two, we showed that treprostinil administration markedly up-regulated liver 
graft cAMP levels early post-OLT throughout the post-operative period.  Taken together, the 
additive effects of preserved tissue ATP content and Bsep mRNA expression in addition to up-
regulated hepatic mRNA levels of P-gp, tissue cAMP and Mrp2 protein are likely to have 
contributed to improved hepatic transport of serum bilirubin early post-OLT.  Further detailed 
investigation is needed to reveal the mediators that regulate hepatic drug transporter expression 
in liver graft post-OLT. 
An integral component of I/R-associated liver injury during OLT is the activation of the 
pro-inflammatory cascade, resulting in the production of pro-inflammatory cytokines.  These 
cytokines are likely to be involved in the decreased mRNA expression of uptake and efflux 
hepatic transporters.  Inflammation has been linked to reduced Mrp2 mRNA expression and 
increased Mrp3 protein levels, to compensate for diminished Mrp2 transport capacity in response 
to inflammation as a protective mechanism to reduce hepatic accumulation of bile salts and the 
down-stream hepatotoxicity [214, 215].  It is important to note that different bacterial strains of 
LPS as well as different causative inflammatory conditions can elicit different responses in 
cytokine release and consequently different patterns of gene expression [216].  Considering the 
liver is the most important site of drug metabolism and clearance, inflammatory-mediated 
changes in the expression of hepatic transporters can have major implications when the capacity 
of the liver, such as the case during liver transplantation, and other organs to handle drugs is 
severely compromised.  Most animal studies of hepatic I/R injury utilize partial ischemia, i.e. 
70% occlusion [51, 217], or ligation of the hepatic artery [218].  A major limitation of these 
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models is the induction of warm ischemia, which does not reflect cold ischemic injury that takes 
place prior to transplantation, during graft storage, and, therefore, does not fully represent the 
effects of I/R injury on hepatic drug transport processes associated with clinical OLT.   
Treprostinil has been shown to inhibit the secretion and gene expression of many pro-
inflammatory cytokines by blocking the translocation of NF-kB in vitro [187].  Again, in Chapter 
two we showed that treprostinil reduced significantly increased mRNA levels of TNF-α, IFN-γ, 
IL-6, and ICAM-1 in liver graft post-OLT, and increased IL-10 mRNA early post-reperfusion. 
Taken together, the preserved ATP content, reduced pro-inflammatory cytokine and increased 
IL-10 mRNA, as well as increased cAMP levels in liver graft are likely to account for the 
improved response in hepatic drug transport processes in the treprostinil-treated group.  
In summary, this study showed that I/R injury lead to impaired hepatobiliary functions 
and altered the expression of hepatic uptake and efflux transporters in liver grafts after rat OLT 
and these effects were partially alleviated by treprostinil administration.  To the best of our 
knowledge, this is the first study to directly examine the effects of I/R injury on the mRNA and 
protein expression of the major hepatic transporters in a rat OLT model.   
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5.0    EVALUATION OF THE DRUG-DRUG INTERACTION POTENTIAL 
BETWEEN TREPROSTINIL AND IMMUNOSUPPRESSIVE MEDICATIONS* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*
N. Ghonem, S. Zhang, A. Sharma, S.C. Strom, R. Venkataramanan.  Evaluation of the Drug-
Drug Interaction Potential between Treprostinil and Immunosuppressive Medications In Vitro.  
Submitted to Drug Metabolism and Disposition, December 2010. 
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5.1 INTRODUCTION 
Orthotopic liver transplantation (OLT) is the only curative therapy available for patients with 
various end-stage liver diseases.  The surgical procedure subjects the transplanted graft to 
varying periods of cold ischemia and warm reperfusion, which inevitably results in varying 
degrees of hepatic injury and dysfunction [25]. I/R injury is an unavoidable process in OLT and 
it is the major cause of both initial poor function and PNF of the liver, with a high mortality rate, 
if patients are not re-transplanted immediately.  The need to prevent I/R injury is imperative; 
however, no therapy is commercially available.   
In Chapter two, it was demonstrated that treprostinil protected liver grafts against I/R 
injury during rat OLT and treprostinil is now being examined for its safety and efficacy in 
ameliorating I/R injury in adult patients undergoing OLT.  Treprostinil, a stable analogue of 
prostacyclin (PGI2), is approved by the US Food and Drug Administration for the treatment of 
pulmonary arterial hypertension (Remodulin®).  Treprostinil is substantially metabolized by the 
liver, but the precise enzymes responsible are unknown [113].  Results of in vitro cytochrome 
P450 studies performed in expressed enzymes show that treprostinil does not inhibit CYP1A2, 
2C9, 2C19, 2D6, 2E1, or 3A [113], however, whether or not treprostinil induces these enzymes 
has not been evaluated.   
Immunosuppressive drugs such as cyclosporine, tacrolimus, and sirolimus predominantly 
undergo hepatic metabolism via cytochrome P450 (CYP) 3A4 [219].  MMF, an ester prodrug of 
mycophenolic acid (MPA) [220] predominantly undergoes hepatic glucuronidation via UDP-
glucuronosyltransferase (UGT) 1A9 to its glucuronide metabolite (MPAG) and, to a lesser 
extent, by UGT2B7 to its non-active MPA-acyl-glucuronide metabolite (AcMPAG) [221].  In 
addition to immunosuppressants, most solid organ transplant recipients are prescribed additional 
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medications to treat transplant-associated conditions, which occur either secondary to 
transplantation or are underlying conditions, including but not limited to osteoporosis, 
hypertension, bacterial and or fungal infections, ulcers, high cholesterol, and depression, i.e. 
antihypertensive, antibacterial and antifungal agents, anti-ulcer, cholesterol-lowering agents, and 
antidepressant medications [222, 223].  Several of these agents are also metabolized by CYP3A 
and UGTs, therefore, each of these medications have the potential to interact with treprostinil.  
Furthermore, literature reports have shown that some prostaglandin analogues, including PGI2, 
can alter the clearance and or half-life of certain immunosuppressive agents [224, 225].  The risk 
for a DDI must be thoroughly investigated whenever a new drug is added to a regimen in a 
transplant patient since most of the immunosuppressive drugs have a narrow therapeutic index.  
In transplant recipients, supra- or sub-therapeutic blood/plasma concentrations can increase the 
risk of organ rejection, or lead to infection or drug-specific side effects, respectively.  
The objective of this study was to examine in vitro the DDI potential of treprostinil when 
co-administered with CsA, TAC, SRL, or MPA. While treprostinil is not a new molecular entity 
per se, the potential use of treprostinil in OLT would be a new indication and, as such, in 
addition to providing essential data regarding the potential for a DDI, this study also complies 
with the FDA guidelines, which requires in vitro DDI studies be performed prior to a drug 
entering a clinical trial [226].  
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5.2 MATERIALS AND METHODS 
5.2.1 Chemicals   
Treprostinil was supplied by United Therapeutics (Research Triangle Park, NC), Cyclosporine A 
was purchased from USP Pharmacopeia (Rockville, MD).  Tacrolimus (TAC) was supplied by 
Fujisawa (Osaka, Japan), Sirolimus was purchased from LC Laboratories (Woburn, MA) and 32-
desmethoxyrapamycin was a gift from the University of Pittsburgh Medical Center, Pittsburgh, 
PA. Dimethyl sulfoxide (DMSO), mycophenolic acid (MPA), nicotinamide adenine dinucleotide 
phosphate-oxidase (NADPH), uridine 5’diphospho-glucuronic acid (UDPGA), Brij 57, 
rifampicin (RIF), ketoconazole (KTZ), and ascomycin were purchased from Sigma (St. Louis, 
MO). Mycophenolic acid glucuronide (MPAG) was a generous gift from Professor Leslie Shaw 
(University of Pennsylvania, Philadelphia, PA).  Bovine serum albumin (BSA) was purchased 
from Fluka (Buchs, Switzerland, 98% pure). Hepatocyte maintenance medium (HMM) and 
medium supplements, dexamethasone and insulin, were obtained from BioWhittaker 
(Walkersville, MD). Penicillin G/streptomycin was purchased from Gibco Laboratories (Grand 
Island, NY). Falcon 6-well culture plates were purchased from Becton Labware (Franklin Lakes, 
NJ). Reagents for real-time RT-PCR were purchased from Promega (Madison, WI).  Forward 
and reverse primers were purchased from Applied Biosystems (Foster City, CA).  Methanol and 
water [high-performance liquid chromatography (HPLC) grade] were purchased from Thermo 
Fisher Scientific (Waltham, MA). All other chemicals used were of HPLC grade or the highest 
purity available.  
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5.2.2 Evaluation of CsA, TAC, SRL, and MPA inhibition in microsomes 
5.2.2.1 Microsome Preparation  
Microsomes were prepared from five human liver lobes by a standard differential centrifugation 
procedure with minor modifications [172].  Briefly, liver pieces were homogenized with 3 
volumes of a homogenization buffer (50 mM Tris-HCl buffer, 1.0% KCl, and 1 mM EDTA, pH 
7.4) using an electrical homogenizer (Polytron, Brinkmann Instruments, Westbury, NY). The 
crude homogenate was centrifuged (Optima XL-100K ultracentrifuge, Beckman Instruments, 
Palo Alto, CA) at 10,000g for 20 minutes at 4 °C. The supernatant was further centrifuged at 
105,000g for 65 min at 4 °C to sediment the microsomes. The microsomes were reconstituted 
using a manual glass homogenizer (Wheaton, Millville, NJ) in twice their weight of with 50 mM 
Tris-HCl buffer (pH 7.4) containing 20% glycerol. Aliquots were immediately stored at -80 °C 
until used. The protein concentration was determined by Lowry’s method [227] using BSA as 
standard.  
5.2.2.2 Microsome Incubations   
Optimal conditions for microsomal incubations with CsA, TAC, SRL, and MPA were 
determined by performing separate studies for the time of incubation (0-120 minutes) and protein 
concentration (0–2 mg/ml).  To work in the linear range, the time selected for CsA, TAC, and 
MPAG was 30 minutes and for SRL 15 minutes; the protein concentration selected for CSA and 
SRL, TAC, and MPA was 0.3, 0.2, and 0.4 mg/ml, respectively.  The microsomal incubation 
included CsA, TAC, SRL, and MPA, pooled and mixed together from five different human 
livers, MgCl2 (10 mM), and phosphate buffer (0.1 mM), pH=7.4.  The incubation was allowed to 
pre-equilibrate in a shaking water bath for approximately 5 minutes at 37 °C.  Each drug 
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equilibrated in a shaking water bath under the experimental conditions that were determined to 
be linear at 37 oC in the absence or presence of treprostinil.  For CsA, TAC, and SRL 
microsomal reactions, NADPH (1 mM) was added to initiate the reactions.  For MPA 
microsomal reaction, the incubation also included Brij 58 (0.1 mg/mg protein) and UDPGA (1 
mM) to initiate reaction.  The concentration of CsA (5 ug/ml), TAC (200 ng/ml), SRL (200 
ng/ml), MPA (10 ug/ml), and treprostinil (10, 50, and 100 ng/ml) were selected based on 
clinically relevant blood concentrations.  All reactions were terminated upon addition of ice-cold 
methanol.  Following termination, CsA and 32-desmethoxyrapamycin were added as internal 
standard for TAC and SRL, respectively.  Samples were then centrifuged at 3,000 rpm for 10 
minutes at 4 oC and the supernatant was subjected to solid phase extraction (SPE).  Under 
experimental conditions described above, control samples represented regular metabolism, 
omission of co-factor served as negative control.  Co-incubation with ketoconazole (KTZ, 0.5 
uM) served as positive control.   
5.2.3 Solid Phase Extraction (SPE) 
An Oasis HLB C18 cartridge (Waters, Milford, MA) was pre-equilibrated with 1 ml of HPLC 
grade methanol followed by 1 ml of HPLC grade water. The supernatant was passed through the 
column and washed with 40% methanol.  CsA, TAC, and SRL were individually eluted from the 
sample preparation column with dichloromethane. The organic phase was transferred to a new 
tube and the liquid evaporated to dryness under air.  Samples were reconstituted with mobile 
phase and analyzed immediately.   
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5.2.4 Evaluation of CsA, TAC, SRL, and MPA Induction in Human Hepatocytes 
5.2.4.1 Preparation of Human Hepatocytes 
Hepatocytes were prepared from human liver samples obtained from the Liver Tissue Cell 
Distribution System, from the Hepatocyte Transplantation Laboratory at the University of 
Pittsburgh (Pittsburgh, PA).  Donors of human liver tissue had no history of liver disease, but the 
liver was not used for transplantation or the patient underwent liver resection for different 
pathologies.  Informed consent was obtained from all patients for the use of liver tissue for 
research purposes.  Hepatocytes were prepared by a three-step collagenase perfusion technique 
[228].  Cell viability was determined by the trypan blue exclusion method and ranged from 71 to 
92%.  Briefly, equal volumes of trypan blue (0.4%) and cell suspension were mixed and a 
portion of this suspension was then placed on a hemocytometer.  The cells were observed under 
a light microscopy and the numbers of live and dead cells (stained blue), were counted in two 
fields.  Concentration of cells (number of cells / ml) was determined using the following 
formula:  Live cells in two fields x 10,000 = # of cells/ml.  Cells were diluted to final volume of 
1 x 106 cells/mL.  Hepatocytes were plated on Falcon 6-well culture plates at a density of 1.5 x 
106 cells, previously coated with rat tail collagen, and maintained in Hepatocyte Maintenance 
Medium  (HMM; Lonza Walkerville, Inc.) supplemented with 0.1 µM insulin, 0.1 µM 
dexamethasone, 0.05% streptomycin, 0.05% penicillin, 0.05% amphotericin B and 10% bovine 
calf serum.  After cells attached for 4 to 6 h, medium was replaced with serum-free medium 
containing all of the supplements described above (HMM+).  Cells were maintained in culture at 
37 °C in an atmosphere containing 5% CO2 and 95% air.  After 24 h in culture, unattached cells 
were removed by gentle agitation and the medium was changed every 24 hours.    
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5.2.4.2 Hepatocyte Incubations 
After allowing the cells to acclimate for 48 hr after plating, cells were treated with HMM+ 
containing rifampicin (RIF 10 uM), phenobarbital (PB 2 mM), or treprostinil (10, 50, and 100 
ng/ml), all dissolved in DMSO, except for PB (water) for 96 hrs.  The final concentration of 
DMSO (vehicle control) in culture medium was 0.1%.  The cells were observed daily under a 
phase microscope to monitor attachment and cell morphology.  At the end of the incubation 
period, cells were washed with HMM devoid of insulin, dexamethasone, antibiotics and 
amphotericin B.  Following this wash period, media containing CsA (10 ug/ml), TAC (500 
ng/ml), SRL (500 ng/ml), or MPA (10 ug/ml) was applied to the cells and sampled for the time 
of incubation.  At the end of treatment, hepatocytes and the media were collected into 1.5 mL 
Eppendorf tubes.  The samples were sonicated and centrifuged at 3,000rpm for 5 minutes at 4 oC. 
Cyclosporine D, ascomycin, 32-desmethoxyrapamycin were added as internal standard for CsA, 
TAC, and SRL.  Following centrifugation, SPE was applied to the supernatant.  Time zero 
reflects the time at which no metabolism took place and is referred to as the original 
concentration. Control samples reflect regular metabolism when hepatocytes were pretreated 
with vehicle control.  Co-treatment with KTZ served as negative control.  Rifampicin served as 
positive control for CYP3A4- and phenobarbital served as positive control for CYP3A4-, 
UGT1A9- and UGT2B7-mediated metabolism.  To account for donor variability, experiments 
were performed in hepatocytes from at least three different donors.  Characteristics of human 
liver donors are listed in Table 8. 
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Table 7:  Donor information for human livers used to prepare primary culture of human hepatocytes 
 
Donor Sex Age (yrs) Medical History Viability (%) 
HH997 M 43 Brain Death 73 
HH1117 F 68 Brain Death 82 
HH1234 M 56 Anoxia 87 
HH1286 M 50 ICH 90 
HH1336 M 54 ICH 77 
HH1426 F 23 Anoxia 92 
HH1432 F 72 MCC 77 
HH1434 F 71 MCC 88 
HH1454 F 42 Breast adenocarcinoma 80 
HH1456 F 50 MCC 80 
HH1458 M 43 ICH 88 
HH1460 F 46 MCC 85 
HH1464 F 70 HCC, cirrhosis 75 
HH1466 F 68 CC 82 
HH1467 F 52 MCC 89 
HH1469 F 46 Anoxia 88 
HH1492 F 45 MCC 86 
HH1511 F 67 MCC 71 
HH1582 F 25 Encephalopathy 81 
HH1602 M 40 Head trauma 81 
HH1606 M 28 MCC 74 
M, male; F, female; MCC: Metastatic colon cancer; ICH: Intracranial hemorrhage. 
5.2.4.3 Evaluation of the hepatocyte mitochondrial activity   
The MTT assay was performed according to manufacturer’s guidelines (Invitrogen, Carlsbad, 
CA). Cells were treated with DMSO, RIF (10 uM), PB (2 mM), or treprostinil (10, 50, and 100 
ng/ml),  After 72 hours in culture, cells were incubated with the tetrazolium salt [(3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, a tetrazole), MTT] dissolved in culture 
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media for approximately 30 minutes, washed in blank HMM, and treated with isopropyl alcohol.  
The conversion of MTT into aqueous, soluble, formazan by metabolically active cells was 
determined by measuring the absorbance at 490 nm.  
5.2.5 Analytical methodology 
5.2.5.1 Microsomal incubations 
CsA, TAC, and SRL were individually analyzed on an HPLC system that consisted of an 
autosampler (Waters 717, Milford, MA) and a solvent delivery system (Waters 600E), attached 
to a UV detector (Waters 486), set at 214 nm (for CsA and TAC) and 278 nm (for SRL).  The 
mobile phase consisted of 68% (CsA and SRL) and 60% acetonitrile (TAC) in water.  MPA and 
MPAG were analyzed on an Alliance HPLC system (Waters 2695, Milford, MA) attached to a 
photodiode array detector (PDA, Waters 2998) set at 254 nm was used. The mobile phase 
consisted of 76% acetonitrile in water containing 0.05% phosphoric acid.  Each compound was 
separated individually using a Symmetry® C18 (4.6 x 250 mm, 5um) column (Waters). The 
concentration of each compound was determined from a linear standard curve of the known 
concentrations for CsA (0.5 – 5 ug/ml), TAC (0.2 –5 ug/ml), SRL (0.2 – 5 ug/ml), and MPAG 
(0.675 – 10 ug/ml).  The C.V was less than 10% per assay. 
5.2.5.2 Hepatocyte incubations  
CsA and SRL were quantified using the HPLC system described above.  Following SPE, 
samples for CsA and SRL were reconstituted with mobile phase consisting of 68% acetonitrile 
and 85% methanol in water, respectively.  CsA, CYD, SRL, and 32-desmethoxyrapamycin were 
separated using a Symmetry® C18 (4.6 x 250 mm, 5 um) column (Waters).  The concentration 
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of each compound was determined from a linear standard curve of the known concentrations for 
CsA (0.5 – 10 ug/ml) and SRL (0.5 – 15 ug/ml). 
The concentration of TAC was determined using the Acquity® Ultra Performance 
Acquity Liquid Chromatography (Waters) system with Thermo Finnigan TSQ® Quantum Ultra 
triple quadrupole mass spectrometer (Thermo Scientific), operated in positive electrospray 
ionization mode with unit resolutions at both Q1 and Q3 set at 0.70 full width at half maximum.  
The selected reaction monitoring (SRM) transitions of m/z 821.4 → 768.3 (collision energy 10 
eV, scan time 0.01 s) for TAC and m/z 809.4 → 756.0 (collision energy 19 eV, scan time 0.20 s) 
for ascomycin were monitored. Parameters were optimized to obtain the highest [M+H] ion 
abundance and were as follows: capillary temperature, 360 °C; spray voltage, 3000 V. Sheath 
gas, auxiliary gas, and ion sweep gas pressures were set at 43, 37, and 0, respectively. Collision 
gas pressure was set at 1.0 mTorr.  TAC and ascomycin were separated using an Acquity® 
UPLC BEH C18 1.7 um (2.1 µm x 100 mm) column (Waters). Following SPE, samples were 
reconstituted with mobile phase consisting of 60 % acetonitrile in water.  The standard curve was 
linear from 0.15 – 5 ug/ml.  The C.V was less than 5% for this assay.   
The concentration of MPA and MPAG were detected using the HPLC system described 
above.  The mobile phase consisted of (A) 61% NaAc-HA in acetonitrile, pH 4.4, (B) methanol, 
(C) 5% methanol in water, and (D) acetonitrile.  MPA and MPAG were separated using a 
Symmetry® C18 (4.6 x 250 mm, 5um) column (Waters) set at 25 oC.  The standard curve was 
linear from 0.675 – 10 ug/ml.   
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5.2.6 CYP3A4, UGT1A9, and UGT2B7 mRNA expression 
5.2.6.1 RNA Isolation and Quantitation 
Total RNA was extracted from primary culture human hepatocytes using TRIzol reagent 
(Invitrogen, Carlsbad, CA) as described in Chapter 2.  Real-time RT-PCR was performed with 
the TaqMan® system and conditions designated by Assays on Demand, Gene Expression 
Products (Applied Biosystems, Forster City, CA).  The primers were purchased from Applied 
Biosystems, and are listed in Table 9.  The mRNA expression levels were calculated based on 
the threshold cycles using the Applied Biosystems sequence detection system software, version 
2.0 (Applied Biosystems).  Samples were analyzed in triplicate and relative gene expression was 
measured using the comparative CT method, using CYC as internal control.   
 
Table 8: Real-time PCR Assay IDs for genes detected by TaqMan® gene expression 
 
Gene Symbol Gene Name RefSeq Accession # 
CYP3A4 cytochrome P450, family 3, subfamily A, polypeptide 4 NM_017460.3 
UGT1A9 UDP glucuronosyltransferase 1 family, polypeptide A9 NM_021027.2 
UGT2B7 UDP glucuronosyltransferase 2 family, polypeptide B7 NM_001074.2 
CYC peptidylprolyl isomerase A (cyclophilin A) NM_021130.3 
5.2.7 Statistical Analysis 
The data are presented as the mean ± SEM.  One-way ANOVA followed by group comparisons 
using Dunnette’s multiple comparison was performed using Prism software v4.0 (GraphPad, San 
Diego, CA).  Significance was determined when the P-value < 0.05.   
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5.3 RESULTS 
5.3.1 Enzyme Inhibition Potential of Treprostinil 
Pooled human liver microsomes were used to evaluate the inhibitory potential of treprostinil on 
the metabolism of CsA, TAC, SRL, and MPA.  The formation of hydroxycyclosporine (MI) was 
used as a marker of CsA metabolism (Figure 34A).  Co-incubation with KTZ significantly 
inhibited 64% of MI formation.  In contrast, co-incubation with all three concentrations of 
treprostinil did not inhibit MI formation, compared to control.  The loss of tacrolimus was used 
as a marker of metabolism, shown in Figure 34B.  In control samples, 31% of TAC was 
metabolized, compared to 7% when co-incubated with KTZ.  Co-incubation of TAC with each of 
the three concentrations of treprostinil did not change TAC metabolism (32, 34, and 32% of 
original, respectively).  The loss of sirolimus was used as a marker of metabolism, shown in 34C.  
In control samples, 43% of SRL was metabolized, whereas only 5% of SRL was metabolized 
when co-incubated with KTZ.  Co-incubation with treprostinil (10, 50, and 100 ng/ml) resulted 
in 45, 35, and 36% of SRL metabolism, respectively.  The formation of mycophenolic acid 
glucuronide (MPAG) was used as a marker of MPA metabolism, shown in Figure 34D.  
Compared to control, co-incubation with all three concentrations of treprostinil did not inhibit 
MPAG formation.  The results indicate that co-incubation with treprostinil in pooled human liver 
microsomes did not inhibit the metabolism of CsA, TAC, SRL, or MPAG.  
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Figure 35: Inhibitory potential of treprostinil 
Pooled liver microsomes (n=5) co-incubated with treprostinil (10, 50, and 100 ng/ml) and (A) CsA, (B) TAC, (C) 
SRL, and (D) MPAG; (-) NADPH served as negative control for CsA, TAC, or SRL; (-) UDPGA served as negative 
control for MPA.  Control samples represent regular metabolism (samples not co-incubated with treprostinil). *P < 
0.05 and **P < 0.01 vs. control.  
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5.3.2 Evaluation of Cytotoxicity 
Hepatocytes prepared from four donors (HH1516, HH1582, HH1601, and HH1602) were treated 
with DMSO, RIF (10 uM), PB (2 mM), and treprostinil (10, 50, and 100 ng/ml) for 72 hr to 
determine the effect of treprostinil on hepatocyte mitochondrial activity, using the MTT assay. 
Our lab has previously shown that the concentration of DMSO (0.1%) used for primary culture 
of human hepatocyte experiments does not alter cellular activity compared to cells treated with 
HMM+.  Cellular activity with each of the three concentrations of treprostinil was similar to 
those treated with DMSO, RIF, and PB (Figure 35), which indicated that pre-treatment with 
treprostinil did not alter cellular activity, compared to DMSO-treated cells. 
 
Figure 36: MTT assay 
Rifampicin (RIF 10 uM), phenobarbital (PB, 2 mM), or treprostinil (10, 50, and 100 ng/ml) for 72 hr. 
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5.3.3 Enzyme Induction Potential of Treprostinil 
Primary cultured human hepatocytes were used to examine the induction potential of treprostinil 
on the metabolism of CsA, TAC, SRL, and MPA.  Original samples represent the baseline 
concentration of the immunosuppressant in the system.  Control samples represent regular 
metabolism of the immunosuppressant after pretreatment with DMSO.  Loss of CsA was used as 
a marker of metabolism, shown in Figure 36A.  Under the experimental conditions, 38, 39, and 
61% CsA was metabolized in HH1457, 1464, and 1448, respectively.  Co-treatment with KTZ 
significantly reduced CsA metabolism to 20, 7, and 12%, respectively.  Pretreatment with RIF 
significantly increased CsA metabolism to 56, 60, and 76%, respectively.  Pretreatment with 
treprostinil did not change CsA metabolism.   
  A decrease in TAC concentration was used as a marker of metabolism, shown in Figure 
36B.  In control samples, 19, 69, and 45% of TAC was metabolized in HH1454, HH1492, and 
HH1511, respectively.  Co-treatment with KTZ significantly reduced TAC metabolism to -0.5, 
11, and 6%, respectively.  Pretreatment with RIF significantly increased TAC metabolism to 67, 
85, and 89%, respectively.  Pre-treatment with treprostinil did not increase TAC metabolism, 
compared to control.  A decrease in SRL concentration served as a marker of metabolism, shown 
in Figure 36C.  In control samples, 54, 67, and 65% of SRL was metabolized in HH1426, 
HH1432, and HH1434, respectively.  Co-treatment with KTZ significantly reduced the SRL 
metabolism to 17, 41, and 8%, respectively.  Pretreatment with RIF increased SRL metabolism 
to 82, 83, and 76%, respectively.  Compared to control, pre-treatment with treprostinil did not 
increase SRL metabolism.  The formation of MPAG served as a marker of metabolism (Figure 
36D).  Pretreatment with PB increased MPA metabolism by 163, 234, and 168% in HH1458, 
HH1461, and HH1466, respectively.  Pre-treatment with treprostinil did not increase MPAG 
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formation, compared to control.  Collectively, the results indicate that pretreatment in primary 
culture of human hepatocytes with all three concentrations of treprostinil did not inhibit or 
induce the metabolism of CsA, TAC, SRL, or MPA and is therefore, unlikely to alter the 
metabolism of these drugs when co-administered.   
 
 
 
 
Figure 37: Induction potential of treprostinil 
Primary culture of human hepatocytes pretreated with DMSO (control), RIF (10 uM), PB (2 mM), or treprostinil 
(10, 50, and 100 ng/ml) for 72 hours before treatment with (A) CYA, (B) TAC, (C) SRL, or (D) MPA. Original 
represents baseline concentration. Control represents regular metabolism of the immunosuppressive agent for the 
indicated time without treprostinil pre-treatment. *P < 0.05, ** P <0.01 vs. control (n=3).  
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5.3.4 Effect of Treprostinil on mRNA expression 
To determine whether or not treprostinil altered the mRNA expression of CYP3A4, UGT 1A9, 
or UGT2B7, real-time PCR analysis was performed.  Pretreatment with RIF significantly 
induced mRNA expression of CYP3A4 by 9.2 ± 0.9, 13.3 ± 0.5, and 33.6 ± 5.9-fold in HH1464, 
HH1466, and HH1467, respectively (Figure 37A), compared to DMSO-treated cells.  Likewise, 
PB treatment induced CYP3A4 mRNA expression by 5.4 ± 0.3, 17.1 ± 2.8, and 29.7 ± 2.1-fold, 
respectively. Treatment with treprostinil (10, 50, and 100 ng/ml) had no effect on CYP3A4 
mRNA expression, compared to DMSO-treated cells and positive controls.  Treatment with PB 
induced UGT1A9 mRNA expression by 5.2 ± 0.3, 2.8 ± 0.2, and 4.8 ± 0.6-fold in HH1464, 
HH1466, and HH1467, respectively, compared to DMSO-treated cells, shown in Figure 37B.  
Pretreatment with treprostinil (10, 50, and 100 ng/ml) did not significantly increase UGT1A9 
mRNA expression, relative to positive control.  Similarly, PB induced UGT2B7 mRNA 
expression by 3.5 ± 0.5, 1.9 ± 0.1, and 2.0 ± 0.2-fold in HH1464, HH146, and HH1467, 
respectively (Figure 37C).  Treatment with treprostinil (10, 50, and 100 ng/ml) did not 
significantly increase UGT2B7 mRNA expression, relative to the positive control.  The results 
demonstrated that treprostinil is not expected to alter the clearance of CsA, SRL, TAC, or 
MPAG. 
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Figure 38: mRNA expression in hepatocytes 
Hepatocytes from three donors (HH1464, HH1466, and HH1467) were pre-treated with DMSO (vehicle control), 
Rif (10 uM), PB (2 mM), or treprostinil (10, 50, and 100 ng/ml) for 72 hours to measure mRNA levels of (A) 
CYP3A4, (B) UGT1A9, and (C) UGT2B7 * P <0.05 and ** P <0.01 vs. control.  
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A 
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5.4 DISCUSSION 
In Chapter two, it has been shown that treprostinil is effective in protecting the liver graft against 
I/R injury during rat OLT.  The ultimate goal of treprostinil therapy in orthotopic liver transplant 
recipients is to ameliorate ischemia-reperfusion injury. Liver transplant patients who are likely to 
receive treprostinil are maintained on immunosuppressant therapy to prevent graft rejection and 
several other drugs that are metabolized by the liver.  It is important to assess in vitro inhibition 
and induction potential of treprostinil in liver transplant patients in order to confirm that it can be 
safely administered in combination with immunosuppressive medications.  Previous reports have 
shown that some prostaglandin analogues altered the clearance or half-life of certain 
immunosuppressive agents [224, 225].  Therefore, we performed this study to address the 
question of whether or not there is potential for a drug-drug interaction between treprostinil and 
the four most commonly administered immunosuppressant medications, including cyclosporine 
A, tacrolimus, sirolimus, and mycophenolic acid.  According to the FDA guidelines for drug-
drug interaction studies, the agent under investigation must increase the metabolism of the 
second drug comparatively to a positive control or induce the metabolism by greater than 40% in 
order to be classified as a causative agent of a drug-drug interaction [226].  Current industrial 
practices to assess drug induction of CYP450 enzymes by examining a change in the area under 
the plasma concentration curve (AUC), maximum concentration, or half-life.   
Drug interactions involving the CYP450 isoforms are generally of two types, namely: 
enzyme inhibition or enzyme induction [229].  The two most common mechanisms by which 
enzyme induction occurs include stabilization of the mRNA or enzyme and increased gene 
transcription, mediated by nuclear receptors [230].  In the present study, the inhibition and 
induction potential of treprostinil in human liver microsomes and hepatocytes co-incubated with 
A 
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CsA, TAC, SRL, CsA, and MPA were evaluated at the level of enzyme activity and gene 
transcription.  The results demonstrated that in pooled human liver microsomes all three 
clinically relevant concentrations of treprostinil tested did not inhibit metabolism of the 
immunosuppressive agents tested.  Likewise, in primary cultures of human hepatocytes we 
showed that all three clinically relevant concentrations treprostinil did not induce the metabolism 
of CsA, TAC, SRL, or MPA.  Collectively, the results from this study demonstrate that clinically 
relevant concentrations of treprostinil are unlikely to alter the clearance of CsA, TAC, SRL, or 
MPA when administered concomitantly.  Some CYP and UGT isoforms are subject to induction 
by xenobiotics via activation of nuclear hormone receptors, with a consequent result of decreased 
exposure of the affected compound leading to therapeutic failure.  Real-time RT-PCR results 
confirmed that treprostinil had no induction potential on CYP3A4 mRNA expression.  The 
ligand-activated nuclear hormone receptor, peroxisome proliferator-activated receptors (PPAR)-
α is a common regulator of the gene expression of UGT1A9 [231] and UGT2B7 [221] and 
various PGI2 analogues, including treprostinil, have been reported to be ligands for the different 
PPARs isoforms [232].  As a PGI2 analogue, we investigated the effects of treprostinil on mRNA 
expression of UGT1A9 and UGT2B7, as these two UGT isoforms have been reported to be the 
dominate UGT isoforms responsible for the metabolism of MPA to its active and inactive 
metabolites, respectively [221, 233, 234].  Interestingly, RT-PCR results indicated that in one 
case of hepatocytes (Figure 377B, HH1466), treatment with treprostinil resulted in a slight 
increase in UGT1A9 mRNA expression but not of UGT2B7, compared to the positive control 
and vehicle control.  However, the increase was minor and was less than 40% of the positive 
control.  Therefore, according to regulatory guidelines, there is no concern for a DDI via this 
pathway.  The observed effects are most likely attributed to the inherent inter-individual 
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variation among human hepatocytes.  The UGT1A9 and 2B7 isoforms are both reported to have 
genetic polymorphisms [235], which may partially explain the observed inter-individual 
variations. Since administration of treprostinil is expected to be acute, i.e. during the 
transplantation procedure and up to 48 hours post-transplantation, and in vitro formation of 
MPAG is not increased greater than 40%, no DDI is expected between treprostinil and the 
immunosuppressive agents tested.   
Taken together, the results demonstrate that treprostinil is unlikely to alter the 
metabolism of the four most widely used immunosuppressant medications when co-
administered, thus supporting continued investigation with treprostinil for its targeted indication 
in orthotopic liver transplantation.   
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6.0  CONCLUSIONS AND FUTURE RESEARCH 
6.1 DISCUSSION AND SUMMARY 
Orthotopic liver transplantation is the only curative therapy for patients with end-stage liver 
diseases; however, there is a tremendous shortage of organs available for transplantation.  This 
shortage has prompted the use of what would otherwise be discarded organs, i.e. extended 
criteria donors (ECDs), in efforts to increase the donor pool.  Although ECDs provide additional 
grafts, they are more susceptible to cold ischemia and reperfusion injury.  The process of I/R 
injury to the liver graft combines interrelated factors that produce a cascade of events, which can 
ultimately lead to hepatic graft failure.  Ischemia-reperfusion injury remains a significant 
limitation in clinical liver transplantation.  Despite extensive research, no therapeutic approach is 
available to alleviate I/R injury during OLT. 
Of the various pharmacological agents that have been explored to minimize I/R injury, 
the prostaglandin class of drugs has been evaluated to the greatest extent.  Prostacyclin, an 
endogenous metabolite of arachidonic acid, has a critical role in maintaining cellular 
homeostasis, largely due to its vasodilatory and anti-platelet aggregatory properties.  Because the 
half-life of prostacyclin is very short (2-3 minutes), several analogues have been developed with 
extended half-lives.  Considering the many factors involved in I/R injury and the role of PGI2 in 
maintaining cellular homeostasis, PGI2 analogues have been evaluated to reduce I/R injury 
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associated with OLT, however, no attempts to date have successfully made their way to the 
clinic.  As such, extensive efforts have continued to identify an approach to minimize I/R injury 
associated with OLT.  Treprostinil sodium, a recently FDA-approved PGI2 analogue 
(Remodulin®), possesses potent pulmonary and systemic and vasodilatory and platelet anti-
aggregatory effects [236] and has a higher potency and the longest elimination half-life than 
other PGI2 analogues currently commercially available [127].  These advantages of treprostinil 
make it an attractive candidate for protection of the liver graft against I/R injury associated with 
OLT.  This dissertation examined the hypothesis that treprostinil would protect the liver graft 
against I/R injury during OLT.  This is the first study in the field of I/R injury during OLT to 
investigate treprostinil as a therapeutic approach to protect the liver graft against I/R injury in 
OLT.  Also, this dissertation provides a deeper understanding of the metabolic changes in the 
liver graft during the post-operative period, and the widespread protective effects of treprostinil.  
The work presented herein has generated several key and novel findings, summarized below.  
 
1. Treprostinil minimizes hepatic I/R injury to the liver graft during OLT.  
  
To examine our hypothesis, the first step was to perform proof of concept studies in an animal 
OLT model following cold graft storage.  The initial evidence that treprostinil reduced hepatic 
injury post-transplantation was noted by a drastic reduction in serum aminotransferases at 6, 24, 
and 48 hrs post-reperfusion.  These findings warranted additional studies be carried out to further 
investigate the extent of protection conferred by treprostinil.  These studies examined the degree 
of I/R-induced hepatic damage by neutrophil infiltration, necrosis, pro-inflammatory cytokines, 
energy status, and SEC structure.  The results demonstrated that administration of treprostinil to 
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donor and recipient animals prior to hepatectomy and transplantation, respectively, significantly 
reduced neutrophil infiltration and hepatic necrosis, as well as hepatic mRNA levels of pro-
inflammatory cytokines early post-reperfusion.  In addition, cold storage of liver grafts resulted 
in a significant reduction in adenosine nucleotide levels in the liver graft of placebo-treated 
animals, compared to normal liver.  In contrast, treprostinil restored ATP levels in liver grafts 
similar to normal following reperfusion.  Furthermore, structural analysis by electron microscopy 
revealed the finding that treprostinil preserved the sinusoidal endothelial cell lining and reduced 
platelet deposition very early post-transplantation compared to placebo. Hepatic tissue blood 
flow was significantly compromised in the placebo-treated group, whereas treprostinil 
maintained blood-flow to near normal values.  To answer the question of whether or not 
treatment administered to the recipient alone would yield protective effects, additional groups of 
recipients only were treated with treprostinil prior to transplantation and until the time of 
sacrifice.  The significant reduction in serum ALT and AST levels post-OLT in the recipient only 
treatment group compared to placebo-treated group further confirmed treprostinil as a viable 
approach to protect liver grafts against I/R injury post-reperfusion.   
For more than two decades, PG analogues have been studied for their ability to reduce 
I/R injury after liver transplantation; however stability issues, side effects, and the inability to 
show significant difference in primary endpoint have limited its clinical application.  This is the 
first study to demonstrate the efficacy of treprostinil in an animal OTL model and to elucidate 
the protective effects of this particular PGI2 analogue on liver grafts against I/R injury following 
OLT.  The findings from Chapter 2 support continued investigation of treprostinil as a 
pharmacological agent to protect the liver graft against I/R injury during clinical OLT.   
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In the clinical study, treprostinil will be administered intravenously to the recipient 
commencing after induction of anesthesia for the transplant surgery, and will continue 
throughout the transplant procedure and for approximately 48 hours after completion of the 
transplantation surgery until termination of the study drug infusion, unless hemodynamic 
changes or tolerability require dose reduction or discontinuation of treprostinil.  Treprostinil 
dosing will follow a standard 3 + 3 Phase 1 dose-escalation study design.  Three patients will be 
enrolled at the first dose of 5 ng/kg/min.  If 0/3 patients experience a dose limiting toxicity 
(DLT), the next 3 patients will be started at 7.5 ng/kg/min, and this procedure will be followed 
with 10, 12.5, and 15 ng/kg/min.  If 1/3 patients experience a DLT then 3 more patients will be 
added at the 5 ng/kg/min dose. If 2/6 patients experience DLT at 5 ng/kg/min, the dose will be 
decreased to 2.5 ng/kg/min, and a maximum of six patients will be treated at this dose level. If 
2/6 patients experience DLT at 2.5 ng/kg/min then the trial arm will be discontinued because of 
excessive toxicity.  If only 1/6 patients experience DLT at 5 ng/kg/min, then dose will be 
escalated to 7.5 ng/kg/min, and dose escalation will be done by 2.5 ng/kg/min.  If <1 out of six 
patients experience DLT at 2.5 ng/kg/min, then 2.5 ng/kg/min will be the maximum tolerated 
dose for the expanded study. Treprostinil undergoes extensive hepatic metabolism [113] and in 
patients with renal insufficiency, the AUC was increased 3-5-fold [236].  Since there will be 
brief periods where patients undergoing liver transplantation are anhepatic, a maximal dose that 
will be used is 15 ng/kg/min using the above scheme.  Also, the dose of treprostinil may be 
temporarily reduced or stopped at any time during the transplant procedure if, in the opinion of 
the investigator, the subject experiences intolerable side effects (e.g. low systemic blood pressure 
or other clinically significant changes in hemodynamics) that may be attributable to study drug.  
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Upon completion of the 48-hour infusion, administration of treprostinil will be terminated.  An 
additional aim of the study is to determine the target dose for use in a larger clinical study.  
 
2. Treprostinil minimizes I/R-mediated changes in the expression and activity of major 
rat CYP450 enzymes.  
 
An integral component of I/R injury is activation of the pro-inflammatory cascade resulting in 
the production of pro-inflammatory cytokines, i.e. TNF-α, IL-1β, and IL-6.  Inflammation is 
known to markedly impair hepatic detoxification pathways, which can alter the disposition of 
certain drugs.  In fact, changes in drug disposition have been linked to alterations in the 
expression of hepatic drug metabolizing enzymes and drug transporters as a result of 
inflammation or infection [81-84, 192].  Therefore, we hypothesized that I/R injury, an 
inflammatory disease-state manifested during OLT, would significantly impair metabolic 
functions of the liver graft, and that treprostinil would alleviate the impaired drug metabolism 
post-transplantation by inhibiting the inflammatory response and improving hepatic tissue blood 
flow.  Continuing with the donor plus recipient treatment model, in Chapter 3 we examined the 
effects of I/R injury and protection of liver grafts against I/R injury by treprostinil on the 
expression and activity of CYP450 enzymes post-OLT.  Results showed a significant decrease in 
the mRNA expression of all CYP isoforms tested in the placebo-treated group with parallel 
reductions in protein expression and microsomal activity post-OLT, compared to normal liver.  
In contrast, administration of treprostinil improved the mRNA expression of CYP2C11, 2E1, and 
3A1/A23, 3A2, and 3A18, compared to placebo and restored CYP2E1 protein expression and 
activity to normal.  Treprostinil also significantly improved protein expression and hepatic 
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activity of CYP2C11 and 3A, compared to the placebo-treated group.  These findings highlight 
the impact of I/R injury on CYP450-mediated drug metabolism in the liver graft post-OLT.  
These data also show the impact of treprostinil and the extent of liver graft protection on several 
of the major rat CYP450 isoforms post-transplantation.  
 
3. Treprostinil reduces I/R-mediated changes in the mRNA and protein expression of 
major drug transporters in the rat.  
Hepatic drug transporters are important determinants of the clearance of endogenous compounds 
and xenobiotics and their expression is variable and subject to complex regulation by drugs, 
metabolites, oxidative stress and pro-inflammatory cytokines.  Consequences of impaired hepatic 
function include altered pharmacokinetics of drugs.  Extending the analysis further, we studied 
the effects of I/R injury and protection by treprostinil on the expression of uptake and efflux 
transporters in liver grafts post-OLT.  Results from Chapter 4 showed that administration of 
treprostinil significantly reduced peak serum bilirubin levels post-OLT, compared to placebo, 
and restored values to normal by 3 hours post-OLT.  In addition to confirming the protective 
effect of treprostinil on hepatic function post-OLT, these results highlight the particular 
improvement on hepatic transport processes.  In the placebo-treated group, the mRNA 
expression Oatp1a1, Oatp1a4, Ntcp, Oct1, Mdr1a (P-gp), Mdr2, Mrp2, and Bsep in liver graft 
were significantly reduced compared to normal expression post-reperfusion.  Treatment with 
treprostinil improved mRNA expression of several transporters as well as up-regulated Mrp2 and 
P-gp protein expression.  Earlier reports indicated that activation of the IP receptor led to 
glycosylation [140].  Knowing that treprostinil activates the IP receptor, these unexpected 
findings of up-regulated Mrp2 and P-gp, in addition, to doublet bands of Mrp2 detected, indicate 
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additional mechanism(s) by which this prostacyclin analogue stabilized CYP and transporter 
protein expression.  Conclusions that can be drawn from this study are that I/R injury associated 
with OLT significantly down-regulated the expression of several hepatic transporters and 
treprostinil improved hepatic transport processes in the liver graft post-OLT.   
4. Treprostinil does not directly alter the metabolism of four most commonly used 
immunosuppressive medications when co-administered.  
Success of solid organ transplantation requires the use of immunosuppressive medications to 
prevent organ rejection in the recipient.  These immunosuppressive agents, including tacrolimus, 
sirolimus, cyclosporine A, and mycophenolate mofetil, have a narrow therapeutic index and 
fluctuations in the blood concentration of these agents could precipitate allograft rejection or 
organ toxicity.  In Chapter 5, we examined the potential for a drug-drug interaction between 
treprostinil and cyclosporine A, tacrolimus, sirolimus, and mycophenolic acid in vitro.  The 
results indicated that treprostinil does not inhibit or induce the metabolism of these drugs, nor 
does it alter the mRNA expression of CYP3A4, UGT1A9, or 2B7.  These results lead to the 
conclusion that treprostinil is unlikely to directly alter the clearance of these immunosuppressive 
medications, when co-administered.  In addition to being clinically relevant, these studies 
comply with the FDA requirements for a new drug approval.    
In conclusion, the significance of this research is the identification of treprostinil, a 
commercially available PGI2 analogue, as a viable approach to protect the liver graft against I/R 
injury associated with OLT.  This finding is an important advancement to the field of liver 
transplantation and, potentially, to the field of solid organ transplantation.  Amelioration of 
hepatic graft injury with treprostinil will likely improve both short- and long-term transplant 
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outcomes.  This is the first study to demonstrate that treprostinil protected the liver graft against 
I/R injury associated with OLT.  Treprostinil has the potential to serve as a therapeutic option to 
protect liver graft against I/R injury in patients undergoing OLT.  The results of this work 
support continuation with the investigation of a clinical Phase I study to examine the efficacy of 
treprostinil in protecting the liver grafts against I/R injury in human OLT.    
6.2 FUTURE RESEARCH RECOMMENDATIONS 
While treatment of donor plus recipient offers the greatest liver graft protection, it is often not 
feasible to treat both the donor and the recipient in the clinical setting.  Therefore, to optimize the 
treatment regimen for human transplantation, the next step is to characterize the extent of 
protection by treprostinil in two additional treatment models: 1) recipient only treatment and 2) 
storage only treatment, and compare the results to those conferred in the current donor plus 
recipient model.  We initiated studies with recipient only treatment model to determine the 
benefit of treprostinil as a more clinically relevant treatment model.  Results confirmed that 
recipient only treatment with treprostinil significantly reduced serum ALT and AST values, 
validating this approach to protect the liver graft against I/R injury in clinical OLT.   
In terms of liver graft protection against I/R injury, the work presented herein 
demonstrates the several ways by which treprostinil protects the liver graft following OLT.  The 
first aim that we set out was to examine was proof of concept.  Specific mechanistic pathways 
remain to be examined in future studies, as outlined below. 
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Methodology and Optimization 
- The ideal treatment model would be to use treprostinil ex vivo added to the liver graft 
during preservation in UW solution, prior to transplantation.  This approach is the simplest and 
least cumbersome during the clinical transplantation procedure.  To examine this treatment 
model, it is first necessary to optimize the concentration of treprostinil applied to the UW 
solution.   
- Lactated Ringers (LR) solution is used to flush the UW preservation solution out of the 
graft immediately prior to engraftment.  Addition of treprostinil to LR represents an additional 
means of enhancing liver graft protection; however, the compatibility of treprostinil in LR 
solution has not been established.  Treprostinil is compatible with normal saline or water for 
injection.  Whether or not this step would yield additional protection has yet to be determined.  
- The ultimate goal for the use of treprostinil in adult orthotopic liver transplantation is 
protect the liver graft against I/R-associated injury, thereby improve patient and graft survival, as 
well as increase the number of suitable grafts for transplantation and patients who successfully 
recover from OLT.  To achieve this goal, survival data are essential to make functional 
conclusions with respect to graft protection offered by treprostinil.  
Mechanistic Experiments 
- Previous reports have shown that treprostinil inhibits the release of pro-inflammatory 
cytokines by inhibiting NF-KB translocation in vitro [187].  An important mechanism of hepatic 
I/R injury is activation of NF-KB and treprostinil’s inhibitory effect on this transcription factor is 
very important and should be examined.   
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- In the current donor plus recipient treatment model, hepatic tissue levels of pro-
inflammatory cytokines were measured at the mRNA level.  Plasma cytokine concentrations 
should be measured to correlate levels with biochemical results. 
Metabolism and Transporter Experiments 
-  Another important finding resulted from studying the impact of I/R injury on the hepatic 
expression and activities of the major rat CYP450 Phase I enzymes.  Extensions of this study 
would be to examine the effects of I/R injury and treprostinil on Phase II enzymes, as this 
pathway is also important for metabolism.   
- To better characterize the time course of the effects of I/R injury and the protection 
offered by treprostinil on hepatic metabolism and transport processes, additional time point post-
OLT, i.e. 12 hr and 24 hrs, should be examined.  Also, studies in rat and human hepatocytes are 
important to compare activity and expression levels between species.   
- Functional assessment of hepatic transporters in an isolated liver perfused system to 
further study the consequences of I/R injury and treatment with treprostinil on the function of 
these transporters and regulation of cellular homeostasis, i.e. bile acid transport and bile flow are 
important.  The current treatment model did not allow for studying bile flow, though this 
function was greatly improved in the treprostinil-treated group (Personal observations, confirmed 
by Dr. Yoshida).  To better understand the implication of up-regulated Mrp2 and P-gp protein 
expression, the effect of I/R injury and treprostinil on Mrp2 and P-gp function in liver graft post-
OLT is worth examining.   
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- It would also be interesting to determine whether or not the protein expression of other 
ABC transporters is preserved in treprostinil-treated group.  For instance, the mRNA expression 
of Bsep was maintained similar to normal in the treprostinil-treated group post-OLT. Finally, the 
implications of the transporter findings raise new questions about the potential use of treprostinil 
for other hepatic disease-states and it is attractive to speculate that treprostinil could have 
addition applications, e.g. cholestasis, which is characterized by impaired Mrp2 function.    
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Thomas Starzl Transplantation Institute Liver Surgeons 
Paulo Fontes, M.D, Mark L. Sturdevent, M.D., Ruy J. Cruz, M.D., Roberto C. Lopez, M.D., and 
Raymond Planinsic M.D.(Liver Transplant Anesthesia Team) 
Montefiore University Hospital,  
3459 Fifth Avenue Pittsburgh, PA 15213  
Phone: 412-692-4553 
 
Starzl Transplantation Institute 
Clinical Research Manager: Sheila Fedorek, RN CCRC  
 
Research Coordinators: Laurie Hope, R.N., Stephanie Kikla, R.N. and Leslie Mitrik, B.S.  
 
TITLE: An Evaluation of the Safety and Preliminary Efficacy of Perioperative Treprostinil 
in Preventing Ischemia and Reperfusion Injury in Adult Orthotopic Liver Transplant 
Recipients 
A.1.1 Study Rationale 
The hypothesis of this study is that treprostinil can be safely administered perioperatively to 
adult patients undergoing OLT, and will ameliorate or prevent I/R-mediated dysfunction of the 
liver graft and thereby reduce morbidity, leading to shorter hospital stays as compared to 
historical controls.    
Treprostinil, as a prostanoid, is expected to facilitate restoration of the blood supply to the 
revascularized graft and provide the well-characterized protective effects of this class of 
compounds in liver transplant patients. Treprostinil has the advantage of having a longer 
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elimination half-life and increased potency than other prostanoids previously tested in this 
patient population.  
A.2 STUDY OBJECTIVES 
A.2.1 Primary Objective:  
To evaluate the safety, pharmacokinetics and preliminary efficacy of a two-day peri-operative 
course of treprostinil in preventing ischemia-reperfusion of the liver graft post-OLT. 
A.3 CLINICAL ASSESSMENTS 
A.3.1 Primary Safety Assessment 
The primary safety assessments include the following hemodynamic measurements in the 
operating room (OR) and in the intensive care unit (ICU):  
• Mean pulmonary arterial pressure (mPAP, mmHg)   
• Transpulmonary gradient (tPG, mmHg) 
• Pulmonary capillary wedge pressure (CPWD, mmHg) 
• Cardiac output (CO, L/min) 
• Cardiac Index (CI, l/min/m2) 
• Left ventricular ejection fraction (LVEF, %) 
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In addition, heart rate (HR, beats per minute) and Systolic blood pressure (SBP, mmHg) will be 
measured/collected every 6 hrs. The need for ionotropes will be noted for 7 days.  
A.3.2 Pharmacokinetic Assessments 
Pharmacokinetic assessments will also be carried out during the study period by collecting 
multiple blood samples.  To measure treprostinil plasma concentration, up to eighteen 3-mL 
blood samples may be obtained in EDTA-coated tubes just prior to, during, and/or after study 
drug administration The sampling will be done prior to initiation of study drug therapy, at 
approximately 2, 4, 6, 12, 18, 24, 30, 36, 42, 48 hrs during therapy and approximately 0.5, 1, 2, 
4, 6, 8 and 12 hrs after therapy. Samples will be analyzed using a validated UPLC-MS-MS assay. 
Various pharmacokinetic parameters will be calculated as per standard methodology, including 
clearance and half-life.  
A.3.3 Preliminary Efficacy Assessment: 
The primary efficacy assessment will be determined by serum bilirubin concentration (peak and 
AUC) measured during the first seven days after transplantation; the secondary efficacy 
assessments will be determined by several biochemical end points in the first seven days after 
transplantation, including:  
• Biochemical end points: Serum ALT and AST levels in the first seven days after 
transplant (Peak and AUC); Post-transplant renal function, as assessed by serum 
creatinine levels in the first seven days following transplant (Peak and AUC); Blood 
biomarkers of ischemia reperfusion injury; INR. 
• Clinical end point: Primary allograft non-function defined as patient death or re-
transplantation within 30 days due to liver failure; Graft survival at day 30, 90 and 180; 
Subject survival at day 30, 90, and 180.  
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• Intra-operative blood product usage;  
• Biopsy: Post perfusion liver biopsy – histology; biomarkers; Liver biopsy is a safe and 
important diagnostic tool for liver disease. Microscopic examination of a biopsy 
specimen can reveal disease-specific patterns. Histological examination of hepatic 
architecture can more accurately stage the disease or estimate the extent of damage.  
 
The biopsy results will be classified as follows:  
0 = no evidence of reperfusion injury  
1 = mild reperfusion injury 
2 = moderate reperfusion injury  
3 = severe reperfusion injury.  
When possible, the following will also be obtained for subsequent analysis as markers of I/R 
injury and subjects will be followed up to study day 180. 
• Duration of time (days) spent in the ICU during the initial hospitalization. 
• Graft up-regulation of pro-inflammatory cytokines (TNF-α, IL-6); chemokines (IL-8) 
• Ultra-structural analysis and immunohistochemistry (CD31) 
• Intra-operative blood product usage  
• Total costs for initial transplant hospitalization  
A.3.4 Number of Subjects 
The total enrollment will be up to 30 patient-subjects. 
A.3.5 Estimated Study Duration 
The estimated study duration will be approximately 3 years. 
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A.4 EXPERIMENTAL PLAN 
A.4.1 Study Design 
This is a single center, open-label, dose-escalation Phase I study of treprostinil in subjects who 
are undergoing orthotopic liver transplantation for end stage hepatic disease at the Thomas E. 
Starzl Transplantation Institute at the University of Pittsburgh Medical Center, Pittsburgh, PA.  
The study will evaluate the safety and preliminary efficacy of treprostinil in adult OLT patients.  
An appropriately signed informed consent form will be obtained for each study subject once 
transplant candidacy is established and prior to any study-related procedures. Informed consent 
will be confirmed at baseline and the subject will be asked if they wish to proceed with the study 
or wish to withdraw prior to any baseline assessments. Approximately 30 subjects who have 
signed informed consent and who continue to meet entry criteria will be enrolled during pre-
transplantation procedures. Treprostinil dosing will follow a standard 3 + 3 phase 1 design. Three 
patients will be enrolled at the first dose level of 5 ng/kg/min. If 0/3 patients experience a dose-
limiting toxicity (DLT*) then the next 3 patients will be started at 7.5 ng/kg/min. If 1/3 patients 
experience a DLT then 3 more patients will be added at the 5 ng/kg/min dose. If 2/6 patients 
experience DLT at 5 ng/kg/min, the dose will be decreased to 2.5 ng/kg/min, and a maximum of 
six patients will be treated at this dose level. If 2/6 patients experience DLT at 2.5 ng/kg/min 
then the trial arm will be discontinued because of excessive toxicity.  If <1 out of six patients 
experience DLT at 2.5 ng/kg/min, then 2.5 ng/kg/min will be the maximum tolerated dose for the 
expanded study. If only 1/6 patients experience DLT at 5 ng/kg/min, then dose will be escalated 
to 7.5 ng/kg/min, and dose escalation will be done by 2.5 ng/kg/min. The maximal dose that will 
be used is 15 ng/kg/min, using the above scheme. The dose of treprostinil may be temporarily 
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reduced or stopped at any time during the transplant procedure if, in the opinion of the 
investigator, the subject experiences intolerable side effects (e.g. low systemic blood pressure or 
other clinically significant changes in hemodynamics) that may be attributable to study drug. 
However, every effort will be made to maintain the study drug dose at the target dose or 
maximum tolerated dose to provide the best chance of a protective effect at the moment of 
reperfusion of the donor organ. At the completion of the 48-hour infusion, administration of 
treprostinil will be terminated. The Follow-up phase will begin after the completion of study 
drug infusion.  Follow-up phase study assessments will occur at Study Days 3-7, 30, 90, and 180.   
 
*DLT is defined as any of the following:  
1. Volume and vasopressor refractory hypotension (norepinephrine or epinephrine > 0.5 
ug/kg/min, dopamine > 10 ug/kg/min, and/or vasopressin > 4 U/hr), for which no other 
reasonable cause(s) can be found and promptly treated. 
2. Sustained (> 4 minutes) hypotension defined as systolic pressure of < 80 mmHg that is not 
responsive to usual interventions for a liver transplant patient, such as fluid bolus and the use of 
vasopressors.  
3. Persistent, uncontrolled and clinically significant hemorrhage. 
4. Vomiting non-responsive to medical intervention such as use of ondansetron, 
prochlorperazine, promethazine and with no other obvious mechanical causes such as bowel 
obstruction and gastric ileus. 
5. Seizure  
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A.4.2 Schedule of Time and Events 
The time and events schedule for the study is presented in Table 10.   
Table 9: Overall Time and Events Schedule for the Study 
Study Phase Screening Baseline Treatment Follow Up 
Study Day -180 to 0 0 1-2 3 4-7 30 90 180 
Informed Consent/Medical 
History 
X X       
Physical Examination/Vital Signs  X X X    X 
MELD Score X X       
Recipient 
Demographics/Indication for 
Transplant 
X X       
Cadaver Donor Demographics  X       
Cold Ischemia Time (hr)   X      
Donor liver biopsy (Back Table 
biopsy) 
 X       
Cytotoxic Crossmatch  X       
Clinical Laboratories1 X X X X X X X X 
Intra-operative Liver Biopsy   X      
Intra-operative blood usage    X      
Total bilirubin (mg/dl)/AST/ALT2 X X X------- ------ ------ ------ ------ X 
International Normalized Ratio 
(INR) 
X X X------- ------ ------ ------ ------ X 
Study Drug Infusion   X------X      
Graft Survival    X-------- ------ ---- --------- --------- -----X 
Subject Survival   X-------- ------ ---- --------- --------- -----X 
Retransplantation   X-------- ------ ---- --------- --------- ------X 
Initial Hospitalization (days)   X-------- ------ ---- --------- --------- -----X 
Time in Intensive Care Unit 
(days) 
  X-------- ------ ---- --------- --------- ------X 
treprostinil  Plasma Level 
Sample(s)3 
 X X------X -------X     
Concomitant Medications   X------- ------ -------X    
Adverse Events   X------ --- ------X    
Heart rate (HR, bpm)  X X------ ------- -------X    
Systolic blood pressure (SBP, 
mmHg) 
 X X------- ------- ------X    
Left ventricular ejection fraction 
(LVEF,%) 
 X X      
Cardiac Index (CI, l/min/m2)  X X      
Cardiac output (CO, L/min) 
 X X      
Pulmonary capillary wedge 
pressure (CPWD, mmHg) 
  X      
Transpulmonary gradient (tPG, 
mmHg) 
 
 X X      
Need for ionotropes 
  X ------- ------X    
1. Clinical laboratories include all liver function tests carried out as part of the standard of care of the liver 
transplant patients and include ALT, AST, Alkaline phosphatase , gamma glutamyl transpeptidase, bilirubin, 
Prothrombin time , Partial Thromboplastin time, International Normalized Ratio, serum creatinine and BUN. 
2. Additional blood samples may be taken so that bilirubin, AST and ALT data are collected at least once every 6 
hours during the first two days, at least once every 12 hrs on days 3-4, and at least once on days 6 and 7.  
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3. Up to eighteen 3-mL blood samples may be obtained in EDTA tubes just prior to, during, and/or after study 
drug administration to evaluate treprostinil plasma levels. The sampling will be done prior to initiation of study 
drug therapy, at approximately 2, 4, 6, 12, 18, 24, 30, 36, 42, 48 hrs during therapy and approximately 0.5, 1, 2, 
4, 6, 8 and 12 hr.  
A.5 SUBJECT ELIGIBILITY CRITERIA 
Inclusion and exclusion criteria will be assessed during the Screening and Baseline phases prior 
to starting study drug. 
A.5.1 Inclusion Criteria 
Subjects must: 
1. Have signed appropriate informed consent. 
2. Be between 18 years and 65 years of age. 
3. Have been accepted as a liver transplant candidate at the UPMC. 
4. Be receiving a cadaver donor liver transplant, including a donor liver with less than 40% 
macrosteatosis; receiving a donor liver with necrosis score of greater than 10; those receiving 
livers with cold ischemia time greater than 6 hours, but less than 12 hours.  
5. Be treated in accordance with the standard of care protocol(s) currently in effect for liver 
transplant recipients at the UPMC, including immunosuppression and other elements of pre- 
and post-operative care.  
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A.5.2 Exclusion Criteria  
Subjects must not: 
1. Be receiving a living donor liver transplant. 
2. Be receiving a donor liver with a cold ischemia time less than 6 hours or greater than 12 
hours.  
3. Be receiving a donor liver with macrosteatosis greater than 40%. 
4. Be receiving any investigational drug (a drug other than treprostinil administered under an 
IND) or participating in any other investigational study, with the exception of alemtuzamab 
(Campath). 
5. Be receiving any prostanoid to treat portopulmonary hypertension.  
6. Have had a failed liver transplant within the previous 180 days. 
7. Be undergoing multi-organ transplantation (transplantation of organs other than liver at the 
same time as the liver transplantation procedure). 
8. Have fulminant hepatic failure 
9. MELD score of > 35 
10. Hepatitis C positive donor liver  
11. On ionotropes at the time of the study 
12. On renal replacement therapy at the time of study 
13. Be receiving any non-standard immunosuppression protocol or other non-standard treatment 
that could affect interpretation of the study results.  
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14. Those currently receiving treatment for portapulmonary hypertension. 
15. Those with significant cardiovascular disease.  
16. Have any known hypersensitivity to prostaglandins, prostacyclin or treprostinil.  
17. If female, be pregnant or nursing (as confirmed by urine pregnancy test at Baseline).  
18. HIV positive  
A.5.3 Concomitant Medications 
Therapy with investigational agents will be prohibited throughout this study.  No alteration in the 
use of immunosuppression or other standard of care drugs or anesthetics at the center will be 
required.  Analgesics including narcotics may be used during this study if needed to treat pain.  
No clinically important drug interactions with treprostinil have been reported [236].  
A.5.4 DRUGS AND DOSING 
A.5.5 Drug Dosage, Administration, and Schedule 
A single strength of commercially available, FDA-approved, treprostinil (1.0 mg/mL, 
Remodulin®, United Therapeutics Inc.) will be provided in 20-mL multi-dose vials. Study drug 
will be administered intravenously (IV) through a dedicated central venous line or peripherally 
inserted central catheter only (PICC).  
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Briefly, treprostinil will be diluted in sterile saline and administered through a dedicated 
line using a pump capable of accurate delivery at the selected infusion rates (normally in the 
range of 1-2 ml/hour).  A PICC may be placed if an appropriate central line is not available.  IV 
treprostinil may not be administered peripherally except for very short periods (a few hours) 
because of the possibility of thrombophlebitis.   
Assistance for this study also will be available from several staff members at UPMC who 
are familiar with administration of treprostinil because of its use in portopulmonary hypertension 
subjects undergoing liver transplantation. 
Treprostinil, at the pre-determined dose level, will be administered intravenously 
commencing after induction of anesthesia for the transplant surgery and continued throughout 
the transplantation procedure and for approximately 48 hrs after the transplantation surgery, 
unless hemodynamic changes or tolerability requires discontinuation of dosing.  If the prescribed 
dose is not well tolerated, the dose may be reduced and the subject maintained at the maximal 
tolerated dose, based primarily on hemodynamics, which will be carefully monitored throughout 
the surgery and during the remainder of the treatment period. If necessary, treprostinil 
administration may be completely terminated.  Note, in this regard, that gradual termination of 
dosing is recommended in the treprostinil package insert for PAH patients because of the 
possibility of acute worsening of PAH symptoms.  However, rebound applies to acute 
decompensation in PAH patients who had been on long-term treatment; which would not apply 
to the patient population being studied under this clinical protocol.  Blood samples to determine 
treprostinil plasma levels may be obtained prior to and/or during surgery from all subjects.  It 
must be understood that treprostinil blood level data will not be available in time to help with 
dosing decisions for an individual subject.  Once study drug infusion has been terminated, the 
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subject will be monitored for at least 24 hours to ensure there are no untoward effects, e.g. 
changes in vital signs.  
A.5.6 Compliance with Dosing 
Because subjects will be hospitalized during the entire Treatment Phase, no special compliance 
assessments will be conducted.   
Adverse events related to treprostinil administration are summarized below, in Table 11.   
Table 10: Expected Events Attributable to Treprostinil 
Abdominal cramping            Nausea 
Backache Leg pain 
Chest pain Pallor 
         Diarrhea Pre-syncope / Syncope 
Dyspnea Premature ventricular contractions 
Jaw pain Restlessness 
Fatigue Sweating 
Flushing Warmness 
Headache Vomiting 
Hypotension Hypoxia 
 
   164 
A.5.7 Storage and Handling of Study Drug 
Treprostinil will be stored in accordance with manufacturer instructions at room temperature of 
15 to 30 °C (59 to 86 °F), and will not be frozen or exposed to heat. The Investigational Drug 
Service (IDS) at the University of Pittsburgh Medical Center will maintain a log sheet of all 
study drug as it is received and used during the study. Treprostinil will not be used beyond the 
expiration date assigned by the manufacturer. 
A.6 EXPERIMENTAL PROCEDURES 
A.6.1 Screening Phase  
The study population will be recruited from all adult, age 18-65 years, subjects who meet routine 
candidacy criteria at the center to undergo liver transplantation and otherwise meet study entry 
criteria.  Eligible subjects will be given the opportunity to sign informed consent for the study as 
soon as transplant candidacy is confirmed, which usually occurs weeks or months prior to 
confirmation that an appropriate donor liver has been procured.  Obtainment of informed consent 
prior to donor liver procurement will be implemented, because subjects may only have a 
relatively brief time in which to make decisions between notification of procurement, 
hospitalization, and the transplant procedure. Screening assessments may be conducted after 
informed consent has been obtained and prior to the Baseline Phase.   
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Screening activities include:  
• Informed consent 
• Medical history 
• MELD score 
• Clinical laboratories 
• Recipient demographics (including indication for transplant) 
A.6.2 Baseline Phase 
The baseline phase activities will occur after donor organ procurement and hospitalization of the 
subject prior to the transplantation surgery.  At this time, informed consent will be confirmed and 
the subject will be asked if they wish to proceed with the study or wish to withdraw.  Baseline 
activities include the following:  
• Medical history (if updated from Screening) 
• Physical examination / vital signs 
• MELD score  
• Clinical laboratories 
• Recipient demographics and indication for transplant (if updated from Screening) 
• Cadaver donor demographic 
• Cytotoxic cross match  
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A.6.3 Treatment Phase 
The Treatment Phase will begin at the initiation of treprostinil after induction of anesthesia for 
the transplant surgery.  The Treatment Phase will continue throughout the surgery, and until 
termination of the study drug infusion (approximately 48 hrs post-transplantation) and Day 2 
assessments are completed.   
The first clinical laboratory specimen acquired immediately following the completion of 
the transplant surgery will be considered the postoperative Day 0 sample.  Clinical laboratory 
samples during the Treatment Phase Day 1 and 2 will be drawn at the institution’s routine 
laboratory collection times.  Table 3 describes the schedule for collecting serum bilirubin, ALT 
and AST levels. The various endpoint assessments including, survival, retransplantation, 
hospitalization times, etc. are continuous assessments that will be obtained. Study drug will be 
infused for approximately 48 hours following completion of the transplant surgery.   
 
Treatment Phase activities include:  
• Physical examination / vital signs  
• Clinical laboratories  
• Whenever possible, an intra-operative post reperfusion liver biopsy for histopathology 
• Cold ischemia time (hr) 
• Subject survival 
• Graft survival 
• Retransplantation 
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• Initial hospitalization (days) 
• Time (days) in ICU 
• Study drug infusion 
• Pharmacokinetic samples  
• Adverse events 
A.6.4 Follow-up Phase 
The Follow-Up Phase will begin after termination of study drug infusion and completion of all 
Treatment Phase assessments, and continue until Study Day 180.  The various endpoint 
assessments (survival, retransplantation, hospitalization times, etc.) will be continuous 
assessments and obtained for entry on the case report form (CRF) from routine documentation at 
the center. Transplant recipients may require extended hospitalizations at the transplant center or 
elsewhere during the recovery period, or they may be released within days of the transplant 
surgery in the absence of complications.  Duration of initial hospitalization, ICU stay, and graft 
and subject survival will be recorded on the CRF based on routine transplant center 
documentation (e.g. discharge summaries).   
 Study-specific laboratory assessments required for Days 3-7 will be collected starting at 
the institution’s first routine morning laboratory collection time.  
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A.7 STUDY TERMINATION 
A.7.1 Subject Discontinuation 
A subject may voluntarily withdraw or be withdrawn from the study and/or study drug 
administration by the investigator or treating sub investigators at any time for reasons including, 
but not limited to, the following: 
• The subject wishes to withdraw from further participation. 
• A serious or life-threatening AE occurs or the investigator considers that it is necessary to 
discontinue study drug to protect the safety of the subject. 
• The investigator elects to discontinue the study 
• Changes in personnel or facilities adversely affect performance of the study 
• The reviewing IRB requires termination of the study for safety or compliance reasons. 
 
In the event that a subject discontinues study drug prematurely due to an AE, the subject will be 
followed until either the investigator determines that the AE has resolved, it is no longer 
considered clinically significant, or the subject is lost to further follow-up. If a subject 
discontinues study drug prematurely for any reason, the subject will be encouraged to remain in 
the study and attend the remaining scheduled study assessments. 
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A.8 ADVERSE EVENT REPORTING 
A.8.1 Adverse Event  
An adverse event (AE) is any untoward medical experience occurring to a subject during a 
clinical trial whether or not it is related to the study drug.  An AE may include a current illness, 
injury, or any other concomitant impairment of the subject’s health, as well as abnormal 
laboratory findings if deemed to have clinical significance.  An AE may also include worsening 
of an existing symptom or condition or post-treatment events that occur as a result of protocol-
mandated procedures.  
A.8.2 Serious Adverse Event  
Serious adverse event (SAE) is an AE occurring at any dose that results in any of the following: 
• Death 
• A life-threatening AE 
• Inpatient hospitalization or prolongation of existing hospitalization 
• A persistent or significant disability / incapacity 
• A congenital anomaly / birth defect 
 
In addition, important medical events that may not result in a fatal outcome, be life-threatening, 
or require hospitalization may be considered serious when, based upon appropriate medical 
judgment, they may jeopardize the subject and require medical / surgical intervention to prevent 
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one of the outcomes listed above.  Examples of such medical events include allergic 
bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias 
or convulsions that do not result in hospitalization, or the development of drug dependency or 
drug abuse.   
Life-threatening means that the subject was, in the view of the sponsor-investigator, at 
immediate risk of death from the event as it occurred.  It does not mean that the event, had it 
occurred in a more severe form, might have caused death. 
A.8.3 Expected Adverse Event  
AEs associated with liver transplant surgery outcome include: 
All study subjects will be liver transplant recipients who may be critically ill from underlying 
liver disease and/or associated conditions prior to transplant surgery, and who will be recovering 
from the transplant procedure afterward.  According to the “Consent to Adult Liver Transplant” 
used at UPMC, the risk of some type of complication (major or minor) from liver transplant 
surgery is 45 to 55%, and the death rate from surgery is 4%.  Subjects are likely to be in an ICU 
with or without ventilator support after the surgery, and to be hospitalized for periods ranging 
from days to months.  Expected non-serious and serious AEs in liver transplant recipients 
include a long list of intra-operative complications and sequelae from major surgery and 
transplant, including bleeding, major infection, renal failure with or without hemodialysis, 
cardiovascular problems, reactions to or side effects from immunosuppressive drugs, acute 
rejection of the donor liver, and many other issues.  
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Events that are normally observed in liver transplant recipients are listed in Table 12.  All 
AEs will be captured on the CRF.   
Any event that occurs under circumstances in which it is considered possible that study 
drug may have caused or contributed to the event MUST be reported as an AE, rather than as a 
normal liver transplant event, because of the possible relationship to study drug. Known adverse 
events related to treprostinil are in the package insert [236]. 
AEs known to be associated with treprostinil therapy:  an expected AE for treprostinil is 
defined as any AE that is defined in terms of nature, severity, and frequency in the current 
Investigators’ Brochure (United Therapeutics, Inc.).  These findings should be listed in the CRF 
as AEs. 
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Table 11: Expected Event is Liver Transplant Patients 
 
Category of Event Events 
Blood disorders Hemorrhage / coagulopathy / thrombosis  
Exposure to communicable disease and other risks of 
blood / blood products as listed on liver transplant consent 
form 
Thrombocytopenia 
Leukopenia 
Anemia 
Disseminated intravascular coagulopathy (DIC) 
Cardiac and vascular disorders Hypotension 
 
Gastrointestinal disorders Ascites 
Hepatobiliary disorders Jaundice 
Hepatic failure 
Portal vein thrombosis  
Bile duct stenosis 
Hepatic artery thrombosis  
Hepatic artery stenosis 
Hepatoportal venous flow-hyperperfusion syndrome 
Immune system disorders Liver transplant rejection  
Immunosuppression 
Infections Sepsis 
Septicemia 
Lower respiratory tract infection 
Peritonitis 
Urinary tract infection  
Pneumonia  
Bacteremias 
Wound infection 
Injury, poisoning and procedural 
disorders 
Post procedural bile leak 
Splenic injury  
Injury to structures in the abdomen  
Damage to nerves due to contact or positioning during 
surgery burns (e.g. from cauterization or other electrical 
equipment) 
Scarring 
Nervous system & Psychiatric 
disorders 
Confusional state / agitation / encephalopathy 
Cerebrovascular accident 
Renal disorders Acute renal failure  
Electrolyte disorders 
Respiratory disorders Acute respiratory failure 
Skin disorders Decubitus ulcer [pressure ulcer] 
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A.8.4 Documentation of Adverse Events 
An AE or SAE occurring during the study, and which is felt to be possibly or likely related to 
treprostinil administration, must be documented in the subject’s source documents and on the 
appropriate CRF page.  Information relating to the AE such as onset and cessation date and 
times, intensity, seriousness, relationship to study drug, and outcome is also to be documented in 
the CRF.  Where possible, AEs should be recorded using standard medical terminology.  If 
several signs or symptoms are clearly related to a medically defined diagnosis or syndrome, the 
diagnosis or syndrome should be recorded on the CRF page, not the individual signs and 
symptoms. 
 All AEs must be followed until resolution (or return to normal baseline values), or until 
they are judged by the investigator to no longer be clinically significant, or for at least 4 weeks if 
the AE extends beyond the Day 180 assessments.  
All treprostinil-related SAEs should be followed until resolution, death, or the subject is 
lost to follow up or up to Day 180 assessments if the SAE is still continuing. Supplemental 
measurements and/or evaluations may be necessary to fully investigate the nature and/or 
causality of an AE or SAE.  This may include additional laboratory tests, diagnostic procedures, 
or consultation with other healthcare professionals.  CRF pages should be updated with any new 
or additional information as appropriate. 
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A.8.5 Reporting Responsibilities of the Investigator 
In accordance with guidelines established by the University of Pittsburgh Institutional Review 
Board (IRB), the sponsor-investigator will promptly notify the IRB of all serious and unexpected 
adverse events felt to be related or possibly related to the study drug.   
A.8.6 Safety Reports 
In accordance with FDA regulations, the sponsor-investigator will notify the FDA, other 
competent authorities, and the sub-investigators of any AE that is considered to be reasonably or 
possibly attributable to study drug and is both serious and unexpected.  
A.9 STATISTICS 
A.9.1 Data Collection and Retrieval 
Results of all assessments will be collected in an excel spread sheet for each subject enrolled in 
the study.  
A.9.2 Primary Safety and Preliminary Efficacy Endpoint 
This is a phase I/II study and by nature is descriptive. It follows a typical phase 1 protocol.  
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A.10 SAFETY ANALYSIS 
The safety of treprostinil will be evaluated by analyses of AEs and clinical laboratory 
parameters. They will be summarized according to intensity, seriousness and causality. For all 
safety endpoints, tabular summaries will be provided. Secondary endpoints will be calculated 
and/or analyzed based on data routinely obtained by the Transplant Institute.   
Pharmacokinetic parameters such as clearance, volume of distribution, half-life, terminal 
disposition rate constant will be calculated.  
Preliminary Efficacy: Peak and AUC values for bilirubin, AST and ALT will be 
calculated. The hospital costs, and total hospitalization days, where relevant will also be 
collected. The data collected in this study will be compared to historical data as preliminary 
estimate of efficacy.  
A.10.1 Interim Analyses 
No interim efficacy analysis is planned.    
A.10.2 Data Monitoring Committee 
The protocol will be submitted to the Institutional Review Board (IRB) at the University of 
Pittsburgh. The Starzl Transplantation Institute PRC/DSMB will serve as the data and safety 
monitoring committee. The data collected from each subject will be reviewed by the 
investigators on a patient to patient basis.  
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A.11 PACKAGING AND FORMULATION 
A.11.1 Study Drug Content  
FDA-approved treprostinil (1 mg/mL) will be obtained from United Therapeutics, Inc. who will 
supply the study drug in 20-mL multiple-entry vials 
A.11.2 Study Drug Storage and Handling 
The treprostinil will be stored securely in a controlled-access area at room temperature of 15 to 
30 °C (59 to 86 °F).  It will not be frozen or exposed to heat.   
A.11.3 Study Drug Accountability 
The sponsor-investigator is responsible for study drug accountability and reconciliation overall 
and on a per subject basis.  Drug accountability records will be maintained during the study and 
these records will include:  the amount of study drug received from the manufacturer for this 
study, the amount dispensed to each subject, and the amount of unused drug.  During the 
Treatment Phase site personnel should assess drug dispensed, drug returned, and dosing 
information to confirm drug accountability and compliance.  
A.11.4 Study Documentation and Storage 
Study records will be retained in accordance with FDA and IRB requirements. 
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A.12 REGULATORY AND ETHICAL OBLIGATION 
A.12.1 Regulatory Requirements 
The investigator will obtain the required FDA and ethics committee approval to conduct the 
study.  During the conduct of the study an Annual Report will be compiled by the sponsor-
investigator for submission to the FDA, as required. Any additional local reporting requirements 
as specified by the IRB or other institutional authorities will also be fulfilled during the conduct 
of the study. 
A.12.2 Informed Consent Requirements 
Before a subject is enrolled in the study, the investigator or their designated sub-investigator(s) 
must explain the purpose and nature of the study, including potential benefits and risks and all 
study procedures to the subject.  The subject must sign and date an IRB-approved informed 
consent form prior to the conduct of any study-related activities.  A copy of the signed consent 
form will be given to the subject and the original will be retained in the study site’s records. 
A.12.3 Institutional Review Board 
Prior to study initiation the investigator will obtain approval for the study from the University of 
Pittsburgh IRB.  This IRB operates in accordance with the FDA regulations at 21 CFR Parts 50 
and 56.  If, during the study, it is necessary to amend either the protocol or the informed consent 
form, the investigator is responsible for obtaining IRB approval of these amended documents 
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prior to implementation.  A written summary of the study will be provided by the investigator to 
the IRB following study completion or termination according to the IRB standard procedures.  
Additional updates will also be provided in accordance with the IRB standard procedures. 
A.12.4 Subject Confidentiality 
Every effort will be made to keep medical information confidential.  The FDA and the IRB may 
inspect the medical records of any subject involved in this study.  The investigator may release 
the subject’s case records to the IRB or the FDA or appropriate local regulatory agencies for 
purposes of checking the accuracy of the data and/or regulatory compliance.  A number will be 
assigned to all subjects and any report published will not identify the subjects’ names. 
A.13 PROTOCOL AMENDMENTS AND STUDY TERMINATION 
Protocol Amendments will be submitted prospectively to the FDA for any change to the protocol 
that significantly affects the safety of the subjects.  Other changes to the protocol will be 
submitted as a Protocol Amendment at the time of requisite Annual Reports to the IND 
application.  All changes to the protocol must be prospectively approved by the University of 
Pittsburgh IRB.  No deviations from the IRB-approved protocol are permitted, except as 
necessary to protect the safety of individual research subjects.  Such deviations from the protocol 
will be promptly reported to the IRB.  A final report will be submitted to the IRB and FDA at the 
time of study termination. 
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APPENDIX B 
B.1 CONSENT FORM 
CONSENT TO ACT AS PARTICIPANT IN A RESEARCH STUDY 
 
 
TITLE: AN EVALUATION OF THE SAFETY AND PRELIMINARY EFFICACY OF 
PERIOPERATIVE TREPROSTINIL IN PREVENTING ISCHEMIA AND REPERFUSION 
INJURY IN ADULT ORTHOTOPIC LIVER TRANSPLANT RECIPIENTS 
PRINCIPAL INVESTIGATOR: Dr. Abhinav Humar,  Professor of Surgery 
Montefoire Hospital North 725, 3459 Fifth Avenue, Pittsburgh, PA 15213 
Phone: 412-692-4553, Fax # 412-692-4180 
 
Co-Principal Investigator: Raman Venkataramanan, Ph.D; F.C.P.;  
Professor of Pharmaceutical Sciences and Pathology  
718 Salk Hall, University; of Pittsburgh School of Pharmacy 
3501 Terrace Street, Pittsburgh, PA 15261 
Phone: 412-648-8547 Fax: 412-383-7436 
 
 
   180 
Co-investigators:  Thomas Starzl Transplantation Institute Liver Surgeons: 
Paulo Fontes, M.D, Mark Sturdevent, M.D., Ruy J. Cruz, M.D., Mark L. Sturdevant, M.D., 
Roberto C. Lopez, M.D., and Raymond Planinsic M.D.(Liver Transplant Anesthesia Team) 
Montefiore University Hospital,  
3459 Fifth Avenue Pittsburgh, PA 15213  
Phone: 412-692-4553 
 
Co-investogators: Pathology 
Anthony Demetris, E737 UPMC-Montefiore, 3459 Fifth Avenue, Pittsburgh, PA 15213 
Phone 412-647-7646 
Co-investigators: School of Pharmacy 
Nisanne Ghonem, PharmD, PhD: 731 Salk Hall, 3501 Terrace Street, Pittsburgh, PA  
 
Phone: 412-648-2377  
 
Starzl Transplantation Institute: 
Tracy Grogan, Unit Director: UPMC Montefiore South 555, 200 Lothrop Steer, Pittsburgh, PA 
15213. Phone: 412-647-8560 
Clinical Research Manager:  Sheila Fedorek, RN CCRC  
 
Research Coordinators: Laurie Hope, R.N., Stephenie Kikla, R.N. and Leslie Mitrik, B.S.  
 
                           
SOURCE OF SUPPORT: United Therapeutics Corporation (Partial); Thomas Starzl 
Transplantation Institute  
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Why is this research being done? 
 
The liver is subjected to low temperature during transportation from the person who donates the 
liver (the donor) to the person who gets it (the recipient). When the liver is put inside the 
recipient it is warmed up to normal body temperature. Sometimes during these steps the liver 
cells may undergo damage and may not function well. If this happens patients may have to stay 
in the hospital for a longer period of time so that the liver will eventually become better or in 
certain cases the patient may need a second liver transplantation. There are no medical 
treatments approved by the U.S. Food and Drug Administration (FDA) to prevent such problems. 
This purpose of this research study is to find out whether a drug called Treprostinil is useful in 
preventing such problems.  
Treprostinil is a drug that is approved by the FDA (Remodulin®) for the treatment of a 
disease called pulmonary arterial hypertension, or PAH.  PAH is a condition where there is high 
pressure in the blood vessels that supply the lungs. Treprostinil works by widening the blood 
vessels and by preventing blood components from sticking together. Drugs like Treprostinil can 
also protect cells from the kinds of injury described above.  Treprostinil has been given to more 
than 2,000 patients with PAH and has been shown to be safe and effective. Treprostinil has also 
been given safely to patients with a form of PAH called Porto-Pulmonary Hypertension, who had 
some degree of liver problems. At UPMC, two patients with end stage liver disease have 
received Treprostinil (36 and 45 ng/kg/min) during liver transplant, continuing throughout the 
transplant procedure and afterward in the intensive care unit without any treprostinil-related 
problems. However, Treprostinil has not been studied before in patients undergoing liver 
transplant surgery as part of a formal clinical investigation. Results from a recent animal study 
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proved that Treprostinil is effective in reducing liver injury during liver transplantation.  In this 
study we will test to see whether or not Treprostinil decreases damage to liver cells and 
decreases the length of stay in the hospital.    
 
Who is being asked to take part in this research study? 
 
You are being invited to take part in this research study because you are a liver transplant 
candidate and will receive a liver transplantation. Female and male liver transplant patients, 
between the ages of 18 and 65 years of age are being asked to participate in this clinical study.  
This study will take place at the University of Pittsburgh Medical Center, Pittsburgh, PA, and 
will include approximately 30 patients.  
 
How will the study be done? 
 
If you decide to participate in this study, you will undergo a screening visit, a baseline visit that 
is on the day of transplantation, a study treatment phase that will start in the operating room and 
last for 2 days, and follow up phase that will last up to day 7 after you receive the new liver. On 
post-op days 30, 90 and 180 we will only be collecting information on your survival and liver 
status, information if you have been retransplanted, initial hospitalization and time in the 
intensive care unit. This information will be obtained from your hospital and clinic records. 
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Screening Visit 
 
The Screening Phase can occur up to 180 days before your liver transplant surgery following 
your selection as a candidate for liver transplantation. To determine if you meet the criteria for 
participation in this study, the doctor will review and collect information about your medical 
history. You will have a physical examination and your vital signs will be taken. Blood tests will 
be done that are part of the clinic’s standard screening for liver transplant surgery and 
information (age, gender, weight, height, medical history, clinical laboratory test results 
indicative of your liver and kidney function) will be collected for the study from these tests. If 
you meet all the study participation conditions and sign the informed consent, you can enter the 
“Baseline visit”.   
 
Baseline Visit 
 
The baseline visit occurs the day you enter the hospital for the liver transplant surgery. During 
this time, your doctor will make a final decision if you can enter the study. The routine pre-
operative examinations and test will be conducted including a physical exam, medical history 
update, and blood tests to evaluate your liver and kidney function. A urine pregnancy test will be 
performed in women of child bearing potential. If you meet all the study entry conditions, you 
will be enrolled in the study and will receive one of the doses selected by your doctor.  Once the 
Baseline assessments are complete, you will enter the Study Treatment Phase.     
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Treatment Phase 
 
You will begin receiving Treprostinil at the time you receive medications that put you to sleep 
and prepare you for the surgery.  Treprostinil will be given through a central line (a tube placed 
into a large blood vessel in your chest) or peripherally inserted central catheter (usually a longer 
tube inserted in a vein in your arm that will reach the larger vessel) that will only be used for 
Treprostinil.  No other medication (drug) can be given in this line. 
You will continue to receive study drug (Treprostinil) during your surgery and for 2 days 
(48 hours) after your surgery and then the study drug will be stopped.  You will be in the hospital 
and will be closely watched by members of your medical team for any problems during this 
entire time.  On the first day after the transplant, in addition to the routine blood sampling, two 
additional blood samples will be taken to measure the certain liver enzymes such as AST, ALT, 
that tell us how your liver is working.  
  Medical information that is part of the routine care of liver transplant surgery will also 
be collected and includes blood tests to evaluate your liver and kidney function, length of the 
liver transplant surgery, any signs or symptoms of liver injury, time admitted to the intensive 
care unit, time spent needing a machine to assist you with breathing (ventilator) and information 
about the donor liver such as age, gender and weight. You may also be asked questions to find 
out whether you had any unusual problems or symptoms that may be related to the 
administration of study drug.  Blood samples or any other biological material (optional liver 
biopsy) already collected may also be used for assessment of substances in the blood that 
indicate injury to the new liver.  They will not be used for any genetic testing.  
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Follow-Up Phase 
 
The Follow-Up Phase visits for the study will be done during the routine follow-up care that you 
receive after liver transplant surgery. Results from blood tests that measure the function of your 
liver and kidney and physical examinations that are done on day 3 and 7 will be collected.    
In addition, on post-op days 30, 90 and 180 we will only be collecting information on the 
condition of your new liver and if you needed another transplant, if you are still in the hospital or 
intensive care unit following the original surgery, and are you alive and well at these time points. 
This information will be obtained from your hospital and clinic records.  Information regarding 
amount of time you may have spent needing a breathing machine will also be collected.     
Throughout the study, you will be asked to report any unusual problems that you 
experience, regardless of whether or not you feel they are related to, or caused by, the study 
medication. It is very important for you to discuss any difficulties or side effects with your 
doctor. If you have any significant side effects or problems, you should quickly contact your 
doctor. Your doctor will then decide if you should receive other treatment. 
If you decide to participate in the study, your medical records will be reviewed for 
demographic information (age, gender, and race), lab results (done as part of your routine post 
transplant care), medication information, and information about the results of testing and 
procedures that are preformed during the transplant follow-up period for days 1 through 7, as 
described above.   
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Additional Assessments That May Be Conducted During the Treatment and Follow-up Phases 
 
Pharmacokinetic (PK) Samples  
Up to eighteen 3 mL of blood samples will be collected.  The times the blood samples may be 
taken include before the start of study drug, during surgery, and after the study drug is stopped 
(48 hours after the start of infusion), and up to 12 hours after the study drug was stopped.  Theses 
blood samples will not be used for any other testing.  
 
What are the possible risks, side effects, and discomforts of this research study? 
 
There may be certain risks associated with participation in this study. These may include side 
effects of Treprostinil, all of which are not known at this time, the risks associated with a line 
used for giving you the drug and risk associated with blood sampling for measuring Treprostinil 
levels.    
As with any investigational drug there may be adverse events or side effects that are 
currently unknown and it is possible that certain of these unknown risks could be permanent, 
serious and life threatening. 
 
Risks of Treprostinil: Common side effects of Treprostinil may include, but are not limited to, 
flushing of the skin, headache, nausea, vomiting, diarrhea, and jaw pain. If these side effects 
develop and are intolerable, the dose of the study drug may be reduced or stopped until the side 
effects disappear.   
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Likely (>25%): Headache; diarrhea;  
Common (10-25%): Nausea, vomiting, rash, itchiness, jaw pain, flushing (increase in diameter 
of blood vessels), leg or foot pain 
Infrequent (1-10%): Dizziness, edema, skin reaction, line infection,  
Rare:   Decreased blood pressure 
 
Risks of Intravenous infusion of treprostinil: The study drug may be delivered using a tube 
placed into a large vein in the chest called a central venous catheter. This route of delivery can 
cause pain and bruising at the insertion site and there is an increase risk of blood stream 
infections (BSI).  Treprostinil is broken down in the body by the liver. In subjects with liver 
problem, blood levels of Treprostinil may be higher than normal. Treprostinil has not been 
studied in patients with severe liver failure, although it has been administered safely to such 
patients at the University of Pittsburgh Medical Center and elsewhere. In one small study, 
Treprostinil blood levels were found to be 2-4 times higher in patients with some degree of liver 
failure. Infusion of Treprostinil or drugs similar to Treprostinil occasionally has been done 
during liver transplant surgery without causing any serious problems.   However, because there is 
period when the diseased liver has been removed and the new liver has not started to work, there 
is a time during the surgery when Treprostinil blood levels may increase five times or more. This 
could cause your blood pressure to decrease during the surgery. Your blood pressure and vital 
signs will be watched very carefully during your surgery and the dose of study drug could be 
reduced or stopped if there are problems.  However, in spite of these precautions the study drug 
may increase the risk of problems resulting from low blood pressure. The medical team may stop 
the study without your agreement based on medical information available to them.   
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Treprostinil has not been shown to cause cancer or affect fertility or mating performance 
in rats at a dose that is 60 times the highest dose used in this study. In pregnant rats a dose that is 
120 times the maximum dose to be used in this study did not have any evidence of harm to the 
fetus. Because animal studies are not always predictive of what might happen in humans, 
pregnant subjects should not use Treprostinil.   
 
Risks of Reproduction: Being a part of this study while pregnant or breastfeeding may expose 
the unborn child or nursing infant to risks known and unknown. Therefore, pregnant and nursing 
women will not be included in this study. If you are a woman of childbearing potential, a urine 
pregnancy test will be done during baseline visit. It must be negative before you can enter this 
study. While receiving study drug, and for a period of 30 days after that you must agree to use 
two appropriate methods of birth control. Medically acceptable birth control methods include: 
(1) surgical sterilization, (2) approved hormonal contraceptives (such as birth control pills or 
Lupron Depot), (3) barrier methods (such as a condom or diaphragm) used with a spermicide, 
or (4) an intrauterine device (IUD).  
You should not take part in this study if you plan to become pregnant with in a month 
after transplant surgery, are currently pregnant, or you are currently breast feeding. You must 
notify your doctor if you suspect you have become pregnant while participating in this study. 
 
Risks of blood sampling:  The risks associated with blood sampling are minimal as the subjects 
will already have a catheter inserted for other blood sampling. In rare cases when a catheter is 
not already in, a small tube will be inserted in the arm vein for blood collection. 
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What are possible benefits from taking part in this study? 
 
There is no guarantee that you will receive any benefit from participating in this study.  
However, it is hoped that this drug will protect your liver and your stay in the hospital following 
liver transplant surgery will be less and you will spend less time in the intensive care unit. Your 
participation may also help others in the future by what the doctors learn from your involvement 
in this study.   
  
What treatment or procedures are available if I decide not to take part in this research study? 
If you decide not to take part in this research study, you will undergo normal procedures 
associated with the liver transplantation surgery. No other routine treatment will be withheld. 
 
If I agree to take part in this research study, will I be told of any new risks that may be found 
during the course of the study? 
You will be promptly notified if, during the conduct of this research study, any new information 
develops which may cause you to change your mind about continuing to participate in this study. 
 
Will my insurance provider or I be charged for the costs of any procedures performed as part 
of this research study? 
All costs and tests done to treat you before and after your liver transplant should be covered by 
your medical insurance. These are tests that would normally be performed in patients undergoing 
liver transplant surgery.  
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Some of the services you will receive during this are “research only services” that are 
being done only because you are in the study. These services will be paid for by the study and 
will not be billed to your health insurance company or you.  United Therapeutics Corporation 
will cover the costs associated with the following procedures and tests carried out for research 
purposes: study drug cost, pump for infusion, and Treprostinil blood level analysis 
University of Pittsburgh Thomas Starzl Transplantation Institute will cover the costs 
associated with the following procedures and tests carried out for research purposes:  
• Drug administration  
• Post reperfusion liver biopsy (optional) 
• Additional ALT/AST on day 1 and 2 
• Study Day 7 procedures, in the event a patient is to be discharged before day 7.   
• Treprostinil pharmacokinetic sampling will be performed by research technician hired to 
perform this.  
 
Some of the services you will receive during this study are considered to be “routine clinical 
services” that you would have even if you were not in the study.  Examples are the actual liver 
transplant, surgery, hospitalization and all associated care.  These services will be billed to your 
health insurance company or you, if you do not have health insurance.   
 
You will be responsible for paying any deductibles, co-payments or co-insurance that are 
a normal part of your health insurance plan.  If you have the Medicare Advantage Plan you could 
be billed as if you were a Fee-for Service patient. You may also be responsible for the total coast 
of the transplant under a 3rd party Medicare plan.  You may want to get more detailed 
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information about what “routine clinical services” your health insurance is likely to pay for.  You 
may want to talk to a member of the study staff and/or a UPMC financial counselor to get more 
information.   
No compensation will be provided by United Therapeutics Corporation.  This includes no 
financial support for lost wages, disability, pain or discomfort. 
 
Will I be paid if I take part in this research study? 
 
You will not receive any payment for taking part in this clinical study. 
 
Who will pay if I am injured as a result of taking part in this study? 
 
University of Pittsburgh researchers and their associates who provide services at University of 
Pittsburgh Medical Center (UPMC) recognize the importance of your voluntary participation in 
their research studies. These individuals and their staffs will make reasonable efforts to 
minimize, control, and treat any injuries that may arise as a result of this research. If you believe 
that you are injured as a result of the research procedures being performed, please contact 
immediately the Principal Investigator or one of the co-investigators listed on the first page of 
this form. 
Emergency medical treatment for injuries solely and directly related to your participation 
in this research study will be provided to you by UPMC. It is possible that UPMC may bill your 
insurance provider for the costs of this emergency treatment, but none of these costs will be 
charged directly to you. If your research-related injury requires medical care beyond this 
   192 
emergency treatment, you will be responsible for the costs of this follow-up care unless 
otherwise specifically stated below. If you are physically injured by the study drug and you have 
followed the directions of the study personnel, United Therapeutics Corporation will cover the 
medical expenses necessary to treat the injury. United Therapeutics Corporation will provide no 
additional financial compensation. There is no plan for monetary compensation. You do not, 
however, waive any legal rights by signing this form. 
 
Who will know about my participation in this research study? 
 
Any information about you obtained from this research will be kept as confidential (private) as 
possible. All records related to your involvement in this research study will be stored in a locked 
file cabinet. Your identity on these records will be indicated by a case number rather than by 
your name, and the information linking these case numbers with your identity will be kept 
separate from the research records. You will not be identified by name in any publication of the 
research results unless you sign a separate consent form giving your permission (release). 
 
Will this research study involve the use or disclosure of my identifiable medical information? 
 
This research study will involve the recording of current and/or future identifiable medical 
information from your hospital and/or other (e.g., physician office) records. The information that 
will be recorded will be limited to information concerning demographics (age, gender, and race) 
and concurrent conditions and medications you are receiving.  
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This research study will result in identifiable information that will be placed into your 
medical records held at UPMC Presbyterian and Montefiore.   
 
Who will have access to identifiable information related to my participation in this research 
study? 
 
In addition to the investigators listed on the first page of this authorization (consent) form and 
their research staff, the following individuals will or may have access to identifiable information 
(which may include your identifiable medical information) related to your participation in this 
research study:  
Authorized representatives of the University of Pittsburgh Research Conduct and 
Compliance Office may review your identifiable research information (which may include your 
identifiable medical information) for the purpose of monitoring the appropriate conduct of this 
research study. 
Authorized representatives of the United Therapeutics Corporation may review your 
identifiable research information (which may include your identifiable medical information) 
related to your participation in this research study for the purpose of monitoring the accuracy and 
completeness of the research data and for performing required scientific analyses for the research 
data.   While the study sponsor understands the importance of maintaining the confidentiality of 
your identifiable research and medical information, the UPMC and University of Pittsburgh 
cannot guarantee the confidentiality of this information after it has been obtained by the study 
sponsor.  The investigators involved in the conduct of this research study may receive funding 
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form the sponsor to perform the research procedures and to provide the sponsor with identifiable 
research and medical information related to your participation in the study. 
Authorized representatives from the Food and Drug Administration may review and or 
obtain your identifiable (which may include your identifiable medical information) related to 
your participation in this research study for the purposes of monitoring the accuracy and 
completeness of the research data.  While the U.S. Food and Drug Administration understands 
the importance of maintaining the confidentiality of your identifiable research and medical 
information, the UPMC and University of Pittsburgh cannot guarantee the confidentiality of this 
information after it has been obtained by the U. S. Food and Drug Administration. 
Authorized representatives of UPMC hospitals or other affiliated health care providers 
may have access to identifiable information (which may include your identifiable medical 
information) related to your participation in this research study for the purpose of (1) fulfilling 
orders, made by the investigators, for hospital and health care services (e.g., laboratory tests, 
diagnostic procedures) associated with research study participation; (2) addressing correct 
payment for tests and procedures ordered by the investigators; and/or (3) for internal hospital 
operations (i.e. quality assurance). 
In unusual cases, the investigators may be required to release identifiable information 
(which may include your identifiable medical information) related to your participation in this 
research study in response to an order from a court of law.  If the investigators learn that you or 
someone with whom you are involved is in serious danger or potential harm, they will need to 
inform, as required by Pennsylvania law, the appropriate agencies. 
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For how long will the investigators be permitted to use and disclose identifiable information 
related to my participation in this research study? 
 
All the blood samples collected from you will be labeled using an identification number without 
your name. They will be stored in the laboratory of the researchers until all the data is obtained 
from these samples. The investigators may continue to use and disclose, for the purposes 
described above, identifiable information (which may include your identifiable medical 
information) related to your participation in this research study for a minimum of 5 years and for 
as long (indefinite) as it may take to complete this research study. 
The blood samples collected in this study will be kept for an indefinite time period until a 
complete report of the study has been published. The sample with out the identification may be 
utilized in future studies by the investigators. These samples will not be shared with any 
secondary investigators not listed on the current research study. 
 
May I have access to my medical information that results from my participation in this 
research study? 
 
In accordance with UPMC Notices of Privacy Practices document that you have been given, you 
are permitted access to information (including information resulting from your participation in 
this research study) contained within your medical records filed with your health care provider 
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Is my participation in this research study voluntary? 
 
Your participation in this research study, to include the use and disclosure of your identifiable 
information for the purposes described above, is completely voluntary. (Note, however, that if 
you do not provide your consent for the use and disclosure of your identifiable information for 
the purposes described above, you will not be allowed to participate in the research study.)  
Whether or not you provide your consent for participation in this research study will have on 
effect on your current and future care at a University or Pittsburgh or UPMC hospital or 
affiliated health care provider or your current or future relationship with a health care insurance 
provider.  
Your doctor may be an investigator in this research study, and as an investigator, is 
interested both in your medical care and in the conduct of this research. Before entering this 
study or at any time during the research, you may discuss your care with another doctor who is in 
no way associated with this research project. You are not under any obligation to participate in 
any research study offered by your doctor.  
 
May I withdraw, at a future date, my consent for participation in this research study? 
 
You may withdraw, at any time, your consent for participation in this research study, to include 
the use and disclosure of your identifiable information for the purposes described above.  (Note, 
however, that if you withdraw your consent for the use and disclosure of your identifiable 
medical record information for the purposes described above, you will also be withdrawn, in 
general, from further participation in this research study.)  Any identifiable research or medical 
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information recorded for, or resulting from, your participation in this research study prior to the 
date that you formally withdrew your consent may continue to be used and disclosed by the 
investigators for the purposes described above. 
To formally withdraw your consent for participation in this research study you should 
provide a written and dated notice of this decision to the principal investigator of this research 
study at the address listed on the first page of this form. 
If you decide to withdraw form study participation after you have received the study 
drug, you should participate in described monitoring follow-up procedures directed at evaluating 
the safety of the study drug.  
 
If I agree to take part in this research study, can I be removed from the study without my 
consent? 
 
It is possible that you may be removed from the research study by the researchers if, for 
example, your pregnancy test proves to be positive. You may be removed from the study if you 
experience unexpected side effects and in the opinion of the investigators that it is in your best 
interest. The study may also be stopped by the investigators or the sponsor if it felt that it is in 
the best interest of the patients.   
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******************************************************************** 
VOLUNTARY CONSENT 
 
All of the above has been explained to me and all of my current questions have been answered.  I 
understand that I am encouraged to ask questions about any aspect of this research study during 
the course of this study, and that such future questions will be answered by the researchers listed 
on the first page of this form.   
 
Any questions which I have about my rights as a research participant will be answered by 
the Human Subject Protection Advocate of the IRB Office, University of Pittsburgh (1-866-212-
2668). By signing this form, I agree to participate in this research study.  A copy of this consent 
form will be given to me. 
 
  By signing this form, I agree to participate in the additional Pharmacokinetic  
      Sampling  
________________________________   __________________ 
Participant’s Signature     Date 
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CERTIFICATION OF INFORMED CONSENT 
I certify that I have explained the nature and purpose of this research study to the above-named 
individual(s), and I have discussed the potential benefits and possible risks of study participation.  
Any questions the individual(s) have about this study have been answered, and we will always be 
available to address future questions as they arise.”  
 
___________________________________  ________________________ 
Printed Name of Person Obtaining Consent  Role in Research Study 
 
_________________________________  ____________ 
Signature of Person Obtaining Consent  Date  
 
ONLY WHEN APPLICABLE FOR PROXY CONSENT: 
The patient is unable to consent because: 
 
I therefore, consent to participation for the patient 
 
_____________________________________              ____________________________ 
Signature                                                                         Date 
_____________________________________             ____________________________ 
Legal Representative                                                     Relationship to Subject 
______________________________________         _____________________________ 
Witness Signature      Date 
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VERIFICATION OF EXPLANATION 
 
I certify that I have carefully explained the purpose and nature of this research to 
____________________________ in appropriate language.  He/She has had an opportunity to 
discuss it with me in detail.  I have answered all of his/she provided affirmative agreement (i.e., 
assent)to participate in this research.   
 
___________________________________              ____________________ 
Printed Name of Person Obtaining Consent  Role in Research Study 
 
_________________________________  ____________ 
Signature of Person Obtaining Consent  Date  
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